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1. Introduction 
 
1.1 Cancer and metastasis 
 
Genetic and epigenetic alterations drive normal cells to turn into tumor cells [1-3]. Based on 
the level of aggressiveness, tumors are divided into two subclasses: (1) benign tumors that 
develop locally and (2) malignant tumors, also termed as cancer, which are characterized by 
a high potential to migrate and invade in other tissues. In recent years, intensive research 
allowed a better understanding of the complex processes of carcinogenesis of primary 
tumors as well as migration, invasion and formation of secondary tumors in the process of 
metastasis. This multistep process consists of a collaborative network between tumor cells 
and the tumor microenvironment including tumor stroma and tumor-associated cells [3].  
As a result of an increasing number of elderly people, increasing risk factors, high incidence 
of therapy resistance and relapse, in both developed and developing countries, cancer 
presents one of the most common cause of death worldwide [4]. Differences in 
morphological and phenotypical tumor characteristics between patients, primary tumor and 
metastases and within the tumor itself, termed as tumor heterogeneity, evolved as major 
bottleneck for effective treatment, as tumor heterogeneity is attributed to therapy resistance 
as well as limited and diverging efficacy of cancer therapeutics [5]. Although a strong variety 
in individual tumor properties were identified, certain capabilities are common for all cancer 
types: sustaining proliferative signaling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, resisting cell death, 
deregulating cellular energetics, avoiding immune destruction, as well as genome instability 
and mutation, tumor-promoting inflammation and the importance of the microenvironment in 
the tumorigenesis process [3]. These hallmarks of cancer as well as new insights in the 
tumor biology, gained over the last decades, promote the development of individualized 
concepts for prevention, detection and therapy of cancer that consider special patients’ 
needs. 
 
1.2 Diagnostic and therapeutic approaches for cancer 
 
Due to the fact that cancer screening evolved as an important healthcare issue, nowadays a 
clinical cancer diagnosis is often made before symptoms become apparent. Diagnostic 
procedures have improved considerably over the last decades. In addition to endoscopy and 
biopsy as invasive methods, noninvasive methods such as computed tomography (CT), 
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magnetic resonance imaging (MRI), x-rays, scintigraphy and positron-emission tomography 
(PET) allow exact localization of the tumorous tissue and provide important information for 
the selection of the best and most suitable treatment strategy in the clinical routine.  
For localized tumors, surgery and radiation are the most effective treatment opportunities [6], 
however, especially for advanced cancer stages, therapeutics for systemic application are 
urgently required. As starting point, agents that destroy rapidly dividing cells were identified 
to act as cancer therapeutics. However, chemotherapeutics, basically acting via DNA-
damaging mechanisms, exhibit strong toxicities due to unselective effects in normal cells and 
patients show a high degree of recurrence or chemo-resistance [6]. A big step forward was 
made in 1946, where for the first time, a cancer-specific strategy was applied and thyroid 
cancer was treated with 131I after thyroidectomy based on the findings that thyroid cancer 
cells are capable of concentrating iodide due to the expression of the sodium iodide 
symporter (NIS) [7].  
Due to new insights in the complex tumor biology gained over the last years, cancer 
treatment strategies turned from relatively unspecific options to more elaborate therapy 
concepts, which focus on selective and mechanisms based processes in a targeted fashion. 
Targeted therapy strategies use the fact that in addition to the unique character of each 
cancer type, some alterations are shared between several tumor types. Growth factor 
receptors, signaling molecules, cell-cycle proteins and components of the microenvironment 
or the angiogenesis process serve as targets [6]. Currently approved targeted agents for 
cancer therapy for a broad range of malignancies are monoclonal antibodies and small 
molecules (tyrosine kinase inhibitors). 
In the last years, cancer gene therapy emerged as highly promising tool to intervene in 
cancer homeostasis. Gene therapy in general describes the introduction of genetic material 
in cells with the intention to interact and interfere with aberrant physiological processes for a 
therapeutic intervention [8]. This adaptable treatment approach offers new perspectives to 
respond to special patients’ needs in an individualized manner. Replacement or silencing of 
malfunctioning genes can be conducted by RNA interference via siRNA or microRNA, 
peptide nucleic acids or via the CRISPR-Cas methodology [9] and insertion of new genes 
can be directed via application of peptides, proteins or plasmid DNA (pDNA) [10-12].  
The tremendous progress over the last years and the effectiveness of cancer gene therapy is 
mirrored by the recent approval in the US of the first cancer gene therapy for leukemia [13]. 
In this therapy concept, human T-cells are engineered ex vivo to produce special receptors 
that bind to epitopes on malignant cells. These anti-CD19-CAR retroviral vector-transduced 
autologous T-cells are then reinjected to destroy the cancerous B-cells [14, 15]. 
Aiming at high therapeutic efficacy and safe application, a great number of genes with 
various modes of action have been investigated. In the last 20 years, the sodium iodide 
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symporter (NIS) emerged as highly promising target gene for cancer therapy, as it combines 
a cytotoxic function, which can induce cell destruction, with a diagnostic function that allows 
exact localization and level of transgene expression based on its ability to mediate uptake of 
diagnostic and therapeutic radionuclides, such as radioiodide [16].  
 
1.3 The sodium iodide symporter (NIS) 
 
The human sodium iodide symporter (NIS; SLC5A5) is a 643-amino acid transmembrane 
plasma protein that is localized mainly in the thyroid and consists out of 13 transmembrane 
domains (Fig.1).  
 
 
 
Fig. 1: Structure of the human sodium iodide symporter (NIS) transmembrane protein (left) and illustration of a 
thyroid follicular cell and the function of NIS in the process of thyroid hormone synthesis (right). With permission 
reproduced from Spitzweg et al., J Clin Endocrinol Metab, 2001. 
 
The active transport of iodide (I-) with cotransportation of two sodium ions (Na+) into the 
thyroid is the first and crucial step in the biosynthesis of thyroid hormones [17]. This uptake is 
driven by a sodium gradient, established by the Na+/K+-ATPase, which is also located at the 
basolateral membrane. In a next step, I- is transported across the apical membrane by a 
chloride/iodide transporter (pendrin) and the process of iodide organification takes place. 
Herein, I- is oxidized to iodine (I2) catalyzed by the thyroperoxidase (TPO) and then I2 is 
incorporated into tyroglobulin (Tg) in the process of thyroid hormone synthesis. After TSH 
stimulation, iodinated Tg is internalized from the follicular lumen and proteolytically cleaved in 
lysosomes to tri-iodothyronine (T3) and tetra-iodothyronine (T4) that are then released into the 
bloodstream [18]. Thyroid hormones are essential for pre- and postnatal development as well 
as for multiple metabolic cell processes. This indispensable function highlights the enormous 
importance of NIS for human health [19].  
Besides the ability to transport I-, NIS further mediates the uptake of other anions, such as 
selenium cyanate (SeCN-), thiocynate (SCN-), chlorate (ClO3
-), nitrate (NO3
-), perchlorate 
(ClO4
-), bromide (Br-), tetrafluoroborate (BF4
-), perrhenate (ReO4
-) and astatide (At-) [20, 21]. 
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In addition to the thyroidal expression, NIS can also be detected in several other nonthyroidal 
tissues, such as stomach, lactating breast, salivary glands and kidneys. Various functions of 
I- in these tissues are discussed. In the salivary glands, I- is supposed to act as antimicrobial 
substance, whereas in lactating breast I- is secreted into the milk and serves as nutrient to 
the newborn. Unlike in the thyroid, in these tissues probably no or only low levels of 
organification of iodide is performed and iodide uptake is not TSH dependent [22-24].  
 
1.3.1 NIS as theranostic tool for thyroid cancer 
 
The fist therapeutic use of the iodide uptake ability of NIS was in 1939 to treat 
hyperthyroidism by application of radioiodide (131I) and in 1946 to treat thyroid cancer after 
thyroidectomy [7]. This indicated the starting point of the most effective systemic anticancer 
radiotherapy strategy to date.  
Due to the continuing capacity of a majority of differentiated thyroid cancers (DTC) to 
express NIS, the NIS-mediated accumulation of radioiodide can further be used to image the 
extent of tumor spread and possible metastases with subsequent dosimetric calculations of 
the tumor absorbed dose as basis for consecutive 131I treatment. Whole body 123I- or 131I -
scintigraphy has been used for diagnostic purposes for many years [17]. Large efforts were 
made in establishing new imaging modalities as well as application of new tracers. Besides 
scintigraphy using y-camera, single photon emission computed tomography (SPECT) and 
PET imaging allow a more precise diagnosis and exact localization of the tumorous tissues 
with improved sensitivity and resolution of images using various diagnostic radionuclides (i.e. 
123I, 124I, 125I, 99mTcO4
-, 188Re, 18F-TFB) [17, 18]. 
After diagnostic evaluation and exact calculation of the suitable dose for therapy, effective 
treatment of thyroid cancer can be performed by application of therapeutic radionuclides (131I, 
188Re, 211At). This therapeutic concept for DTC using the ionizing radiation of 131I to induce 
toxic effects in cancer cells represents an efficient strategy with high response rates, which is 
mirrored by the low mortality of DTC patients even in metastatic stage [25]. The toxic effects 
are provoked by a destruction of cellular proteins and DNA double strand breaks with 
subsequent apoptosis [26]. 
Further, the high efficacy of radioiodide therapy is supported by a bystander effect based on 
the crossfire effect of the beta-emitter 131I, which implies that the cytotoxic effect is not only 
limited to transduced cells, but also affects surrounding cells [27] (Fig. 2). 
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Fig. 2: NIS expression in tumor cells is associated with a bystander effect based on the crossfire effect of the 
beta-emitter 
131
I. This increases the therapeutic effectiveness by affecting non-NIS expressing cells.  
 
This translational approach for diagnosis and therapy, which resulted in the termination of 
NIS as “theranostic” gene [28], may represent a promising therapy approach even in 
nonthyroidal cells after successful NIS gene transfer.  
 
1.3.2 NIS for cancer gene therapy 
 
The identification and cloning of the NIS gene sequence in 1996 [29, 30] opened the exciting 
prospect to administer NIS as theranostic gene even in nonthyroidal cancer types.  
The beneficial concept of image-based targeted radioiodide therapy, with NIS as non-
immunogenic human gene and protein, enables safe and efficient application of various 
radionuclides with a well-known therapeutic window and the ability to adjust dosage in a 
personalized way with regard to individual tumor radio-responsiveness, co-morbidities and 
side effects in patients [16, 31, 32]. Based on the ability of NIS to transport various 
radionuclides, a broad range of imaging modalities can be applied to investigate 
pharmacokinetic and pharmacodynamic capabilities of different NIS gene delivery vectors 
and subsequent NIS gene expression in the target tissue. The reporter function further allows 
calculation of the extent of radionuclide uptake that correlates with cell viability, as only viable 
cells are able to concentrate iodide [33]. 
Limited native NIS expression in other tissues restricts negative and undesired effects in 
healthy cells. Moreover, pretreatment with L-T4 reduces NIS expression in the thyroid and, 
therefore, minimizes thyroidal radionuclide uptake, which protects the thyroid from tissue 
damage and enables prolonged circulation of radionuclides in the body for tumoral uptake 
[34]. 
The efficacy of the dual imaging and therapy concept of NIS has been investigated in several 
preclinical as well as clinical studies using various tumor models and delivery systems with 
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an enormous potential for a future clinical use [35-51]. Although, in NIS transduced cells, the 
organification process is not performed, the accumulated dose in the tumor tissue was high 
enough for a significant therapeutic effect and prolonged accumulation of iodide in 
transfected cells was demonstrated [47, 52]. As a result of the promising preclinical 
achievements, NIS as theranostic gene entered clinical trial (NCT00788307, NCT01846091, 
NCT02068794, NCT02364713, NCT02192775, NCT00450814, NCT03017820, 
NCT01503177). 
Nevertheless, for systemic application, where naked NIS DNA would undergo a rapid 
enzymatically degradation in blood and tissue, further progress is required, as the efficiency 
of the NIS gene therapy concept is dependent on the employed delivery system. One 
promising method is the application of mesenchymal stem cells that are genetically 
engineered to stably express NIS (eMSCs). Due to their excellent tumor-homing property, 
NIS-armed MSCs migrate to tumor cells and NIS can be used for vector imaging and 
therapy. In combination with tumor specific promotors, specific expression can be 
accomplished only in tumor tissue and undesired effects on nontarget tissue can be reduced 
[45]. In a collaboration project between Prof. Dr. Christine Spitzweg and Prof. Dr. Peter 
Nelson, successful NIS gene expression was obtained after administration of adoptively 
transferred MSCs under the control of the constitutively active cytomegalovirus (CMV) 
promoter [42], as well as tumor-selective promotors, such as RANTES (regulated on 
activation, normal T-cell expressed and presumably secreted)/CCL5 promoter [43, 44] and a 
hypoxia responsive HIF1α-promotor [45]. With these concepts, successful vector imaging 
could be performed in hepatocellular cancer xenograft models and in a colon cancer 
metastases model with subsequent therapeutic application of radioiodide that resulted in 
significantly decelerated tumor growth and prolonged animal survival [42-45]. 
A further method is the application of viral vectors, which constitutes the most common 
delivery system in preclinical and clinical studies. The frequent use of viral vectors is owed to 
the enormous transfection efficiency as a result of their inherent genome editing capacity. In 
the group of Christine Spitzweg, genetically engineered replication-selective oncolytic 
adenoviruses were applied, in which the E1a gene is driven by the mouse alpha-fetoprotein 
promoter and the NIS gene is inserted in the E3 region (Ad5-E1/AFP-E3/NIS). NIS enabled 
detailed imaging of vector biodistribution and a combinatorial treatment concept of oncolytic 
virotherapy with radioiodide treatment (radiovirotherapy) [35]. To reduce the negative impact 
of neutralizing antibodies, widespread expression of the coxsackie-adenovirus receptor 
(CAR) and adenovirus sequestration by the liver, coating with poly(amidoamine) dendrimers 
(PAMAM-G5) was performed. Liver detargeting and effective tumor retargeting was obtained 
[37]. This strategy was further improved by coating the viral particles with PAMAM coupled to 
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the epidermal growth factor receptor (EGFR)-specific ligand GE11 to obtain a higher level of 
tumor selectivity [37]. 
 
1.4 Cationic oligomers as nonviral gene delivery vehicles 
 
Since viral delivery systems face significant disadvantages regarding immunogenicity, 
uncontrolled replication, oncogenesis after integration of viral genetic information in human 
chromosomal DNA, limited loading capacity and sophisticated production processes [9], 
synthetic carriers emerged as powerful systems that imitate viral behavior. The synthetic 
systems can be designed in a fashionable manner with multifunctional domains that address 
the challenges of improved safety, exact targeting and easy upscaling [53].  
Nonviral carriers for nucleic acid delivery can be divided into three subclasses: cationic 
polymers (polyplexes after DNA complexation), cationic lipids (lipoplexes after DNA 
complexation) and a combination of these two systems: lipid-polymer-based nanoparticles 
(lipopolyplexes) [54]. 
The first use of nonviral delivery systems for NIS gene transfer was performed by Kathrin 
Klutz in Prof. Dr. Christine Spitzweg’s group in close collaboration with Prof. Dr. Ernst 
Wagner, using pseudodendritic oligoamines with high intrinsic tumor affinity (G2-HD-
OEI) [38, 40]. High tumor accumulation and NIS expression in the target tissue was obtained. 
However, accumulation was dependent on the enhanced permeability and retention (EPR) 
effect, which bears limitations for small fenestrated and low vascularized tumors. A big step 
forward was made by the successful application of LPEI-PEG-GE11/NIS in a subcutaneous 
HCC tumor model [39]. Incorporation of the peptide GE11 as EGFR-specific ligand allowed 
specific tumor targeting and enhanced internalization rates could be achieved.  
 
1.4.1 Oligomer-based nonviral NIS gene delivery process and major 
challenges 
 
Nevertheless, efficient and tumor-selective delivery with nonviral synthetic systems remains a 
major issue [55, 56]. Various extra- and intracellular barriers have to be considered for 
targeting the tumor tissue [56-58]. Formation of stable structures is essential to protect the 
nucleic acid in the blood stream and avoid rapid enzymatic degradation. Anionic DNA can be 
condensed with cationic polymers and lipooligomers, as a result of an electrostatic force 
driven by the entropy process. After reaching the target tissue, the (lipo)-polyplex can bind 
via its ligand to the corresponding cell surface structure, whereupon the (lipo)-polyplex is 
internalized mainly through endocytosis. Escape of the endosome and release into the 
  Introduction 
8 
 
cytosol enables trafficking to the nucleus, where the gene information is processed [55, 56] 
(Fig.3).  
 
 
 
Fig. 3: Uptake process after complexing of NIS DNA with cationic polymers and systemic application via active 
ligand targeting and endocytosis into tumor cells. 
 
However, for this optimized process, several requirements have to be fulfilled: 
 
1. Capability of the polymer to stably compact the nucleic acid, while being able to 
release the DNA after cellular uptake in a controlled fashion 
2. Prolonged circulation time in the blood stream  
3. Ideal size for systemic application  
4. Protection from enzymatic degradation before delivery and reduced interaction with 
extracellular components 
5. Tumor specific targeting and efficient uptake in tumor cells along with minimal off-
target effects 
6. Ability to escape out of the endosome 
7. Biocompatibility and biodegradability 
 
On the basis of the substantial benefits of nonviral carriers acting as “artificial viruses” these 
systems may represent a promising strategy for safe and specific NIS gene delivery. The 
requirements for successful gene delivery stated above, may be addressed by functionalizing 
the nonviral delivery system in specialized synthesis strategies. 
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1.4.2 Functionalization of nonviral oligomers 
1.4.2.1 DNA complexation 
 
Formation of stable complexes with ideal size and stability is a prerequisite for systemic 
application of the genetic information. The critical issue of nanoparticle size is reflected by 
rapid clearing of particles < 5 nm [59]. Furthermore, only particles up to 400 nm can benefit 
from the EPR effect and only particles up to 200 nm are supposed to enter the cell via a 
clathrin-dependent active pathway [60-62]. Reduced interactions with extracellular 
components in the blood stream to ensure long-term stability of the genetic information, low 
self-aggregation, low immunogenicity, as well as the optimal balance to degrade after cellular 
uptake to release the genetic information are further important capacities. This can be 
addressed by influencing charge density of the used cationic oligomer for compaction and by 
further implementation of hydrophobic sections.  
Polyethyleneimine (PEI) has been the most prominent cationic carrier for pDNA delivery as it 
bears high transfection efficiency in vitro and in vivo [63]. The linear form of PEI (LPEI) with 
different molecular weight ranges (Fig. 4) allows controlling of stability, transfection efficiency 
and safety to some degree [64].   
 
 
 
High amount of protonable secondary amine groups in the LPEI structure result in a high 
density of cationic charges and hence enormous efficiency in DNA compaction. The 
transfection capacity is dependent on the molecular weight of the formulation. High molecular 
weight PEIs show intense transduction efficiency compared to reduced effects with low 
molecular weight PEI. Likewise, with increasing molecular weight, cytotoxicity is increasing 
and a balance between efficacy and cytotoxicity is essential for in vivo application. Therefore, 
the ideal balance between transfection efficiency and biocompatibility is the limiting factor of 
the application of LPEI. Along with a high degree of polydispersity of LPEI structures and the 
uncontrollability of polyplex formation, currently, better and more biocompatible structures 
are being developed [65]. 
Using solid-phase supported synthesis [66], precise, biodegradable sequence-defined 
polymers with structure-activity relationships have been designed. Exemplary structures for a 
sequence defined polymer can be seen in Figure 5 and a schematic structure of a sequence 
defined lipooligomers is displayed in Figure 6. 
Fig. 4: Chemical sturcture of linear 
polyethyleneimine (LPEI). 
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Fig. 5: Schematic structure of an exemplary two-arm sequence defined oligomer. 1. Diamino ethane domain with 
artificial aminoacids for DNA binding and buffering capacity (here: Stp); 2. Amino acids with additional buffering 
capacity (here: histidine); 3. Shielding domain (here: polytheylene glycol; PEG); 4. Reactive sites for crosslinking; 
5. Ligand for active tumor cell targeting. Modified figure adapted from [67]. 
 
 
 
Fig. 6: Schematic structure of an exemplary sequence defined lipooligomer (here the topology of 454). 1. Diamino 
ethane domain with artificial aminoacids for DNA binding and buffering capacitiy (here: Stp); 2. Amino acids with 
additional buffering capacity (here: histidines); 3. Lipid domain (Oleic acid; OleA) for hydrophobic interaction with 
endosomal membrane; 4. Reactive sites for crosslinking and postmodification with shielding domain and specific 
targeting ligands. Modified figure adapted from [67]. 
 
These structures contain a diaminoethane motif, which mimics the PEI structure. Repeating 
units of various artificial amino acids such as succinoyl-tetraethylenepentamine (Stp), 
succinoyl-pentaethylene hexamine (Sph) or glutaryl-triethylene tetraamine (Gtt) equip the 
polymer with a functional site that exhibits optimal DNA condensation ability along with 
enhanced biodegradability and low toxicity [68, 69].  
 
1.4.2.2 Shielding 
 
The positive surface charge of polyplexes is responsible for efficient cellular uptake as it 
allows interaction with negatively charged plasma membranes, but also increases the risk of 
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self-aggregation, binding of extracellular components and unspecific cell attachment [70]. 
Incorporation of non-cationic hydrophilic copolymers enables sufficient surface shielding and 
consequently results in a higher safety profile and lower immunogenicity of polyplexes. 
Hydrophilic domains, such as polyethylene glycol (PEG), saccarides or poly(N-(2-
hydroxypropyl)methacrylamide) (pHPMA) were applied to obtain better tolerated 
nanoparticles with reduced cytotoxicity [71-74]. 
Integration of a shielding domain can be performed by covalent attachment or by 
postintegration onto predefined nanoparticles (Fig.7) [75]. The postintegration approach may 
represent an advantageous strategy, as diminished particle compaction and uncontrolled 
complex formation were detected in various systems, when using polyplexes with covalentely 
bound PEG [76, 77]. 
 
 
Fig. 7: Schematic illustration of different approaches to obtain shielding: covalent attachment of shielding and 
postmodification of preformed complexes. 
 
For in vivo application enhanced shielding is a mandatory requirement; however reduced 
level of membrane interaction reveal decreased transfection efficiency. This phenomenon is 
described as the “PEG-dilemma” [78]. To reduce the impact of shielding on transfection 
efficiency, active targeting is applied to minimize this effect. 
 
1.4.2.3 Specific tumor cell targeting 
 
Exploiting the individual tumor characteristics of increased vascularization and enhanced 
permeability due to leaky vascular structure [79, 80], unspecific accumulation of nonviral 
delivery vehicles in the tumor tissue can be obtained. This effect is referred to as “enhanced 
permeability and retention” (EPR) effect [81]. However, the lack of specific tumor targeting 
also results in effects in non-target cells as well as reduced efficacy in poor vascularized 
tumors and metastases [53, 56, 57]. Therefore, active ligand-mediated targeting represents 
  Introduction 
12 
 
an elegant method to improve tumor specificity with enhanced transgene expression to 
compensate reduced transfection efficiency due to active surface shielding in tumoral tissues 
and reduced side effects in non-target organs [57]. 
Various receptors are overexpressed in a high range of tumor types and play a crucial role in 
tumor progression and metabolic maintenance and can function as suitable targets. 
Antibodies and their fragments that recognize different epitopes on the receptor have been 
applied; however their use in vivo is limited. Large size, rapid clearing from the bloodstream 
and sensitivity against temperature, pH, salt concentration and organic solvents make it 
difficult to transfer their applicability into clinical application. Therefore, the focus switched to 
the identification of short, specific peptide ligands with the advantages of easy synthesis, 
smaller particles, reduced immune reactivity and improved stability [82]. 
Several peptide ligands have been developed and tested in the laboratory of Prof. Dr. Ernst 
Wagner to target various receptors, such as the folate receptor [61], cMET/hepatocyte 
growth factor receptor [69], epidermal growth factor receptor (EGFR) [39, 68], transferrin 
receptor (TfR) [83] and integrin receptors [68]. 
In addition to single receptor targeting, dual targeting approaches have been performed. The 
simultaneous targeting of various receptors may enhance particle uptake by receptor 
crosslinking that mimics biphasic uptake of viral vectors [84-86], as well as improve efficacy 
and reduce therapy resistance by addressing the phenomenon of tumor heterogeneity with 
expression of several surface receptors at variable levels [68, 87, 88]. 
 
1.4.2.4 Endosomal escape 
 
After cellular uptake, release into the cytosol is the next crucial step. A high amount of 
protonable functions in the polymer backbone is associated with a high buffering capacitiy. 
LPEI with the repeating structure of two aliphatic carbon groups and amino nitrogen contains 
a high content of protonable amine groups with high cationic charge density and buffering 
capacity in the endosome [63, 65]. Two possible effects that support the endosomal escape 
are discussed. The so called “proton sponge effect”, where the absorption of protons lead to 
an increased influx of chloride and water that results in swelling and vesicle rupture and the 
“needle effect”, which states that a pH dependent increase in cationic charge density 
destabilize directly the phospholipid membrane of the endosome [65]. 
For new generation sequence-defined oligomers, building blocks of artificial amino acids, 
which contain a diaminoethane motif, were assembled. These domains contain a high 
amount of protonable groups, which equip the polyplex with buffering capacity. Additional 
histidines for buffering can further be integrated to improve endosomal escape for adequate 
release of polymers in target cells. Another option is the incorporation of lipid domains, such 
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as oleic acid, stearic acid and cholesterol to enhance hydrophobic interaction of polyplexes 
and the endosomal membrane, where the lytic activity entails enhanced release in the 
cytosol [55, 56, 58, 69].   
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2. Aims of the thesis 
 
Gene therapy has great potential to become an efficient and novel tool for cancer therapy in 
the clinical setting. In particular, the sodium iodide symporter (NIS) evolved as highly 
promising target gene taking advantage of its theranostic function to serve as both, reporter 
and therapy gene. Based on the advanced approaches in NIS gene therapy performed in the 
laboratory of Prof. Dr. Christine Spitzweg, the next logical step, which should be attempted in 
this thesis, was to broaden the application of nonviral methods of NIS gene delivery to more 
advanced tumor stages with regard to tumor heterogeneity as well as to develop and apply 
more efficient and more biocompatible vectors with the prospect of clinical translation.  
 
The first aim of this thesis was to investigate novel peptide ligands for their suitability to 
function as highly effective and specific targeting moieties for nonviral NIS gene delivery. 
Three ligands (B6, GE11, cMBP) were coupled to established vectors and should be applied 
in different tumor models in order to obtain a broad platform of ligands that can be used in 
regard to various receptor expression levels of different tumors.  
 
To adequately reflect the clinical situation for successful translation to human clinical trials, 
the second aim was to investigate the feasibility of established vectors in advanced tumor 
models. A hepatic colon cancer metastases model should be used to investigate the 
potential of the nonviral EGFR-targeted NIS gene therapy approach. In this setup, 18F-
tetrafluoroborate (TFB) should be applied as novel NIS PET tracer that promises higher 
resolution and more differentiated images. The suitability for imaging of small metastases 
after NIS gene delivery should be examined followed by evaluation of therapeutic efficacy 
after application of 131I. 
 
The third aim was to enhance efficacy as well as to minimize response failure in regard to 
tumor heterogeneity. As one of the most powerful strategies to circumvent resistance in the 
clinical situation is the combination of different therapy strategies, a dual combination of two 
different targeting ligands for cMET and EGFR should be performed. By using this double 
bifunctional strategy, simultaneous targeting of two receptors should be performed, together 
with utilizing the theranostic function of the NIS gene to allow monitoring of gene delivery 
efficiency by noninvasive imaging of tumoral NIS expression and therapeutic intervention by 
application of cytotoxic 131I.  
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As next aim, to further improve systemic application with regard to safety, biocompatibility 
and transduction efficacy, novel sequence defined vectors based on solid phase supported 
synthesis should be applied. These sequence-defined vectors with various functional 
domains were coupled to a cMET-specific ligand and utilized, for the first time, in vivo for 
tumor specific NIS gene delivery to obtain bioimaging of functional NIS gene expression in 
tumorous tissue and therapy of hepatocellular cancer. 
 
Shielding and covalent attachment of hydrophobic ligands, which are prerequisites for in vivo 
application, can result in diminished particle compaction and hence increased sizes of 
nanoformulations. As final aim, a post-integration concept of a shielding and binding domain 
in preformed nanoparticles should be established to avoid the limitations of prePEGylation. 
Analytical characteristics and transfection efficiency using luciferase and NIS as reporter 
genes should be determined. This critical step should pioneer future in vivo application of the 
novel strategy for successful NIS gene delivery exhibiting improved chemical features 
regarding size and stability, a higher biocompatibility as well as a possible combination with 
more hydrophobic ligands. 
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3. Systemic tumor-targeted sodium iodide symporter (NIS) 
gene therapy of hepatocellular carcinoma mediated by B6 
peptide polyplexes 
 
This chapter has been adapted from:  
 
Urnauer S1*, Klutz K1*, Grünwald GK1, Morys S2, Schwenk N1, Zach C3, Gildehaus FJ3, Rödl 
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(NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. J Gene 
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3.1 Abstract 
 
Non-viral polymer-based gene transfer represents an adaptable system for tumor-targeted 
gene therapy, as various design strategies of shuttle systems together with the mechanistic 
concept of active tumor targeting lead to improved gene delivery vectors resulting in higher 
tumor specificity, efficacy and safety.  
Using the sodium iodide symporter (NIS) as theranostic gene, non-viral gene delivery 
vehicles based on linear polyethylenimine (LPEI), polyethylene glycol (PEG) and coupled 
with the synthetic peptide B6 (LPEI-PEG-B6), which specifically binds to tumor cells, were 
investigated in a hepatocellular carcinoma (HCC) xenograft model for tumor-selectivity and 
transduction efficiency. 
In vitro incubation of three different tumor cell lines with LPEI-PEG-B6/NIS resulted in 
significant increase in iodide uptake activity as compared to untargeted and empty vectors. 
After establishment of subcutaneous HuH7 tumors, NIS-conjugated nanoparticles were 
injected intravenously followed by analysis of radioiodide biodistribution using 123I-
scintigraphy showing significant perchlorate-sensitive iodide accumulation in tumors of LPEI-
PEG-B6/NIS-treated mice (8.0±1.5% ID/g 123I; biol. half-life 4 h). After four cycles of repetitive 
polyplex/131I applications, significant delay of tumor growth was observed, which was 
associated with markedly improved survival in the therapy group.  
These results clearly demonstrate that systemic in vivo NIS gene transfer using nanoparticle 
vectors coupled with B6 tumor-targeting ligand is capable of inducing tumor-specific 
radioiodide uptake. This promising gene therapy approach opens the exciting prospect of 
NIS-mediated radionuclide therapy in metastatic cancer together with the possibility of 
combining several targeting ligands to enhance selective therapeutic efficacy in a broad field 
of cancer types with various receptor expression profiles. 
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3.2 Introduction 
 
The sodium iodide symporter (NIS) acts as key mediator of thyroidal iodide uptake and 
accumulation, which is required for thyroid hormone synthesis [89]. Due to its iodide-
concentrating ability, NIS forms the basis of multimodal molecular imaging of tumorous tissue 
by NIS-mediated cellular uptake of various radionuclides, such as 123I, 125I, 124I, 131I, 188Re, 
211At, as well as effective treatment of differentiated thyroid cancer by application of 131I [48, 
90]. Radioiodide therapy has been used clinically for many decades and represents an 
approved anticancer therapy in thyroid cancer with a well-understood therapeutic window 
and safety profile [91]. Cloning of NIS in 1996 [29, 30], as one of the major milestones in 
thyroidology in the last 20 years, opened the way for the use of this potent dual reporter and 
therapy gene concept in the treatment of a broad range of cancer types by targeting NIS to 
non-thyroidal cancer cells. Extensive characterization of the applicability of NIS as diagnostic 
and therapeutic gene by several research groups including our own [35-47, 49, 92-95], 
revealed NIS as remarkable and powerful tool to detect and treat different extrathyroidal 
cancer types, even in metastatic disease [16, 50, 96, 97]. The high incidence of 
hepatocellular carcinoma (HCC) due to late diagnosis and poor prognosis along with limited 
treatment strategies urgently requires the development of new treatment strategies. For this 
purpose the NIS gene therapy concept may represent a promising strategy [98].  
However, the major obstacle of current NIS gene therapy is lack of efficient and tumor 
specific systemic gene delivery approaches. For future medical application, in particular in 
metastatic cancer, the design of improved vector systems with high transduction efficacy, low 
systemic toxicity and outstanding specific tumor targeting ability is of high importance. In this 
regard, several non-viral gene delivery systems including lipoplexes, polyplexes and other 
nanoparticles have been evaluated [56, 99-107]. The polycationic molecule polyethylenimine 
(PEI) has been shown to be an efficient non-viral gene delivery vector both in vitro and in 
vivo [108-113]. The transfection strategy was further improved by using the linear form of PEI 
(LPEI), the designated “gold standard” [114] which has also been used in clinical studies 
[111, 115]. However, biocompatibility and low biodegradability remain critical issues 
especially when systemic administration is considered [116-118]. A step towards improved 
biocompatibility was made by conjugating LPEI with polyethylene glycol (PEG) of optimal 
molecular weight to shield interactions with blood components, while sustaining delivery 
performance and transfection efficiency [76, 119-121]. To improve gene delivery to tumor 
sites and enhance availability of the relevant substance within the tumor, while reducing 
systemic toxicity at the same time, active receptor targeting displays an advantageous 
strategy.  
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Using the ligand-receptor-interaction platform for tumor-specific cellular uptake, we already 
investigated the epidermal growth factor receptor (EGFR)-specific ligand GE11 and a cMET-
binding peptide (cMBP2), which were coupled to a polymer backbone, together with our NIS 
gene therapy concept. Both ligands demonstrated high tumor specificity in vivo after 
systemic application of polyplexes resulting in high iodide accumulation in tumor areas 
mediated by NIS expression [39, 46]. With the aim of providing a broad platform of ligands 
for variable surface receptor expression levels, in this study, we selected the peptide 
sequence CGHKAKGPRK (B6) as tumor-binding peptide, which was originally obtained from 
a phage display screen on TfR-binding [122]. Recently, we confirmed B6 as a ligand that 
promotes cell binding of nanoparticles [68, 88], although the real cellular receptor remains 
unidentified and is most probably different from TfR [123]. But irrespective of the nature of 
the cellular target receptor, the new fully synthetic LPEI-PEG-B6 conjugates demonstrate 
encouraging tumor targeting properties, which were investigated by using the dual function of 
NIS as reporter and therapy gene. 
Consequently, in the current study, we evaluated the efficacy of the non-viral ligand-
mediated gene delivery vehicle based on the potent LPEI-PEG platform coupled with the 
tumor-targeting peptide B6 for systemic NIS gene delivery in a human hepatocellular 
carcinoma (HCC) xenograft mouse model.   
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3.3 Materials and methods 
 
Cell culture 
The human HCC cell line HuH7 (JCRB0403; Japanese Collection of Research Bioresources 
Cell Bank, Osaka, Japan) was cultured in Dulbecco’s modified eagle medium (DMEM; 1 g/l 
glucose; Sigma-Aldrich, St.Louis, Missouri, USA), the second HCC cell line Hep3B (HB-
8064; American Type Culture Collection (ATCC, Manassas, VA) was cultured in Eagle's 
Minimum Essential Medium (EMEM; Sigma-Aldrich) and the breast cancer cell line MDA-MB-
231 (ATCC) was cultured in Dulbecco’s modified eagle medium (DMEM; 4 g/l glucose; 
Sigma-Aldrich, St.Louis, Missouri, USA). All three media were supplemented with 10% (v/v) 
fetal bovine serum (FBS Superior, Biochrom/Merck Milipore, Berlin, Germany) and 1% (v/v) 
penicillin/streptomycin (Sigma-Aldrich). Cells were maintained at 37°C and 5% CO2 in an 
incubator with 95% humidity. Cell culture medium was replaced every second day and cells 
were passaged at 85% confluency. 
 
Plasmid and polymer synthesis 
The NIS cDNA was synthesized by GENEART (Regensburg, Germany) codon-optimized 
(pCpG-hCMV-NIS driven by the human elongation factor 1α promotor and human 
cytomegalovirus enhancer element) for gene expression in human tissue and cloned as 
described previously [39].  
The synthesis of LPEI-PEG-B6 and LPEI-PEG-Cys was performed by Wolfgang Rödl 
(Department of Pharmacy, Pharmaceutical Biotechnology, LMU) by coupling 
heterobifunctional (poly)ethylene glycol (NHS-PEG-OPSS, 2 kDa, Rapp Polymere GmbH, 
Tübingen, Germany) via N-hydroxy succiniminyl ester to amine groups of linear polyethylene 
imine (LPEI) followed by a purification step via cation exchange chromatography. The B6 
peptide (CGHKAKGPRK) was synthesized by solid phase peptide synthesis and coupled to 
the terminal OPSS group (orthopyridyl disulfide). A final purification step by size exclusion 
chromatography was performed on a Superdex 75 column (GE Healthcare Europe GmbH, 
Freiburg, Germany). LPEI-PEG-Cys was synthesized analogously using cysteine instead of 
the B6 peptide. The resulting conjugates were dialyzed against HBS (20 mM HEPES pH 7.4, 
150 mM NaCl) and stored at -80°C as 1 - 5 mg/ml stock solutions until further use. 
 
Polyplex formation 
Polymer and plasmid DNA (pDNA) were diluted in same volumes of HEPES (2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid)-buffered glucose (HBG: 20 mmol/l HEPES, 
5% glucose (w/v) at pH 7.4) at PEI conjugate/plasmid (c/p) - ratio (w/w) of 0.8. Polymers 
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were added to the DNA by rapid mixing and incubated at room temperature for 20 min prior 
to use [124].  
 
Particle size measurements  
Experiments were performed together with Stephan Morys (Department of Pharmacy, 
Pharmaceutical Biotechnology, LMU). Particle sizes of polyplexes were measured by 
dynamic laser-light scattering (DLS; Zetasizer Nano ZS, Malvern Instruments, 
Worcestershire, U.K.) and transmission emission microscopy (TEM; JEM 1011, Jeol, 
Freising, Germany). For DLS measurement, 2 µg pDNA was complexed with polymers in a 
total volume of 60 µl. After 20 min of incubation at room temperature, 740 µl of 10 mM 
sodium chloride solution (pH 7.4) was added and samples were measured. For TEM 
experiments, samples were prepared with 1 µg DNA in a total volume of 100 µl. The 
formvar/carbon coated 300 mesh copper grids (Ted Pella Inc., Redding, USA) were activated 
by mild plasma cleaning. The grids were then incubated with 20 µl of the polyplex solution for 
1 min. Excess liquid was blotted off using filter paper until the grid was almost dry. Prior to 
staining, the grids were washed with 5 µl of staining solution for 5 s. Then the copper grids 
were incubated for 20 s with 5 μl of a  2% aqueous uranyl formate solution, excess liquid was 
blotted of using filter paper, followed by air-drying for 30 min. TEM was performed at 80 kV. 
 
Serum stability measurements  
Experiments were performed together with Stephan Morys (Department of Pharmacy, 
Pharmaceutical Biotechnology, LMU). Stability of polyplexes was determined in 90% FBS by 
DLS. Polyplexes were prepared with 8 µg pDNA in a total volume of 50 µl HBG. After 
incubation for 20 min 30 µl of HBG and 720 µl FBS were added to reach a final concentration 
of 90% FBS. 60 µl were placed in a DTS1070 cuvette and values for t=0 min were measured. 
Then polyplexes were incubated under continuous shaking at 37°C in serum and aliquots 
were taken for further measurements after 0, 1, 2, 4, 24, 48 h. For each time point 
measurement from 15 runs were averaged. 
 
Transient transfection and iodide uptake assay 
For in vitro transfection experiments, cells were grown to 60 - 80% confluency. Cells were 
incubated for 4 h with polyplexes (final DNA concentration of polyplexes was 2 µg/ml), in the 
absence of serum and antibiotics followed by incubation with growth medium for 24 h. 
Transfection efficiency was determined by measurement of iodide uptake activity at steady-
state conditions as described previously [47]. Results were normalized to cell survival 
measured by cell viability assay (see below) and expressed as cpm/A620 nm. 
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Cell viability assay 
After transfection, cell viability was analyzed. Cells were incubated with a commercially 
available MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent (Sigma-
Aldrich) for 2 h at 37°C followed by a washing step with PBS (phosphate-buffered saline). 
The formazan product was measured after incubation with 10% DMSO (v/v) (dimethyl 
sulfoxide) in isopropanol at 620 nm in a Sunrise microplate absorbance reader (Tecan, 
Männedorf, Switzerland). 
 
Cellular internalization 
HuH7 cells were seeded in 24-well plates at a density of 50 000 cells per well. 24 h later 
culture medium was replaced with 400 μl fresh growth medium and cells were incubated for 
45 min with polyplexes LPEI-PEG-B6/NIS or LPEI-PEG-Cys/NIS or empty polyplexes LPEI-
PEG-B6/HBG which served as control. For pDNA polyplexes (c/p 0.8) in 100 μl HBG 1 μg 
pDNA was used, where 20% of the nucleic acid was Cy5-labeled. Cells were then washed 
with 500 μl PBS/1000 I.U. heparin for 15 min on ice to remove polyplexes on the cell surface. 
After washing with PBS, cells were detached with trypsin/EDTA and taken up in PBS with 
10% FBS. Cellular uptake was determined by measurement of the excitation of Cy5 at 635 
nm and detection of emission at 665 nm on a BD Accuri C6 flow cytometer (BD Bioscience). 
Cells were gated by forward/sideward scatter and pulse width for exclusion of doublets. 
Propidium iodide (PI, Sigma Aldrich) was used to discriminate between viable and dead 
cells. Experiments were performed in triplicates. 
 
Analysis of NIS mRNA expression using quantitative real-time polymerase chain 
reaction (qPCR) 
Total RNA was isolated from HuH7 cells and HuH7 tumors or other tissues using the RNeasy 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. 
Single stranded oligo (dT)-primer cDNA was generated using Superscript III Reverse 
Transcriptase (Invitrogen). Following primers were used: hNIS: (5`-
ACACCTTCTGGACCTTCGTG-3´) and (5`-GTCGCAGTCGGTGTAGAACA-3´), GAPDH: (5`-
GAGAAGGCTGGGGCTCATTT-3´) and (5`-CAGTGGGGACACGGAAGG-3´). qPCR was 
performed with the cDNA from 1µg RNA using the SYBR green PCR master mix (Quiagen) 
in a Rotor Gene 6000 (Corbett Research, Morthlake, New South Wales, Australia). Relative 
expression levels were calculated using the comparative ∆∆Ct method and internal GAPDH 
for normalization. 
 
Establishment of xenograft tumors in nude mice 
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HuH7 xenografts were established in female CD-1 nu/nu mice (Charles River, Sulzfeld, 
Germany) by subcutaneous injection of 5x106 HuH7 cells suspended in 100 µl PBS into the 
flank region. Animals were maintained under specific pathogen-free conditions with free 
access to mouse chow and water ad libitum. The experimental protocol was approved by the 
regional governmental commission for animals (Regierung von Oberbayern). 
 
Tumor-specific NIS gene transfer and radioiodide uptake studies in vivo 
Experiments started when tumors had reached a size of 8 - 10 mm after a 10-day 
pretreatment with L-thyroxin (L-T4; 5 mg/ml; Sigma-Aldrich) in drinking water to suppress 
thyroidal iodide uptake. For systemic in vivo NIS gene transfer polyplexes (c/p 0.8) were 
applied intravenously (i.v.) via the tail vein at a DNA dose of 2.5 mg/kg (50 µg DNA in 250 µl 
HBG, final DNA concentration of polyplexes for in vivo studies: 200 µg/ml). Four groups of 
mice were established and treated as follows: (1) LPEI-PEG-B6/NIS (n=9); (2) LPEI-PEG-
B6/NIS+NaClO4 (sodium perchlorate; 2 mg/mouse; Sigma Aldrich) (n=9); (3) LPEI-PEG-
B6/Antisense-NIS (n=9), (4) LPEI-PEG-Cys/NIS (n=9). 24 h after polyplex application, mice 
received an intraperitoneal (i.p.) injection of 18.5 MBq (0.5 mCurie (mCi)) 123I and iodide 
biodistribution was assessed using a gamma camera equipped with UXHR collimator (Ecam, 
Siemens, Germany) as described previously [93]. Regions of interest were quantified and 
expressed as a fraction of the total initial dose of applied radioiodide per gram tumor tissue 
(% ID/g). The retention time within the tumor was determined by serial scanning after 
radionuclide injection and dosimetric calculations were performed according to the concept of 
Medical Internal Radiation Dose (MIRD) with a dosis factor from the RADAR-group 
(www.doseinfo-radar.com). 
 
Immunofluorescence analysis of NIS protein expression 
Immunofluorescence staining on frozen tissue sections derived from HuH7 tumors after 
systemic gene delivery was performed using a mouse monoclonal antibody directed against 
hNIS (kindly provided by John C. Morris, Mayo Clinic, Rochester, MN, USA) as described 
previously [125]. Sections were imaged on an Olympus BX41 microscope (Olympus, 
Shimjukum Tokio, Japan) equipped with an Olympus XC30 CCD camera (Olympus).  
 
Radioiodine therapy study in vivo 
Following a 10-day L-T4 pre-treatment, mice bearing subcutaneous HuH7-tumors received 
55.5 MBq (1.5 mCi) 131I as a single i.p. injection 24 h after systemic application of LPEI-PEG-
B6/NIS (n=11) or LPEI-PEG-B6/Antisense-NIS (n=9). As an additional control, mice were 
treated with saline instead of 131I after injection of LPEI-PEG-B6/NIS (n=9) or received saline 
instead of polyplexes and iodide (n=9). Polyplex/131I or saline cycle was conducted four times 
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on days 0/1, 3/4, 7/8 and 14/15. Tumor sizes were measured before treatment and daily 
thereafter for up to five weeks and tumor volume estimated using the equation: tumor volume 
= length x width x height x 0.52. 
 
Indirect immunofluorescence assay 
Immunofluorescence staining was performed on dissected frozen tumor tissues, which were 
fixed in 80% methanol at 4°C for 5 min and acetone at -20°C for 2 min. After rehydration in 
PBS and blocking with 12% bovine serum albumin/PBS for 30 min at room temperature, 
incubation with a rabbit polyclonal antibody against human Ki67 (Abcam, Cambridge, UK; 
dilution 1:1000) and a rat monoclonal antibody against mouse CD31 (BD Pharmingen, 
Heidelberg, Germany; dilution 1:200) was performed. A secondary anti-rabbit Alexa488-
conjugated antibody (Jackson ImmunoResearch, West Grove, Pennsylvania, USA) for Ki67 
staining and secondary anti-rat Cy3-conjugated antibody (Jackson ImmunoResearch) for 
CD31 staining were used. Nuclei were counterstained with Hoechst bisbenzimide (5 mg/ml) 
and sections were embedded in Fluorescent Mounting Medium (Dako, Hamburg, Germany). 
An Axiovert 135 TV fluorescence microscope equipped with an AxioCam MRm CCD camera 
and AxioVision Re. 4.8. Software (Carl Zeiss, Munich, Germany) was used for examination of 
stained sections. 
 
Statistical methods 
All in vitro experiments were carried out in triplicate. Results are expressed as mean +/- SD 
of triplicates. Statistical significance was tested using Student´s t test. P values ≤0.05 were 
considered significant (*p≤0.05, **p≤0.01, ***p≤0.001). 
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3.4 Results 
 
Particle Sizes 
DLS measurements revealed an average particle size of 107.1 nm for LPEI-PEG-B6/NIS, 
135.3 nm for LPEI-PEG-Cys/NIS and 120.5 nm for LPEI/NIS, each with a PDI (polydisersity 
index) between 0.135 and 0.231, where 1.0 represents highest polydispersity (Fig. 1A). 
TEM measurements showed two different particle subtypes, linear and round particles in all 
three polymer solutions (LPEI-PEG-B6/NIS, LPEI-PEG-Cys/NIS and LPEI/NIS) with sizes 
between 40 and 150 nm (Fig.1 B).  
 
 
Fig. 1: (A,B) DLS measurements showed particle sizes between 107-135 nm for all three polymer solutions LPEI-
PEG-B6/NIS, LPEI-PEG-Cys/NIS and unPEGylated LPEI/NIS, demonstrating no clear difference in size (A). 
Detailed structure of polyplexes was obtained by TEM, which revealed two particle subtypes in all there solutions: 
linear (100-200 nm) and round particles (30-60 nm) (B). Experiments were performed together with Stephan 
Morys (Department of Pharmacy, Pharmaceutical Biotechnology, LMU). Adapted from [126]. 
 
Serum stability  
Polyplex stability and changes in size distribution were analyzed in 90% FBS and determined 
by DLS. Time points for size measurements were set at t=0, 1, 2, 4, 24 and 48 h. Only time 
points 0 h (red in Fig. 1 C-F), 4 h (green in Fig. 1 D-F) and 24 h (blue in Fig. 1 D-F) are 
shown, as time points 1 h and 2 h did not show any differences to time points 0 h and/or 4 h 
and no further changes were observed after 48 h compared to 24 h. 
The peak pattern of FBS can be seen in Fig. 1 C and did not change over 48 h. For all three 
polymer solutions (LPEI-PEG-B6/NIS (Fig. 1D), LPEI-PEG-Cys/NIS (Fig. 1E) and LPEI/NIS 
(Fig. 1F)) the same peaks were detected as for the polyplex-free 90% FBS solution at 0 h, 
though an additional peak >1000 nm was detected for LPEI/NIS. This peak was not seen in 
both PEGylated polyplex mixtures. After 4 h, this additional peak ranging from 1-10 µm was 
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obtained in all three polyplex solutions. No further changes in particle sizes were detected 
after 48 h. 
 
 
 
Fig. 1: (C,D) Polyplex stability and change in size distribution was analyzed in 90% FBS with DLS. The peak 
pattern of FBS did not change over 48 h (C). All three polymer solutions (LPEI-PEG-B6/NIS (D), LPEI-PEG-
Cys/NIS (E) and LPEI/NIS (F) in 90% FBS demonstrated same peaks as the pure FBS solution at 0 h (red line), 
only in the LPEI/NIS solution, a peak >1000 nm was detected, where in both PEGylated polyplex mixtures, this 
peak was not obtained. After 4 h an additional peak ranging from 1-10 µm was obtained in all three polyplex 
solutions. Experiments were performed together with Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Adapted from [126]. 
 
Tumor cell-targeted NIS gene transfer in vitro 
Transfection conditions using LPEI-PEG-B6/NIS were optimized in HuH7 cells by 
measurement of perchlorate-sensitive iodide uptake activity 24 h after application of 
polyplexes (data not shown). An optimal PEI conjugate: pDNA (c/p) ratio of 0.8 (w/w) was 
found to result in highest transfection efficiency at lowest cell cytotoxicity. This ratio was used 
in all subsequent experiments. 24 h after transfection with LPEI-PEG-B6/NIS, all three cell 
lines showed a significant increase in 125I accumulation as compared to cells incubated with 
LPEI-PEG-B6/Antisense-NIS. Transfection with untargeted LPEI-PEG-Cys/NIS polyplexes 
resulted in significantly lower iodide uptake activity in all three cell lines, exhibiting similar 
ratios of LPEI-PEG-B6/NIS to LPEI-PEG-Cys/NIS transfected cells (Fig. 2A). Furthermore, 
no perchlorate-sensitive iodide uptake above background level was observed in cells 
transfected with the empty vector LPEI-PEG-B6/HBG.  
Transfections of all three cell lines did not result in cell cytotoxicity shown by MTT assay (Fig. 
2B). 
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Fig. 2: (A,B) Iodide uptake was measured in HuH7, Hep3B and MDA-MB-231 cells following in vitro transfection 
with LPEI-PEG-B6/NIS, control polyplexes LPEI-PEG-Cys/NIS, LPEI-PEG-B6/Antisense-NIS or empty vectors 
LPEI-PEG-B6/HBG. Cells transfected with LPEI-PEG-B6/NIS showed an increase in perchlorate-sensitive 
125
I 
accumulation. After transfection with LPEI-PEG-Cys/NIS, iodide uptake was decreased to approx. 70%. No 
perchlorate-sensitive iodide uptake above background level was observed in cells transfected with LPEI-PEG-
B6/Antisense-NIS or without DNA (A). No effects on cell viability after transfections were obtained shown by MTT 
assay (B) (***p <0.001). Adapted from [126]. 
 
Cellular uptake and NIS gene expression in vitro 
To verify the advantageous targeting effect of LPEI-PEG-B6, uptake of Cy5-labeled NIS-DNA 
was measured by flow cytometry. After 45 min of polyplex incubation, HuH7 cells 
demonstrated a higher cellular uptake of LPEI-PEG-B6/NIS polyplexes compared to LPEI-
PEG-Cys/NIS (Fig. 2C), which was further demonstrated on the molecular level by analyzing 
NIS gene expression by qPCR. Cells transfected with the targeted B6-polyplex showed high 
NIS mRNA expression levels compared to cells treated with LPEI-PEG-Cys/NIS (Fig 2D).  
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Fig. 2: (C,D) Flow cytometry uptake studies with Cy5-labeled DNA revealed the beneficial targeting by B6, 
showing a marked shift towards a higher Cy5-intensity of LPEI-PEG-B6/NIS transfected cells (C).These results 
were further confirmed on molecular level, where higher NIS mRNA expression levels after transfection with LPEI-
PEG-B6/NIS could be detected by qRT-PCR in comparison to incubation with LPEI-PEG-Cys/NIS polyplexes (D). 
Adapted from [126]. 
 
Induction of iodide accumulation after systemic tumor-targeted NIS gene transfer in 
vivo 
To investigate iodide uptake activity in HuH7 tumors after systemic in vivo NIS gene transfer, 
123I biodistribution was monitored in tumor bearing mice 24 h after administration of NIS 
polyplexes (Fig. 2). High levels of iodide uptake were observed in 80% of HuH7 tumors 
following systemic injection of LPEI-PEG-B6/NIS (Fig. 2A), whereas no significant iodide 
uptake was observed in non-target organs, including lungs and liver, confirming tumor-
specificity of LPEI-PEG-B6-mediated NIS gene delivery. No iodide accumulation was 
detected in tumors after application of LPEI-PEG-B6/Antisense-NIS (Fig. 2C), and weak 
tumoral iodide accumulation was observed after application of LPEI-PEG-Cys/NIS (Fig. 2D). 
To confirm that tumoral iodide uptake was indeed NIS-mediated, LPEI-PEG-B6/NIS-injected 
mice received sodium-perchlorate (2 mg, i.p.) 30 min prior to 123I administration, which almost 
completely blocked tumoral iodide accumulation in addition to the physiological iodide uptake 
in stomach and thyroid gland (Fig. 2B). As determined by serial scanning, approximately 
8.0±1.5% ID/g 123I was accumulated in NIS-transduced tumors with a biological half-life of 4 h 
after application of LPEI-PEG-B6/NIS (Fig. 2E). Considering a tumor mass of 1 g and an 
effective half-life of 6 h for 131I, a tumor-absorbed dose of 50 mGy/MBq 131I was calculated.  
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Fig. 3: Gamma-camera imaging of mice harboring HuH7 tumors 3 h after an i.p. injection of 18.5 MBq 
123
I 24 h 
after LPEI-PEG-B6-mediated NIS gene delivery
 
revealed significant tumor-specific iodide accumulation (A), which 
was completely abolished upon pretreatment with perchlorate (B). In contrast, mice treated with control 
polyplexes LPEI-PEG-B6/Antisense-NIS (C) or LPEI-PEG-Cys/NIS (D) showed no significant tumoral iodide 
uptake. Iodide was also accumulated physiologically in thyroid, stomach and bladder (A, C, D). 
Serial 
123
I-scanning of HuH7 tumors after systemic LPEI-PEG-B6-mediated NIS gene delivery was detected over 
time with a maximum tumoral iodide uptake of 8.0±1.5% ID/g tumor with a biological half-life of 4 h (E). Adapted 
from [126]. 
 
Analysis of NIS protein expression in HuH7 tumors 
Immunofluorescence analysis of HuH7 tumors after systemic application of LPEI-PEG-
B6/NIS revealed an intense heterogeneous staining pattern of membrane-associated NIS-
specific immunoreactivity (Fig. 4A, arrows), whereas LPEI-PEG-Cys/NIS (Fig. 3B) treated 
mice showed much less tumoral NIS expression. In contrast, HuH7 tumors of mice treated 
with LPEI-PEG-B6/Antisense-NIS showed no evident NIS-specific immunoreactivity (Fig. 
4C).  
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Fig. 4: (A-C) Immunofluorescence staining of HuH7 tumors 24 h after LPEI-PEG-B6/NIS application using a hNIS 
specific antibody showed clusters of primarily membrane-associated NIS-specific immunoreactivity (A). In 
contrast, HuH7 tumors treated with the control polyplexes (LPEI-PEG-Cys/NIS (B), LPEI-PEG-B6/Antisense-NIS 
(C)), did not reveal NIS-specific immunoreactivity. Magnification: 100x. Adapted from [126]. 
 
Analysis of NIS mRNA expression by quantitative real-time PCR analysis 
NIS mRNA level 24 h after systemic NIS gene transfer were analyzed on various tissues by 
quantitative real-time PCR (qPCR) with a pair of NIS-specific oligonucleotide primers. High 
levels of NIS gene expression were induced in HuH7 tumors after systemic injection of LPEI-
PEG-B6/NIS (Fig. 4D), whereas only low background levels were detected after application 
of LPEI-PEG-B6/Antisense-NIS and LPEI-PEG-Cys/NIS. As expected, administration of the 
competitive NIS inhibitor sodium-perchlorate had no influence on NIS mRNA expression in 
NIS-transduced tumors. Furthermore, analysis of non-target organs such as lungs and liver, 
showed no significant NIS mRNA expression above background level (Fig. 4D). 
 
 
Fig. 4: (D) Analysis of human NIS mRNA expression by qPCR demonstrated high levels of NIS mRNA in HuH7 
tumors after systemic LPEI-PEG-B6-mediated NIS gene transfer with or without sodium-perchlorate pretreatment. 
Only a low background level of NIS mRNA expression was detected in untreated tumors, which was set as one 
arbitrary unit. Moreover, no significant NIS expression above background level was found in tumors after 
application of LPEI-PEG-B6/Antisense-NIS and LPEI-PEG-Cys/NIS, whereas non-target organs showed no 
significant NIS mRNA expression after treatment of LPEI-PEG-B6/NIS. Adapted from [126]. 
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Radioiodine therapy studies after in vivo NIS gene transfer 
24 h after systemic administration of polyplexes, a therapeutic dose of 55.5 MBq 131I or saline 
was administered (days 0/1). The cycle consisting of systemic NIS gene transfer followed by 
radioiodine was repeated three times on days 3/4, 7/8 and 14/15. Mice treated with LPEI-
PEG-B6/NIS and 131I showed a significant delay in tumor growth as compared to all control 
groups (Fig. 5A). While all the mice in the control groups had to be killed within 3 weeks after 
the onset of the experiments due to excessive tumor growth, 70% of mice in the therapy 
group survived up to 5 weeks after therapy start (Fig. 5B).  
 
 
Fig. 5: (A,B) Radioiodide treatment of HuH7 tumors after systemic polyplex-mediated NIS gene transfer in vivo. 
24 h after i.v. polyplex injection (small arrow), 55.5 MBq 
131
I were injected i.p. (big arrow). This treatment cycle 
was repeated on days 3/4, 7/8 and 14/15. 
131
I therapy after systemic LPEI-PEG-B6/NIS application resulted in a 
significant delay in tumor growth (A) which was associated with markedly improved survival (B, Kaplan-Meier-plot) 
as compared to control groups that were injected with saline only, with LPEI-PEG-B6/NIS followed by saline 
application, or with LPEI-PEG-B6/Antisense-NIS followed by 
131
I application. Adapted from [126]. 
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Immunofluorescence analysis 
Three to four weeks after treatment, mice were sacrificed, tumors were dissected and 
processed for immunofluorescence analysis using a Ki67-specific antibody (green) to identify 
tumor cell proliferation and an antibody against CD31 (red) to label blood vessels (Fig. 5). 
NIS-transduced tumors (LPEI-PEG-B6/NIS) (Fig. 5C) exhibited a considerably lower 
intratumoral blood vessel density and proliferation index after 131I therapy compared to 
tumors of mice that received saline instead of 131I (Fig. 5D).  
 
 
Fig. 5: (C,D) Immunofluorescence analysis using a Ki67-specific antibody (green) and an antibody against CD31 
(red, labeling blood vessels) showed significantly decreased proliferation and blood vessel density in NIS-
transduced tumors following 
131
I treatment (A) as compared to tumors of mice that received saline instead of 
131
I 
(B). Tumor sections were counterstained with Hoechst. Magnification 100x. Adapted from [126]. 
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3.5 Discussion 
 
The growing global incidence of cancer [127] together with increasing resistance to 
conventional chemo- and/or radiotherapy result in limited success of cancer therapy 
concepts [128], thus highlighting the importance to develop novel therapeutic alternatives, 
especially for HCC, where a high percentage of patients is diagnosed at a late stage when 
no curative therapies are available [98]. 
The existing therapeutic concept for differentiated thyroid cancer using the ionizing radiation 
of 131I to induce toxic effects in cancer cells represents an efficient strategy with high 
response rates, which are mirrored by the low mortality of patients even in metastatic stage 
[25]. The thyroidal expression of NIS that is maintained in the majority of differentiated 
thyroid cancer cells enables uptake of various radionuclides (123I, 125I, 124I, 131I, 188Re, 211At) 
into the cell. This capability of concentrating iodide forms the molecular basis for multimodal 
non-invasive imaging of functional NIS expression by 123I-scintigraphy and 124I-/18F-
tetrafluoroborate positron emission tomography (PET), as well as exact dosimetric 
calculations before proceeding to therapeutic application of 131I [27, 50, 51, 129, 130]. After 
identification and cloning of NIS in 1996 [29, 30], it was possible, to transfer this beneficial 
and powerful concept of image-based targeted therapy to other tumor types and opened the 
prospect of radioiodide therapy in non-thyroidal tumor tissues. Preclinical and first clinical 
applications of NIS (NCT00788307, NCT01846091, NCT02068794) [49, 131] as theranostic 
gene have been intensively investigated and several research groups, including our own, 
have shown the feasibility and the enormous potential of NIS for the treatment of different 
extra-thyroidal cancer types after systemic gene delivery, including cellular (mesenchymal 
stem cells), virus- and polymer-based gene delivery vehicles [35-40, 42-46]. Based on the 
extensive experience gained over the last decades in the clinical application of radioiodide in 
thyroid cancer patients, the NIS gene therapy approach offers a promising new alternative in 
the treatment of cancer together with an already well-known therapeutic window, which, in 
addition, allows adjustment of dosage in a personalized manner with respect to individual 
tumor radio-responsiveness, co-morbidities and side effects in patients. 
However, using radioiodide to detect and treat distant cancer metastases requires improved 
efficiency of systemic gene delivery systems to ensure sufficient functional tumor-selective 
NIS expression. For in vivo gene delivery, a series of additional extracellular barriers have to 
be considered. Interactions of particles with plasma proteins, erythrocytes or non-target 
tissues, aggregation and clearance of transfection particles by the reticuloendothelial system 
(RES) and the restricted extravasation of transfection particles from the bloodstream limit the 
availability of relevant substances in target tissues [132]. The key feature of non-viral gene 
delivery vehicles for systemic administration is the formation of stable and non-toxic vectors 
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that can compact and sufficiently deliver genetic materials specifically into tumor cells with 
high efficiency [70, 133]. LPEI (with average molecular weight of 22 kDa), the “gold standard” 
of PEI-based gene carriers, shows remarkable transfection efficiency along with high stability 
of DNA complexes. Since LPEI exhibits dose dependent cytotoxicity, a more biocompatible 
system was developed by inserting a short PEG chain to reduce interactions with blood 
components. Recent advances in the identification of the ideal shielding agents with optimal 
molecular weight led to improved carries with high delivery performance and reduced 
cytotoxicity (LPEI-PEG2kDa) [119]. The advantage of short PEG chains was also highlighted 
in most recent work [76, 134]. LPEI-PEG2kDa as biocompatible and technically feasible 
starting point for complete synthetic targeting conjugates was further modified by biological 
targeting strategies to direct these synthetic gene delivery particles towards the tumor site by 
taking advantage of the special architecture of tumors and unique tumor properties [39, 88, 
119]. Tumor cells are often characterized by a high proliferation rate and subsequent up-
regulation of growth factor receptors such as EGFR, cMET or TfR characteristic for rapidly 
dividing cells. Therefore, tumor targeting ligands were applied that recognize their cognate 
receptors on the cell membrane of target cells, resulting in receptor-mediated endocytosis of 
polyplexes. Cell-targeting ligands included vitamins, carbohydrates, peptides, proteins and 
antibodies [56, 83, 135-139].  
In consideration of pharmaceutical production, the use of whole protein ligands such as 
transferrin or EGF may be challenging in advanced synthesis and storage stability of LPEI 
conjugates. For a future medical application, synthetic systems such as small specific 
targeting peptides would be favorable [88]. The short peptide B6, which was originally 
isolated as TfR-specific ligand in a phage display array [122], was selected as targeting 
ligand for this study and coupled to the LPEI-PEG-platform. Former studies have already 
demonstrated the strong tumor cell binding promoting capacity of B6 [68, 88, 140], which 
resulted in a high tumor-specific gene delivery, and makes B6 a promising and interesting 
ligand for improving the concept of NIS gene delivery. However, as recent studies discovered 
that the corresponding receptor is most probably different from TfR, exact binding and 
interaction mechanisms of B6 remain unclear [123].  
But even without knowing the exact cellular receptor, on the basis of the outstanding tumor 
cell binding capacity of the B6 ligand and with the focus of a possible future combination of 
two subsidiary targeting ligands to mimic the potent dual-receptor binding concept of viruses 
[68], B6 serves as promising ligand for further optimization of the NIS gene therapy concept.  
For characterization of LPEI-PEG-B6/NIS and evaluation of a possible impact of the PEG 
shielding domain and the B6 ligand on particle size, shape and stability, DLS and TEM 
measurements were performed. DLS revealed particles of 107 nm in size for LPEI-PEG-
B6/NIS polyplexes in comparison to 135 nm for LPEI-PEG-Cys/NIS polyplexes. These minor 
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differences in size were further examined by TEM, which revealed two different particle 
types: round and linear formed particles with no clear difference between LPEI-PEG-B6/NIS, 
LPEI-PEG-Cys/NIS and LPEI/NIS polyplexes. The combination with PEG as shielding agent 
to obtain longer circulation and reduced interactions with blood components [138] did not 
result in any alterations in size or shape in comparison to the PEG-free LPEI/NIS polyplexes. 
Building on these results, the size of polyplexes does not seem to be a crucial parameter for 
transfection efficiency both in vitro and in vivo, as particles <200 nm are postulated to be 
taken up into cells by clathrin dependent pathways, our particle sizes lay in the scope of 
being internalized by an active pathway [62].  
In addition to polyplex size, behavior and stability of polyplexes after systemic application is a 
major point that influences efficiency of targeted LPEI-PEG-B6-mediated gene transfer. 
Interactions with serum components after systemic application may lead to aggregation 
and/or DNA degradation and hence to diminished targeted gene transfer and gene 
expression. Polyplex stability was analyzed in 90% FBS by DLS over 48 h. As internal 
control 90% FBS without polyplexes was measured. No change in peak formation was 
observed over 48 h. Solutions containing polyplexes showed the same pattern of peaks as 
the 90% FBS control. As the main polyplex peak is expected to be at 50-150 nm, likely the 
second FBS peak mashed the polyplex peak, which lies in the same region. In the LPEI/NIS 
polyplex solution a peak >1000 nm was detected at 0 h, whereas in both PEGylated polyplex 
mixtures (LPEI-PEG-B6/NIS and LPEI-PEG-Cys/NIS), this peak was not seen, confirming 
findings that non-PEGylated polyplexes are less stable than PEGylated ones [56]. After 4 h, 
this additional peak ranging from 1-10 µm was found in all three polyplex solutions. No 
further changes in particle sizes were detected after 48 h. These results demonstrate that a 
high amount of our compact polyplexes exhibit a long stability (4-24 h), with no fast and 
major aggregation or dissociation in serum, suggesting lasting stability, which is a 
prerequisite for tumor targeting and retention in tumor tissues. 
To evaluate the capability of B6 as targeting ligand for non-viral NIS gene delivery, the 
reporter function of NIS was used to demonstrate tumor-specific NIS-mediated iodide uptake. 
LPEI-PEG-B6 polymers were complexed with human NIS (hNIS) cDNA under the control of 
the strong human elongation factor 1 alpha promoter and in vitro transfection of three 
different tumor cell lines resulted in significantly increased iodide uptake activity. A 
significantly lower uptake was obtained in cells that were treated with polyplexes where the 
targeting ligand was replaced by cysteine (LPEI-PEG-Cys/NIS).  
To further investigate the beneficial targeting using B6 polyplexes that was observed in the 
iodide uptake assay, cell uptake studies with labeled DNA were performed to compare 
specific polyplex-mediated transfection of targeted LPEI-PEG-B6/NIS and untargeted LPEI-
PEG-Cys/NIS in HuH7 cells. The advantageous conjugation to the ligand could be verified by 
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a higher Cy5 activity in LPEI-PEG-B6/NIS transfected cells. qPCR complemented these 
results by showing higher NIS mRNA expression levels in LPEI-PEG-B6/NIS treated cells. 
After this proof of concept by in vitro studies, the diagnostic function of NIS was further used 
for demonstration of vector biodistribution and functional NIS expression in vivo. Mice 
carrying HuH7 xenografts showed a tumor-specific 123I accumulation of 8.0±1.5 % ID/g with a 
biological half-life of 4 h and a tumor absorbed dose of 50 mGy/MBq 131I 24 h after an i.v. 
injection of LPEI-PEG-B6/NIS. In line with these results, tumors of animals that received 
untargeted LPEI-PEG-Cys/NIS polyplexes showed significantly lower tumoral iodide uptake, 
further confirming the ligand-mediated enhanced tumor specificity of LPEI-PEG-B6. The low, 
but measurable iodide uptake activity in HCC tumors after LPEI-PEG-Cys/NIS treatment 
suggests that passive tumor targeting due to the “enhanced permeability and retention-
effect” is sufficient for a low level of tumoral NIS transduction [81], which can be significantly 
increased after coupling to the tumor specific ligand B6. Besides tumoral uptake, significant 
radioiodine accumulation was observed in tissues physiologically expressing NIS, including 
stomach and thyroid, as well as in the urinary bladder (average of approximately 10% ID, 
depending on diuretic activity) due to elimination of radioiodine through the kidneys. NIS 
specificity could be confirmed by pretreatment with the NIS-specific inhibitor perchlorate, 
resulting in an almost complete inhibition of radioiodide uptake in the tumor and tissues that 
physiologically express NIS. Results of both in vitro and in vivo experiments using the B6 
ligand strongly underline the high tumor specificity and ligand-dependent uptake of 
polyplexes, especially when comparing to unspecific LPEI-PEG-Cys/NIS polyplexes by using 
the reporter function of NIS.  
In addition, NIS-mediated uptake could further be confirmed by immunohistochemical 
staining of human NIS protein in tumor sections. LPEI-PEG-B6-treated mice exhibited NIS-
specific immunoreactivity in tumor tissue, which was primarily membrane-associated and 
occurred in clusters. The patchy staining pattern nicely correlates with earlier experiments 
using G2-HD-OEI polyplexes for systemic NIS gene transfer in a syngeneic neuroblastoma 
mouse model [38] and with a study using EGFR-targeted polymers (LPEI-PEG-GE11) for 
targeting the NIS gene to HCC xenografts. 
As next step, the therapeutic impact of radioiodide after B6-mediated gene transfer was 
tested. The systemic NIS gene transfer, which resulted in tumor-specific iodide uptake 
activity in HCC tumor-bearing mice, was sufficiently high for a significant therapeutic effect of 
131I. The used beta-emitting radioisotope 131I exhibits a high bystander effect, based on the 
crossfire effect of 131I, which had a cytotoxic effect not only in transfected cells, but even 
proximate cells (2.4 mm). After four cycles of systemic polyplex application followed by 131I 
injection, tumor-bearing mice showed a significant delay of tumor growth associated with a 
significantly prolonged survival for up to 40 days after therapy onset and convincingly prove 
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the promising tumor specific targeting effect of nonviral delivery systems coupled to the 
targeting ligand B6.  
The applied therapy scheme consisting of 4 treatment cycles was applied in reference to 
commonly used multi-cycle treatment schemes used in current anti-cancer treatments. As 
immunohistochemical staining revealed heterogeneous NIS staining, we aimed at optimizing 
NIS transduction levels by repetitive NIS gene transfer into the heterogeneous tumor tissue 
in order to optimize therapeutic efficacy [141-143].  
Due to the persistent and growing problem of drug resistance in cancer treatment, it is 
becoming more difficult to apply and develop efficient therapy concepts [144, 145]. Various 
processes that result in decreased response to drug-induced tumor cell growth inhibition are 
hypothesized, including altered membrane transport, modified genetic responses, as well as 
induced changes in expression levels of growth factor receptor [145]. Therefore, even for the 
new method of a cytoreductive gene therapy approach based on NIS gene delivery, the 
evaluation of novel targeting ligands is of high relevance to have a broad ligand-portfolio for 
the treatment of different cancer types with variable receptor expression and back-up 
alternatives for ligands, when resistance or decreased receptor expression occurs.  
Regardless of the exact resistance mechanism, one of the most powerful strategies to 
circumvent resistance is the combination of different therapy strategies. In this context, a 
future dual combination of ligands may not only increase the efficacy of the therapy 
approach, but as well minimize the possibility of non-response by targeting two different 
receptor pathways. We have already investigated the EGFR-specific non-viral NIS gene 
delivery using GE11 as ligand coupled to the LEI-PEG-backbone. High transduction 
efficiency of LPEI-PEG-GE11/NIS was confirmed by significant EGFR-specific iodide 
accumulation both in vitro and in vivo resulting in significant delay of tumor growth associated 
with prolonged survival of animals after therapeutic application of 131I [40]. Levels of specific 
tumor accumulation and therapeutic efficacy of NIS gene transfer mediated by non-viral 
delivery vehicles with the targeting ligand B6, are comparable to the study using the EGFR-
specific ligand GE11 [39], thus opening the exciting prospect of a future combination of these 
two highly effective ligands for multiple target sites.  
Tumor localization may have an impact on results due to differences in blood vessel density 
and permeability and infiltration of macrophages, which abolish DNA [79]. Consequently, as 
a next step toward clinical application, we are currently planning to investigate the efficacy of 
our LPEI-PEG-B6/NIS polyplexes in an advanced orthotopic HCC tumor model or 
metastases model that better reflect the natural tumor environment, including 
microenvironment and stroma, of HCC patients and therefore allows a better prediction of 
therapy outcome.  
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In conclusion, the current study demonstrated that using B6 as targeting ligand for systemic 
NIS gene delivery shows considerable promise for effective tumor targeting with high levels 
of NIS gene and protein expression that lead to a strong therapeutic effect of radioiodide. 
This paves the way for the use of B6-targeted non-viral delivery vehicles to specifically 
introduce NIS to cancer tissue even in a combinatorial ligand set-up depending on the 
individual receptor expression and represents an innovative concept to improve efficacy and 
safety of systemic NIS gene delivery in a broad range of cancer types. 
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4.1 Abstract 
 
Liver metastases present a serious problem in the therapy of advanced colorectal cancer 
(CRC), as more than 20% of patients have distant metastases at the time of diagnosis with 
less than 5% being cured. Consequently, new therapeutic approaches are of major need 
together with high-resolution imaging methods that allow highly specific detection of small 
metastases. 
The unique combination of reporter and therapy gene function of the sodium iodide 
symporter (NIS) may represent a promising theranostic strategy for CRC liver metastases 
allowing non-invasive imaging of functional NIS expression and therapeutic application of 131I.  
For targeted NIS gene transfer polymers containing linear polyethylenimine (LPEI), 
polyethylene glycol (PEG) and the epidermal growth factor receptor (EGFR)-specific ligand 
GE11 were complexed with human NIS DNA (LPEI-PEG-GE11/NIS). Tumor specificity and 
transduction efficiency were examined in high EGFR-expressing LS174T metastases by non-
invasive imaging using 18F-tetrafluoroborate (18F-TFB) as novel NIS PET tracer. Mice that 
were injected with LPEI-PEG-GE11/NIS 48 h before 18F-TFB application showed high 
tumoral levels (4.8±0.6% of injected dose) of NIS-mediated radionuclide uptake in 
comparison to low levels detected in mice that received untargeted control polyplexes. Three 
cycles of intravenous injection of EGFR-targeted NIS polyplexes followed by therapeutic 
application of 55.5 MBq 131I resulted in marked delay in metastases spread, which was 
associated with improved animal survival. 
In conclusion, these preclinical data confirm the enormous potential of EGFR-targeted 
synthetic polymers for systemic NIS gene delivery in an advanced multifocal CRC liver 
metastases model and open the exciting prospect of NIS-mediated radionuclide therapy in 
metastatic disease. 
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4.2 Introduction 
 
Metastatic dissemination of tumor cells is mostly responsible for the high mortality of patients 
with colorectal cancer (CRC), especially due to late diagnosis. Although the incidence of 
CRC is decreasing, CRC is the third leading cause of cancer-related death worldwide [45, 
127, 146]. For early stages, surgical resection represents the first-line therapy concept, while 
in advanced stages a combination of surgical resection and chemotherapy are applied. As 
the 5-year survival of patients at the metastatic stage is about 6%, new potent therapeutic 
options are highly important [147].  
For evaluation of novel CRC therapy approaches, especially in metastatic disease, it is a 
prerequisite to have models that give a detailed reflection of the morphological and molecular 
situation of cancer. Therefore, the establishment of advanced preclinical models that mimic 
human metastases, tumor microenvironment and tumor stroma are indispensable to obtain a 
valuable prediction of the therapeutic efficacy of new treatment strategies for a future 
application in humans [148, 149]. To this end, a human colon carcinoma metastases model 
was established by injecting CRC cells directly into the spleen. This resulted in induction of 
multifocal liver metastases highly similar to the metastatic process in humans, where the liver 
represents the most common metastatic site in patients with CRC [150].   
A new evolving sector in cancer treatment is based on gene therapy [11], as utilizing and 
manipulating the particular biological characteristics of tumor cells provide a wide range of 
possible interactions to target different steps of the carcinogenesis process. In recent years 
there have been many attempts to knock out genes that are involved in tumor formation, 
growth and dissemination, to introduce suicide genes as well as inserting new genes 
containing specific anti-tumoral functions [10]. In this regard, the sodium iodide symporter 
(NIS) represents an advantageous and highly efficient target gene, as functional NIS gene 
expression allows exact localization of the tumorous tissue by administration of NIS specific 
tracers such as 123I, 124I and the novel NIS positron-emissions-tomography (PET) tracer 18F-
tetrafluoroborate (18F-TFB) and at the same time gives the possibility of cytotoxic radioiodide 
treatment.  
This dual concept, which is based on the iodide uptake activity of NIS [30], was proven by 
several groups including our own using a broad spectrum of gene delivery vehicles, such as 
viral vectors, mesenchymal stem cells and non-viral polymer-based vectors [27, 35-45, 47, 
92, 93, 129]. Especially non-viral polymeric vehicles proved to be advantageous both 
technically and biologically due to the ease of adjusting chemical properties of synthetic 
particles for increased efficacy and biocompatibility [9, 12]. A modular synthesis concept 
allows incorporation of functional groups, such as polyethylene glycol (PEG) to achieve 
shielding against blood components in vivo and polymers can specifically be designed to 
  Theranostic treatment of CRC metastases 
43 
 
interact with individual tumor tissue properties to achieve tumor specific targeting [119]. To 
this end, polymers were coupled to ligands that bind to receptors overexpressed on the 
tumor cell, which results in tumor-directed uptake of delivery vehicles and minimizes off-
target effects. In former studies, we tested polyplexes with an EGFR-specific targeting 
peptide (GE11) as NIS gene delivery vehicles in a subcutaneous HuH7 xenograft tumor 
model [39] as well as in orthotopic pancreatic ductal adenocarcinoma [151], which resulted in 
high tumor-specific NIS-mediated iodide accumulation.  
To take the next step in the translation of this novel theranostic NIS gene strategy from 
laboratory scale to the clinical situation, in the current paper, we applied the NIS pDNA 
polyplexes in a high EGFR-expressing tumor model of metastatic colorectal cancer. This 
setting mimics the complex and functional environment of metastases including tumor stroma 
and tumor microenvironment and serves as ideal model for evaluation of the feasibility of the 
NIS gene therapy concept after EGFR-targeted nonviral gene transfer. In addition, the 
combination with the novel NIS PET tracer 18F-TFB as improved diagnostic tool is utilized for 
optimized localization of single metastases and the therapeutic potency after application of 
131I is evaluated.  
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4.3 Materials and methods 
 
Cell culture 
The human colon carcinoma cell line LS174T (ATCC-CCL188; American Type Culture 
Collection, Manassas, VA) was cultured in Eagle's Minimum Essential Medium (EMEM; 
Sigma-Aldrich, St.Louis, MO) supplemented with 10% (v/v) fetal bovine serum (FBS 
Superior, Biochrom/Merck Milipore, Berlin, Germany), 5% (v/v)  L-glutamine (Sigma-Aldrich) 
and 1% (v/v)  penicillin/streptomycin (Sigma-Aldrich). Cells were maintained at 37°C and 5% 
CO2 in an incubator with 95% humidity. Cell culture medium was replaced every second day 
and cells were passaged at 80% confluency. 
 
Plasmid and polymer synthesis and polyplex formation 
Polymer syntheses were carried out by Stephan Morys and Wolfgang Rödl (Department of 
Pharmacy, Pharmaceutical Biotechnology, LMU). Polymers with LPEI-PEG backbone 
(EGFR-targeted: LPEI-PEG-GE11; control polymer without ligand: LPEI-PEG-Cys) and 
codon-optimized human NIS cDNA (NIS pDNA) were synthesized as described previously 
[39, 46]. Polymers and cDNA were diluted in same volumes of HEPES (2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid)-buffered glucose (HBG: 20 mmol/l HEPES, 
5% (w/v) glucose at pH 7.4) at a N/P ratio of 6 (w/w). Polymers were added to the DNA by 
rapid mixing and incubated at room temperature for 20 min prior use [124]. For in vitro 
studies the concentration of DNA for polyplex formation was 2 µg/ml, for in vivo studies 
200 µg/ml.  
 
EGFR expression levels in vitro  
1 × 106 LS174T cells were detached with trypsin, centrifuged and incubated with an EGFR-
specific antibody (1:100; monoclonal mouse IgG1 - Dako, Glostrup, Denmark) or with an IgG-
anti-mouse antibody (BD Bioscience, Franklin Lakes, USA) as negative control in FACS 
buffer (PBS with 10% FBS) for 1 h on ice. Cells were washed with FACS buffer and 
incubated with an AlexaFluor 488 labeled goat anti-mouse secondary antibody (1:400 - 
Invitrogen, Langenselbold, Germany) for 1 h on ice. After washing, cells were resuspended 
in FACS buffer and flow cytometry analysis was performed on a BD Accuri C6 flow cytometer 
(BD Bioscience, Franklin Lakes, USA). Cells were gated by forward/sideward scatter and 
pulse width for exclusion of doublets. PI (propidium iodide, Sigma-Aldrich) was used for 
discrimination between viable and dead cells.  
 
Transfection studies 
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CRC cells LS174T were plated at a density of 1×106 cells per well, grown to 60 - 80% 
confluency in 6-well plates and incubated for 24 h with either LPEI-PEG-GE11/NIS, LPEI-
PEG-Cys/NIS or empty polymer LPEI-PEG-GE11/HBG. Transfection efficiency was 
determined by measurement of iodide uptake activity at steady-state conditions as described 
previously [47]. Results were normalized to cell survival measured by cell viability assay (see 
below) and expressed as cpm/A620. 
 
Cell viability assay 
Cell viability after transfection was analyzed after incubation of cells with a commercially 
available MTT reagent (Sigma-Aldrich) for 2 h at 37°C followed by a washing step with PBS 
(phosphate-buffered saline). The formazan product was measured after incubation with 10% 
DMSO (v/v) (dimethyl sulfoxide) in isopropanol at 620 nm in a Sunrise microplate 
absorbance reader (Tecan, Männedorf, Switzerland). 
 
Establishment of hepatic colorectal metastases in nude mice 
For the establishment of CRC metastases in female CD-1 nu/nu mice (Charles River, 
Sulzfeld, Germany), animals were fully anesthetized and after laparotomy, 50 µl of tumor cell 
suspension (1×106 cells in 1×PBS) was injected into the upper splenic pole. After 3 days, the 
abdominal wall was re-opened at the same site and a splenectomy was performed. Mice 
were pre- and post-treated with Metacam (0.5 mg/kg) to minimize wound pain and reduce 
risk of inflammation. 2-3 weeks after intrasplenic injection mice bore multifocal liver 
metastases. Mice were sacrificed when healthy liver tissue reached less than 30%, in case of 
weight loss of more than 10% of initial weight, or when impairment of breathing, drinking or 
eating behavior was observed. Animals were maintained under specific pathogen-free 
conditions with access to mouse chow and water ad libitum. The experimental protocol was 
approved by the regional governmental commission for animals (Regierung von Oberbayern) 
and all animal experiments were carried out according to the guidelines of the German law of 
protection of animal life. 
 
EGFR-immunohistochemistry staining 
Immunohistochemistry staining of EGFR on paraffin-embedded tumor tissue was performed 
as described previously [152]. 
 
PET imaging studies after systemic NIS gene transfer in vivo 
Experiments started 2-3 weeks after intrasplenic injection of tumor cells. To demonstrate 
tumor-specific NIS expression in vivo, mice received polyplexes systemically via the tail vein 
(i.v.) at a DNA dose of 2.5 mg/kg (50 μg DNA in 250 μL HBG). Mice were treated as follows: 
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(1) LPEI-PEG-GE11/NIS (n=5); (2) LPEI-PEG-Cys/NIS (n=3); (3) LPEI-PEG-GE11/NIS + 
NaClO4 (n=2): pretreatment with an i.p. injection of 2 mg of the competitive NIS inhibitor 
sodium perchlorate (NaClO4) 30 min before PET tracer administration. 48 h after polyplex 
injection the novel NIS PET tracer 18F-TFB (10 MBq; synthesized by the Radiopharmacy, 
Klinikum rechts der Isar, TU Munich, as described previously [96]) was applied i.v. and tracer 
accumulation in metastatic liver areas was determined by small-animal PET (Inveon, 
SIEMENS Preclinical Solutions, Erlangen, Germany). Regions of interest were analyzed with 
the software Inveon Acquisition Workplace (Siemens) and quantified using Inveon Research 
Workplace (Siemens) and expressed as a fraction of the total amount of initial dose (% of 
ID). The retention time of the tracer 18F-TFB within metastases was determined by serial 
scanning after 0.5 h, 1 h and 2 h. To suppress thyroidal iodide uptake, a 10-day pretreatment 
with L-thyroxin (L-T4; 5 mg/ml; Sigma-Aldrich) in drinking water was conducted before PET-
imaging.  
 
Analysis of NIS mRNA expression by quantitative real-time PCR 
For quantification of NIS expression in metastatic tissue, total RNA was isolated using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
recommendations. Reverse transcription was performed using SuperScript III First-Strand 
Synthesis System (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Quantitative 
real-time PCR was run with the QuantiTect SYBR Green PCR Kit (Qiagen) in a Mastercycler 
ep gradient S PCR cycler (Eppendorf, Hamburg, Germany). Relative expression levels were 
calculated from ΔΔCt values normalized to internal β-actin. As primers, the following 
sequences were used: 
hNIS: (5’ACACCTTCTGGACCTTCGTG-3’) and (5’-GTCGCAGTCGGTGTAGAACA-3’),  
β-Actin: (5’AGAAAATCTGGCACCACACC-3’) and (5’-TAGCACAGCCTGGATAGCAA-3’). 
 
Immunohistochemistry analysis of NIS protein expression 
Immunohistochemical staining of paraffin embedded tumor tissue derived from hepatic 
metastases sections after NIS gene delivery were performed using a mouse monoclonal 
antibody directed against human NIS (kindly provided by John C Morris, Mayo Clinic, 
Rochester, MN, USA) as described previously [42, 153]. Immunohistochemically stained 
sections were imaged on an Olympus BX41 microscope equipped with an Olympus XC30 
CCD camera (Olympus, Shimjukum Tokio, Japan). 
 
Radioiodide therapy studies 
Therapy trials were started two weeks after intrasplenic injection, when mice showed low 
hepatic metastases load (<20%), which was determined by CEUS. To this end, animals were 
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injected i.v. with either LPEI-PEG-GE11/NIS followed by an i.p. application of 55.5 MBq 131I 
or saline 48 h later or received saline only (LPEI-PEG-GE11/NIS + 131I (n=9); LPEI-PEG-
GE11/NIS + NaCl (n=9); NaCl + NaCl (n=9)). The cycle consisting of systemic NIS gene 
transfer followed by radioiodide was repeated for a total of three times on days 0/2, 3/5 and 
7/9.  
Hepatic colorectal metastases load was monitored by CEUS as described by Eichhorn et al. 
[154]. CEUS was performed on an Acuson Sequoia 512 (Siemens) in combination with a 
15L8W ultrasound probe using the Cadence contrast pulse sequencing technology. 
Metastases were imaged in brightness-mode with a frequency of 14 MHz and a mechanical 
index of 0.2 or less. The contrast agent SonoVue (Bracco, Milano, Italy) was applied via a tail 
vein catheter. Hepatic contrast agent distribution and accumulation in normal liver tissue and 
metastases was recorded on digital cine clips before and up to 30 s after the application of 
the contrast agent at a frame rate of 8-10 Hz. Digital cine clips were exported in a Digital 
Imaging and Communications in Medicine (DICOM) format for off-line analysis with VueBox 
(Bracco Suisse, Geneve, Switzerland) using a bolus kinetic model as described previously 
[45]. In a blinded experimental set-up, hepatic metastases load was estimated by an 
experienced radiologist with more than 16 years’ experience in CEUS measurement using 
high-end ultrasound devices. For estimation of perfusion and contrast agent uptake, region of 
interests were drawn around the entire liver of each animal. The contrast agent concentration 
was estimated using pre-defined calibration curves [154]. 
Two independent therapy trials were conducted. For the first trial, the follow-up CEUS 
measurements were performed on days 8 and 12 after therapy start, in the second therapy 
trial a single follow-up CEUS measurement was performed on day 5. For evaluation of 
sonographic parameters, only animals from the second therapy trial with CEUS 
measurement on day 5, where clips were analyzable due to  hepatic in-flow of the contrast 
agent, were included in calculations to enable a parallel comparison of all three treatment 
groups (LPEI-PEG-GE11/NIS + 131I (n=2); LPEI-PEG-GE11/NIS + NaCl (n=2); NaCl + NaCl 
(n=3)).   
 
Indirect immunofluorescence assay 
Immunofluorescence staining was performed on dissected frozen tumor tissues as described 
previously [46]. A rabbit polyclonal antibody against human Ki67 (Abcam, Cambridge, UK; 
dilution 1:1000) and a rat monoclonal antibody against mouse CD31 (BD Pharmingen, 
Heidelberg, Germany; dilution 1:200) were used. For detection, an anti-rabbit Alexa488-
conjugated secondary antibody (Jackson ImmunoResearch, West Grove, Pennsylvania, 
USA) for Ki67 staining and an anti-rat Cy3-conjugated secondary antibody (Jackson 
ImmunoResearch) for CD31 staining were applied. Nuclei were counterstained with Hoechst 
  Theranostic treatment of CRC metastases 
48 
 
bisbenzimide (5 mg/ml) and sections were embedded in Fluorescent Mounting Medium 
(Dako, Hamburg, Germany). ImageJ software (NIH) was used for quantification of 
proliferation (Ki67-staining) and blood vessel density (CD31-staining) by analyzing 6 visual 
fields per metastatic liver section of every mouse. 
 
Statistics 
All in vitro experiments were carried out at least in triplicates. Results are expressed as mean 
± SEM, mean fold change ± SEM and, for survival plots, in percent. Statistical significance 
was calculated by two-tailed Student’s t-test. P values ≤0.05 were considered significant 
(Student’s t-test: *p≤0.05; **p≤0.01; ***p≤0.001). For therapy studies, in addition, Mann-
Whitney U test was performed. P values ≤0.05 were considered significant (Mann-Whitney U 
test: #p≤0.05; ##p≤0.01; ###p≤0.001). 
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4.4 Results 
 
NIS-mediated iodide uptake studies in vitro 
To evaluate optimal transfection conditions for complexes of LPEI-PEG-GE11 and NIS pDNA 
(LPEI-PEG-GE11/NIS polyplexes) in human CRC cells LS174T, which showed EGFR 
expression as determined by FACS analysis (Fig 1A), radioiodide uptake activity was 
evaluated 24 h after polyplex application. To obtain highest transfection rate with lowest 
impact on cell viability, a nitrogen/phosphate (N/P) ratio of 6 was chosen for all subsequent 
experiments. At 24 h after transfection with EGFR-targeted LPEI-PEG-GE11/NIS polyplexes, 
cells demonstrated a significantly higher uptake of 125I in comparison to cells that were 
incubated with LPEI-PEG-Cys/NIS, where the targeting ligand was replaced by cysteine. 
Additional pretreatment of cells transfected with LPEI-PEG-GE11/NIS with the NIS-specific 
inhibitor perchlorate resulted in decreased uptake levels, comparable to the background 
levels measured after transfection with empty polymer in HBG buffer (LPEI-PEG-GE11/HBG) 
(Fig. 1B). No effects on cell viability after transfections were detected (Fig. 1C). 
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Fig. 1: Incubation of EGFR expressing (A) LS174T cells with polyplexes at an N/P ratio of 6 resulted in high 
transduction efficiency and EGFR-specificity of NIS-encoding LPEI-PEG-GE11/NIS (n=4) polyplexes compared to 
polyplexes without ligand (LPEI-PEG-Cys/NIS; n=4) and empty polymers (LPEI-PEG-GE11/HBG; n=4) (B). Pre-
treatment with the NIS-specific inhibitor perchlorate resulted in reduced iodide uptake confirming NIS-specificity. 
Cell viability was not affected by polyplex-mediated NIS gene transfer (C) (*p≤0.05; **p≤0.01; *** p≤0.001; n/s = 
not significant). Results are reported as mean ± SEM. Adapted from [155]. 
 
18F-TFB PET imaging after EGFR-targeted NIS gene delivery 
Once animals had developed hepatic colon cancer metastases (Fig. 2A,B), tumor sections 
were dissected and investigated for EGFR-expression. High EGFR expression levels were 
detected in metastatic areas by immunohistochemical staining, whereas in normal liver tissue 
only low EGFR expression was observed (Fig. 2C). Based on these results, animals with 
hepatic metastases received EGFR-targeted polyplexes LPEI-PEG-GE11/NIS or control 
polyplexes LPEI-PEG-Cys/NIS and functional NIS expression was imaged by 3-dimensional 
high resolution small animal PET 48 h after polyplex injection. High accumulation of the NIS 
PET tracer 18F-TFB was detected in metastases of animals that received LPEI-PEG-
GE11/NIS polyplexes (Fig. 2D). Serial scanning revealed an accumulated dose of 4.8±0.6 % 
of initial dose (ID) (Fig. 2G). Non-targeted gene delivery via LPEI-PEG-Cys polymers 
resulted in a significantly reduced tumoral tracer uptake of 2.2±0.6 % of ID (Fig. 2E,G). 18F-
TFB uptake was also observed in physiologically NIS-expressing tissue (thyroid, mammary 
glands, salivary glands and stomach), as well as in the urinary bladder that is responsible for 
radionuclide elimination (Fig. 2D,E). To verify that the tracer uptake in metastases was 
indeed NIS-mediated, LPEI-PEG-GE11/NIS-injected mice were additionally treated with the 
competitive NIS inhibitor perchlorate 30 min before tracer administration (Fig. 2F). In these 
animals, NIS-mediated tracer accumulation was blocked in metastases and in tissues that 
exhibit endogenous NIS expression.  
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Fig. 2: Hepatic colon cancer metastases (A, B) showed high EGFR expression (C) in contrast to normal liver 
tissue. Significant tumor-specific accumulation of the NIS PET tracer 
18
F-TFB was detected in metastases of 
animals that received LPEI-PEG-GE11/NIS (D; n=5) in contrast to mice injected with control vectors (E; n=3). To 
verify NIS-mediated tracer uptake, LPEI-PEG-GE11/NIS-injected mice received the competitive NIS inhibitor 
perchlorate 30 min before tracer administration (F; n=2), which blocked NIS-mediated tracer accumulation in 
metastases and tissues that exhibit endogenous NIS expression. Serial scanning revealed an accumulated dose 
of 4.8±0.6% of injected dose (G) (*p≤0.05). Results are reported as mean ± SEM. (M=metastases; S=nasal 
secretion; T=thyroid; MG=mammary gland; St=stomach; B=bladder). Adapted from [155]. 
 
Ex vivo analysis of NIS expression in CRC metastases 
To determine NIS mRNA expression in liver metastases by qPCR, mice were sacrificed 48 h 
after polyplex administration and tumors dissected. High NIS mRNA expression was 
detected in metastatic areas in mice injected with LPEI-PEG-GE11/NIS as compared to 
untreated tumors. In addition, low NIS mRNA expression levels were observed in tumors of 
mice treated with the control vector LPEI-PEG-Cys/NIS (Fig. 3A). 
For further evaluation of NIS protein expression, tumor sections were stained with a human 
NIS-specific antibody. Immunohistochemical staining revealed areas of NIS-specific 
immunoreactivity in metastatic tissue of LPEI-PEG-GE11/NIS-treated mice, whereas 
surrounding normal liver and tumors from mice treated with the control vector LPEI-PEG-
Cys/NIS showed no NIS-specific immunoreactivity (Fig. 3B). 
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Fig. 3: qPCR revealed high NIS mRNA expression in metastatic areas of mice injected with LPEI-PEG-GE11/NIS 
(n=5) compared to untreated tumors (n=2) and low NIS mRNA expression levels were observed in tumors of mice 
that were treated with the control vector LPEI-PEG-Cys/NIS (n=3) (A). Results are reported as mean ± SEM. 
Immunohistochemical staining confirmed NIS expression specifically in metastatic tissue of LPEI-PEG-GE11/NIS 
treated mice. NIS-specific immunostaining was visible only in metastatic tissue and occurred in clusters. No NIS 
expressing cells were found in normal liver tissue (B). Adapted from [155]. 
 
NIS-mediated 131I therapy  
Metastases-bearing mice were treated with three cycles of either LPEI-PEG-GE11/NIS 
followed by 131I (therapy group) or saline 48 h later or received saline only. Mice in the 
therapy group showed a significant reduction of tumor growth reflected in hepatic metastases 
load as determined by contrast-enhanced ultrasound (CEUS), while aggressive tumor growth 
was observed in both control groups (Fig. 4A). The reduced tumor growth in the therapy 
group resulted in an enhanced survival of these animals of up to 15 days post therapy start in 
contrast to control animals, that died within 8 days (NaCl/NaCl group) or 13 days (LPEI-PEG-
GE11/NaCl group) (Fig. 4B). 
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Fig. 4: Metastases-bearing mice were treated with three cycles of either LPEI-PEG-GE11/NIS followed by 
131
I 
(n=9) or saline (n=9) 48 h later or received saline only (n=9). Hepatic tumor load (A) and animal survival (Kaplan-
Meier-Plot) (B) of the three different treatment groups were compared (Student’s t-test: *p≤0.05; **p≤0.01; 
***p≤0.001; Mann-Whitney U test: 
#
p≤0.05; 
##
p≤0.01; 
###
p≤0.001).  Results are either reported as mean ± SEM for 
tumor volumes or in percent for survival plots. Adapted from [155]. 
 
For sonographic measurements 100 μl of the contrast agent SonoVue, which consists of 
gas-filled microbubbles (diameter 2.5 μm), was intravenously applied. CEUS images showing 
the entire liver on day 5 after therapy start revealed a more homogenous uptake of contrast 
agent with only small areas with lower contrast agent uptake that represent metastases in 
animals that received LPEI-PEG-GE11/NIS + 131I (Fig. 5A). In comparison both control 
groups, which exhibit higher hepatic metastases load with highly hypovascularized central 
areas, showed severely inhomogeneous contrast agent uptake (Fig. 5B,C). To determine 
perfusion of disseminated liver metastases, echo signals were calculated by including the 
perfusion of the entire liver. A typical distribution of contrast agent in the LPEI-PEG-
GE11/NIS + 131I group was detected, which showed a maximum peak of liver uptake 10 s 
after injection, followed by a quick tail off due to elimination. In the control groups no peak 
was observed. Regions of interest (ROI) were drawn around the entire liver to calculate and 
compare perfusion in the different treatment groups. While therapy animals that received 
LPEI-PEG-GE11/NIS + 131I revealed an increased overall signal, decreased amount of 
contrast agent uptake in the liver of control animals was detected (Fig. 5D).  
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Fig. 5: CEUS imaging of the entire liver on day 5 after therapy start revealed strong differences in contrast agent 
uptake and perfusion between therapy (A; LPEI-PEG-GE11/NIS + 
131
I) and control groups (B; LPEI-PEG-
GE11/NIS + NaCl and  C; NaCl + NaCl). Due to hypovascularization of metastases and necrotic areas 
metastases (M) appear dark. Animals treated with 
131
I showed an overall enhanced contrast agent signal and a 
higher maximum uptake (D), in comparison to both control groups, which exhibited higher hepatic metastases 
load, reduced amount of healthy hepatic tissue and thus overall decreased perfusion levels. Adapted from [155]. 
 
Immunofluorescence staining for tumor cell proliferation and blood vessel density 
Metastatic liver tissue of mice after therapy was examined for cell proliferation with a Ki67-
specific antibody (green) and for blood vessel density with a CD31-specific antibody (red) 
(Fig. 6A-C). Ki67 and CD31 staining in metastatic tissue differs from staining of normal liver 
tissue (Fig. 6D). Metastatic tissue of LPEI-PEG-GE11/NIS-treated mice that received 131I 
showed significantly decreased proliferation and lower blood vessel density as compared to 
control groups (Fig.6 E,F). 
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Fig. 6: Frozen metastatic tissue sections of the three different treatment groups exhibited reduced cell 
proliferation (green; Ki67) and blood vessel density (red; CD31) in animals treated with               LPEI-PEG-
GE11/NIS + 
131
I (A) (n=9) compared to control groups that received LPEI-PEG-GE11/NIS + NaCl (B) (n=9) or 
NaCl + NaCl (C) (n=9). Differences in Ki67 and CD31 staining between metastatic tissue and normal liver tissue 
can be seen in (D). Higher cell proliferation and increased pattern of vascularization of tissue surrounding 
metastases along with low vascularization inside metastases was found in both control groups (E, F). Results are 
reported as mean ± SEM. Adapted from [155]. 
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4.5 Discussion 
 
In the emerging field of theranostics, which combine the capacities to function as imaging 
tool as well as a therapeutic agent, NIS has been evaluated as promising and beneficial 
target for cancer gene therapy. Due to its iodide concentration ability, NIS expression in 
nonthyroidal tumor cells induced by targeted gene transfer enables noninvasive tumor 
monitoring and exact localization of the tumorous tissue by various imaging modalities (y-
camera, PET, SPECT) and tracers (123I, 188Re, 124I, 18F-TFB, 18F-SO4) before therapeutic 
radionuclide application (131I, 188Re, 211At). The dual mechanism of NIS has been investigated 
in several nonthyroidal tumor models [35-51] and the concept of NIS gene therapy is 
currently under clinical evaluation for local treatment of prostate cancer after intratumoral 
application of adenoviral NIS gene carriers (NCT00788307, NCT01846091, NCT02068794) 
[49, 131]. Based on these results, the powerful image-based cytoreductive NIS gene therapy 
approach may also represent a promising cancer treatment strategy even for metastatic 
disease. 
However, a worthwhile evaluation of novel therapeutics for clinical use against metastases 
remains challenging. Thus, tumor models that give a detailed reflection of the natural 
processes in tumorigenesis, invasion and angiogenesis are highly important, especially for 
metastases formation, which is defined by a multi-step process. This process involves cell 
migration of tumor cells via blood vessels and lymphatic vessels to distant sites followed by 
generation of one or more micro-metastases that transform to macroscopic metastases with 
a unique microenvironment that is formed of the tumor cells themselves, tumor stroma and 
tumor-associated cells [3].  
With respect to the high incidence of CRC as third most common cancer worldwide [146], 
which lacks new therapeutic options with clinical benefits, improved response and survival, 
especially for metastatic CRC where only a low percentage of patients are eligible for 
surgery, we established an in vivo metastases colon cancer model to investigate the NIS 
gene therapy concept as a new treatment option for CRC metastases. The CRC cell line 
LS174T, which was well characterized in vitro and showed promising results after NIS gene 
transfections, was injected directly into the mouse spleen, which results in tumor cell 
migration via the splenic vein and portal vein to the liver with cell invasion into the liver 
followed by formation of small metastases. After three days a splenectomy was performed to 
eradicate interference from a primary tumor in the spleen. With about 90% of mice 
developing liver metastases, this model is highly reproducible and metastases in other 
tissues, e.g. in the lungs were not observed. 
To obtain effective NIS gene expression specifically in metastases, potent carrier systems 
are required. Various vector systems for systemic NIS gene transport have been 
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investigated, including mesenchymal stem cells, viral and nonviral vehicles [35-46]. Nonviral 
vectors as part of the nanotechnology field showed promising features for a targeted delivery 
to tumor tissue due to the variable design strategies, which allow adjustment on efficacy, 
biocompatibility and safety conditions [119]. Since the epidermal growth factor receptor 
(EGFR) is overexpressed in a high range of CRC tumors [156, 157], it represents an 
auspicious target for tumor-specific NIS gene delivery via actively targeted nanoparticle 
transfer. Based on promising earlier in vivo results [39, 151], for NIS gene transfer to 
metastatic CRC tissue, LPEI-PEG-based polymers coupled to the EGFR-specific ligand 
GE11 were applied. LPEI as nonviral gene shuttle vector demonstrates high DNA binding 
capacity along with high transduction efficiency in vitro and in vivo and has already been 
evaluated in human clinical studies (NCT00712530) [158]. The additional PEG-shielding 
domain enables higher colloidal stability after systemic application and allows a safer in vivo 
application by reducing interactions with serum proteins and aggregation. 
In vitro transfection studies in CRC LS174T cells using EGFR-targeted LPEI-PEG-GE11/NIS 
polyplexes resulted in significant perchlorate-sensitive 125I accumulation, whereas 
transfections with untargeted polyplexes showed only low iodide uptake over background 
levels. These results confirm the advantage of EGFR-targeting compared to the Cys control 
that lacks a specific cell-binding structure. This has already been demonstrated in former 
studies using various high EGFR expressing cell lines such as HuH7 liver cancer cells and 
SKOV-3 ovarian carcinoma cells [39]. Perchlorate sensitivity of LPEI-PEG-GE11/NIS 
transfected cells confirmed NIS-mediated uptake. 
Liver sections with metastases derived from intrasplenic injection of LS174T cells where 
stained for EGFR. High expression levels could be detected in the metastatic tissue 
providing the basis for EGFR-targeted NIS gene transfer in vivo. To be able to see NIS 
expression in single metastases and thereby confirming the suitability of our EGFR-targeted 
vectors for NIS gene delivery, we applied the novel NIS PET tracer 18F-TFB. Due to the small 
size of metastases with a diameter of around 1-5 mm, a precise evaluation for exact 
quantitative calculations of radionuclide uptake was required. Compared to the drawbacks of 
124I as tracer with its long half-life, low positron yield, high positron energy, high energy 
gamma emission, limited availability and complex and expensive production, the new NIS 
PET tracer 18F-TFB promises a higher resolution and more differentiated images [96]. TFB 
was identified to be a substrate for NIS and by coupling 18F to TFB an ideal PET tracer with a 
short half-life and higher resolution images was developed [96]. Once mice had developed 
metastases, 2-3 weeks after tumor cell injection, animals were injected with LPEI-PEG-
GE11/NIS or LPEI-PEG-Cys/NIS at a N/P ratio of 6. At 48 h after polyplex administration, 
mice received an intraperitoneal dose of 10 MBq 18F-TFB. To demonstrate that tracer uptake 
was indeed NIS dependent, a subgroup of the LPEI-PEG-GE11/NIS mice was injected with 
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the NIS specific inhibitor perchlorate 30 min prior to 18F-TFB application. Whereas 
metastases could nicely be detected in the LPEI-PEG-GE11/NIS group due to strong NIS-
mediated 18F-TFB accumulation, only weak radionuclide uptake was detected in metastases 
of the control group.  
After this first series of encouraging animal imaging experiments, which confirmed high NIS 
expression in single metastases, the therapeutic efficacy of this approach was investigated. 
Animals received three cycles of polyplexes followed by 131I or saline application 48 h later or 
received saline only. Hepatic metastases load was monitored by conventional sonography 
and CEUS performed by an experienced radiologist in a blinded, randomized trial. 
Significantly reduced hepatic metastases load was detected in the LPEI-PEG-GE11/NIS 
group that received 131I, which was associated with prolonged survival, compared to both 
control groups.  
For a detailed evaluation of the therapeutic effect, contrast agent distribution and liver 
perfusion were determined. As a consequence of the strong dissemination of small 
metastases pervading the entire liver, the evaluation of single metastasis was not feasible. 
Consequently, regions of interest (ROI) were drawn around the entire liver to calculate and 
compare perfusion in the different treatment groups.   
For sonographic measurements 100 μl of the contrast agent SonoVue, which consists of 
gas-filled microbubbles (diameter 2.5 μm), was intravenously applied. The process of 
contrast agent distribution in the liver consists of two dynamic phases. First, the arterial 
phase, which starts a few seconds after injection of the contrast agent, followed by the portal 
phase, where an overall enhancement of perfusion of normal liver tissue takes place [159]. 
The typical distribution of contrast agent results in a maximum peak of liver uptake and is 
followed by a quick elimination by respiration and elimination by the liver [160]. The majority 
of liver metastases derived from colorectal cancer is hypovascularized and shows contrast 
agent accumulation only at the periphery of the lesion [159, 161]. This pattern of increased 
vascularization of the tissue surrounding metastases along with low vascularization inside 
metastases could be confirmed by immunofluorescence analysis of vascularization (CD31-
staining). Moreover, the extensive spread of the LS174T derived metastases in control mice 
lead to highly necrotic areas in the center of metastases, further diminishing vascularization 
inside metastases [162, 163].  
Due to this hypovascularization of metastases together with a lower fractional vascular 
volume of metastases compared to normal liver tissue, absence of portal supply and a 
greater extent of necrotic areas, metastases generally appear dark [161, 164]. Hence, the 
livers of therapy animals that were injected with LPEI-PEG-GE11/NIS + 131I, where a reduced 
hepatic metastases load was detected, exhibit a more homogenous contrast agent uptake 
with only small areas that appear dark and represent metastases. In contrast, both control 
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groups showed strongly inhomogeneous agent distribution and a high extent of metastases 
pervading the livers. Owing to the higher hepatic metastases load and thus reduced amount 
of healthy hepatic tissue where contrast agent uptake and perfusion can be detected, this 
resulted in overall decreased perfusion levels of control animals. 
As hypovascularization often constitutes a major drawback for efficient delivery, in this study 
an active EGFR targeting approach was used. Hereby, gene delivery is not only dependent 
on the enhanced permeability and retention effect (EPR), where hypervascularization is an 
essential prerequisite for effective accumulation of vectors at the target site [165]. Efficacy of 
the active EGFR targeting strategy was proven by imaging and therapy studies. Further, 
different sizes of polyplexes and contrast agent particles may affect liver distribution. Sizes of 
polyplexes were detected to have an average size of around 100 nm, whereas particles of 
the contrast agent are specified to be at 2.5 μm. Thus, polyplexes are able to reach even 
small blood vessels.  
In addition, the bystander effect that is associated with radioiodide therapy supports an 
effective treatment of non-transfected tumor cells in the surrounding tumor tissue due to the 
crossfire effect of the beta-emitter 131I of up to 2.4 mm. Hence, areas with diminished blood 
vessel density benefit from this bystander effect and can be efficiently destroyed even though 
they do not exhibit sufficient vascularization. 
In conclusion, our data clearly demonstrate the potential of LPEI-PEG-GE11 carrier systems 
to target the NIS gene to hepatic CRC liver metastases. NIS as reporter gene allows for 
quantification of the extent of gene expression and quantitative analysis of tracer uptake. In 
its function as therapeutic gene, after applying the therapeutic tracer 131I, NIS-mediated 131I 
accumulation induces decelerated metastatic tumor growth with prolonged animal survival. 
The established metastases model is a valuable tool to reflect the clinical situation on a 
morphological and molecular level and serves as an ideal advanced tumor model to 
investigate our EGFR-targeted NIS-mediated gene therapy approach. 
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5.1 Abstract  
 
Purpose: Tumor heterogeneity poses a major problem in cancer therapy, not only between 
patients, but even between primary tumor and metastases and within the tumor itself. To 
address the variability of tumor characteristics and improve gene delivery for therapy of 
hepatocellular cancer (HCC), a dual-targeting approach was performed.  
Experimental Design: For tumor-targeted gene delivery, synthetic LPEI-PEG2kDa-based 
polymer backbones were coupled to tumor-specific peptide ligands GE11 for EGFR-targeting 
or cMBP for cMET-targeting and mixed at equal amounts (1:1) before complexing with 
pDNA. The dual-targeting approach was used to deliver the sodium iodide symporter (NIS) 
gene to orthotopic HCC xenografts. NIS as well characterized theranostic gene allows 
diagnostic analysis of functional NIS gene expression by noninvasive imaging and effective 
anticancer radioiodide therapy. 
Results: Enhanced tumor specificity and transduction efficiency of dual-targeted polyplexes 
in comparison to single-targeted polyplexes were demonstrated in vitro using tumor cell lines 
with different EGFR and cMET expression levels. Taking advantage of the reporter function 
of NIS in vivo, 124I-PET-imaging of mice bearing orthotopic HCC xenografts revealed higher 
levels of tumor-specific NIS-mediated radionuclide uptake after dual-targeting. Evaluating the 
therapeutic efficacy of this bispecific concept, mice received 3 cycles of dual-targeted 
polyplexes followed by 131I or saline 48h later. Significantly reduced tumor growth and 
perfusion in 131I-treated animals was detected along with prolonged survival. 
Conclusions: The dual-targeting approach resulted in higher tumor-specific radioiodide 
accumulation and significant therapeutic efficacy in an advanced orthotopic HCC model. This 
bifunctional strategy enhances the applicability of the NIS gene therapy concept in 
heterogeneic tumors. 
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5.2 Translational relevance 
 
Tumor heterogeneity, within and between tumors, may have severe implications for tumor 
therapy, especially for targeted gene therapy, where single-targeted approaches often result 
in limited efficacy and therapy resistance. Polymer-formulated nonviral vectors provide a 
potent delivery platform for cancer therapy. To improve applicability of polymers for future 
clinical use in a broad range of patients and cancer types, tumor heterogeneity is a crucial 
aspect that has to be taken into account. The current study evaluates the beneficial effect of 
simultaneously targeting EGFR and cMET for nonviral gene delivery of the theranostic 
sodium iodide symporter (NIS). Imaging studies based on the reporter function of NIS and 
therapeutic application of radioiodide provided evidence for enhanced tumor-specific gene 
delivery after dual-targeting. This highlights the benefits of a bifunctional strategy with 
improved efficacy for a future clinical translation allowing efficient targeting of heterogeneic 
tumors with variable receptor expression levels.   
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5.3 Introduction 
 
Hepatocellular cancer (HCC), one of the most common cancers worldwide, is characterized 
by high mortality and  resistance to conventional chemo- and radiotherapies [98]. The limited 
success of available treatment options is attributed to the complex prooncogenic 
microenvironment of chronic liver diseases that often proceed the development of HCC, as 
well as the high level of tumor heterogeneity [166, 167]. Tumor heterogeneity not only occurs 
between patients, but even between primary tumor and metastases and within the tumor 
itself and represents a major hurdle for the development of effective therapy strategies for 
HCC patients [166]. Against this background, even individualized and molecularly targeted 
therapy strategies as promising novel approaches for HCC treatment have to be designed in 
a way that takes heterogenous tumor characteristics into account.  
Nonviral delivery vectors have been confirmed as potent agents for the delivery of genes 
specifically to tumor cells for cancer gene therapy. High precision synthesis allows the design 
of multifunctional systems for effective tumor cell targeting [168]. Functional groups for 
nucleic acid binding, as well as endosomal buffering can be complemented by a shielding 
domain that improves in vivo biocompatibility and lateral stabilization by crosslinking of 
polyplexes [119, 169]. Most importantly for specific tumor targeting, incorporation of active 
targeting ligands provides the mechanistic rationale to enhance tumor-specific binding, 
cellular uptake and transfection efficiency. Various ligands that bind receptors that are highly 
expressed in a wide range of tumors, including epidermal growth factor receptor (EGFR), 
cMET/hepatocyte growth factor receptor (HGFR), transferrin receptor, integrin receptors and 
folate receptor, have served as promising candidates for molecularly targeted cancer gene 
therapy [39, 68, 69, 88, 123, 126, 151, 169]. Nevertheless, efficacy of nanoparticle-based 
carriers often varies after translation from in vitro conditions to in vivo models and between 
different tumor models [170], which is most likely attributable to tumor heterogeneity.  
One promising strategy to minimize the effect of tumor heterogeneity and resistance to 
cancer therapies in the clinical setting is the combination of different therapeutics that either 
show different pharmacological modes of action or have different targets [171]. In the present 
study, a dual receptor targeting strategy for a single nanotherapeutic using LPEI-PEG2kDa-
based nonviral vectors for delivery of the potent theranostic sodium iodide symporter (NIS) 
gene was developed. To reduce the impact of variable receptor expression levels due to 
inter- and intratumoral heterogeneity, GE11 and cMBP were chosen as ligands for EGFR- 
and cMET-targeting, respectively. Both ligands proved to be highly specific and effective in 
single-targeting experiments [39, 46, 68, 69, 123, 151]. By simultaneously targeting both 
receptors, the postulated crosstalk between cMET/HGFR and EGFR [172] and enhanced 
  Dual EGFR/cMET targeting 
65 
 
particle uptake by receptor crosslinking that mimics biphasic uptake of viral vectors by 
binding to two different receptor types, can be exploited to increase efficacy [84-86].  
Since its cloning in 1996 [30], NIS has proven its function as potent theranostic gene and is 
already being investigated clinically in cancer patients [30, 47, 49, 94, 129, 131, 173, 174]. 
The transduction efficiency in vitro and in vivo can be monitored by taking advantage of the 
reporter function of NIS that allows determination of radionuclide uptake in transfected cells. 
This enables exact localization of tumorous tissue by noninvasive bioimaging as well as 
quantification of trapped radionuclides (125I, 123I, 124I, 18F-TFB). At the same time, NIS 
provides the possibility for an effective treatment strategy by application of 131I, 188Re and 
211At [41, 175]. 
In the current study, nonviral NIS gene transfer was investigated in vitro in different tumor cell 
lines by comparison of the dual-targeting strategy to single-targeting of EGFR or cMET. 
Based on these results, the efficacy of polyplexes for dual-targeting and single-targeting was 
further examined in an orthotopic in vivo model of HCC using the reporter function of NIS for 
noninvasive positron emission tomography (PET) imaging followed by evaluation of the 
therapeutic efficacy of the dual-targeting approach. 
This novel approach utilizes two bifunctional strategies: (1) simultaneous targeting of two 
receptors to improve efficacy and reduce effects of variable receptor expression levels in 
heterogeneic tumors and (2) using the dual function of NIS for monitoring of the efficiency of 
gene delivery by noninvasive imaging of tumoral NIS expression as well as effectiveness of 
therapeutic intervention after application of 131I for cancer treatment.  
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5.4 Materials and methods 
 
Plasmid and polymer synthesis and polyplex formation 
Polymers with LPEI-PEG2kDa-backbone were synthesized by coupling heterobifunctional 
(poly)ethylene glycol (NHS-PEG-OPSS, 2 kDa, Rapp Polymere GmbH, Tübingen, Germany) 
to amine groups of linear polyethylene imine (LPEI) via N-hydroxy succiniminyl ester followed 
by a cation exchange chromatography purification step as described previously [39, 126]. 
Specific targeting was achieved by coupling peptide ligands to the polymer backbone. GE11 
was used for EGFR-targeting (LPEI-PEG-GE11; peptide sequence: YHWYGYTPQNVI) and 
cMBP was applied for cMET-targeting (LPEI-PEG-cMBP; peptide sequence: 
KSLSRHDHIHHH). The conjugates were stored at -80°C as 1-5 mg/ml stock solutions until 
further use. Polyplexes were formed by complexing polymer with codon-optimized human 
NIS plasmid DNA [46, 126]. Polymers and cDNA, diluted in the same volumes of HEPES (2-
[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid)-buffered glucose (HBG: 20 mmol/l 
HEPES, 5% (w/v) glucose at pH 7.4) at a nitrogen/phosphate (N/P) ratio of 6 (w/w), were 
mixed and incubated at room temperature for 20 min prior to use [124].  
For single-targeted polyplex solutions, 100% of polymer was added, for dual-targeted 
polyplexes a 1:1 mixture of cMET-targeted and EGFR-targeted polymers was prepared (total 
N/P=6) before adding to DNA and then complexed with pDNA. For in vitro studies the DNA 
concentration for polyplex formation was 2 µg/ml, for in vivo studies 200 µg/ml.  
 
Particle size measurements  
Particle sizes of single-targeted and dual-targeted polyplexes were determined by 
transmission emission microscopy (TEM; JEM 1011, Jeol, Freising, Germany). Samples 
were prepared with 1 µg DNA in a total volume of 100 µl. The formvar/carbon coated 300 
mesh copper grids (Ted Pella Inc., Redding, USA) were activated by mild plasma cleaning. 
Subsequently, the grids were incubated for 1 min with 20 µl of the polyplex solution. Excess 
liquid was blotted off using filter paper until the grid was almost dry. Then, the grids were 
washed with 5 µl of staining solution for 5 s and incubated for 20 s with 5 μl of a 2% aqueous 
uranyl formate solution. Excess liquid was blotted off using filter paper, followed by air-drying 
for 30 min. TEM was performed at 80 kV. 
 
Cell culture 
The HCC cell line HuH7 (JCRB0403; Japanese Collection of Research Bioresources Cell 
Bank, Osaka, Japan) was cultured in Dulbecco’s modified eagle medium (DMEM; 1 g/l 
glucose; Sigma-Aldrich, St.Louis, Missouri, USA). The breast cancer cell line MCF-7 
(American Type Culture Collection, Manassas, Virginia, USA) was cultured in Dulbecco’s 
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modified eagle medium (DMEM; 4 g/l glucose; Sigma-Aldrich). The human follicular thyroid 
carcinoma cell line FTC-133 (Sigma-Aldrich) was cultured in DMEM/F12 (Sigma-Aldrich). All 
media were supplemented with 10% (v/v) fetal bovine serum (FBS Superior, Biochrom/Merck 
Millipore, Berlin, Germany) and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich).  
Cells were maintained at 37°C and 5% CO2 in an incubator with a relative humidity of 95%. 
Cell culture medium was replaced every second day and cells were passaged at 80% 
confluency. 
 
EGFR and cMET receptor expression levels in vitro 
0.8-1 × 106 cells were detached with trypsin/EDTA (Sigma-Aldrich), washed with phosphate 
buffered saline (PBS; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; 
Sigma-Aldrich) and incubated with an EGFR-specific antibody (1:200; monoclonal mouse 
IgG1, Dako, Glostrup, Denmark) or with an antibody that detects human cMET/HGFR (1:200; 
monoclonal mouse IgG1, R&D Systems, Minneapolis, Minnesota, USA) or with an IgG-anti-
mouse antibody (1:200; BD Biosciences, Franklin Lakes, New Jersey, USA) as negative 
control for 1 h on ice. Then, cells were washed with PBS with 10% FBS and incubated with 
an AlexaFluor 488 labeled goat anti-mouse secondary antibody (1:400; Invitrogen, 
Langenselbold, Germany) for 1 h on ice. Cells were washed and resuspended in PBS with 
10% FBS for analysis, which was performed on a BD Accuri C6 flow cytometer (BD 
Biosciences). Cells were gated by forward/sideward scatter and pulse width for exclusion of 
doublets. PI (propidium iodide; Sigma-Aldrich) was used for discrimination between viable 
and dead cells.  
 
Cellular binding and internalization 
Cells were seeded in 24-well plates at a density of 50 000 cells per well. After 24 h, cell 
culture medium was replaced with 400 μl fresh growth medium. Cells were transfected with 
polyplexes for single-targeting, i.e. LPEI-PEG-GE11/NIS or LPEI-PEG-cMBP/NIS 
(subsequently specified as EGFR-targeting or cMET-targeting respectively) or polyplexes 
formed with a 1:1 mixture of polymers for simultaneous cMET- and EGFR-targeting 
(subsequently labeled as dual-targeting). HBG served as control. For pDNA polyplexes 
(N/P=6) in 100 μl HBG 1 μg pDNA was used, where 20% of the nucleic acid was Cy5-
labeled. To determine cellular association, polyplexes were added to cells and incubated for 
30 min on ice. Afterwards, cells were washed twice with 500 µL PBS, detached with 
trypsin/EDTA and resuspended in PBS with 10% FBS.  
For cell uptake experiments, cells were incubated for 30 min with polyplexes. Cells were then 
washed with 500 μl PBS/1000 I.U. heparin for 15 min on ice to remove polyplexes on the cell 
surface. Cells were then detached with trypsin/EDTA and taken up in PBS with 10% FBS.  
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Samples were examined on a BD Accuri C6 flow cytometer by determination of the excitation 
of Cy5 at 635 nm and detection of emission at 665 nm. Cells were gated by forward/sideward 
scatter and pulse width for exclusion of doublets. PI was used to discriminate between viable 
and dead cells.  
 
Transfection studies 
Cells were plated at a density of 2 × 105 cells per well in 6-well plates and incubated for 45 
min with polyplexes for dual-targeting or single EGFR- or cMET-targeting. Transfection 
efficiency was determined by measurement of iodide uptake activity at steady-state 
conditions 24 h after transfection as described previously [47].  
 
Cell viability assay 
Cell viability 24 h after transfection was analyzed after incubation of cells with a commercially 
available MTT reagent (Sigma-Aldrich) for 2 h at 37°C followed by a washing step with PBS. 
The formazan product was measured after incubation with 10% DMSO (v/v) (dimethyl 
sulfoxide) in isopropanol at 620 nm in a Sunrise microplate absorbance reader (Tecan, 
Männedorf, Switzerland). 
 
Establishment of orthotopic HuH7 xenografts 
For orthotopic HCC xenografts in female CD-1 nu/nu mice (Charles River, Sulzfeld, 
Germany), 1×106 HuH7 cells resuspended in 50 μl were injected into the liver after 
laparotomy of 7-week old mice under full anesthesia. Animals were pre- and post-treated 
with Metacam (0.5 mg/kg). Mice were sacrificed when healthy liver tissue dropped below 
30% as determined by sonography or animals showed any other symptoms of illness. 
Animals were maintained under specific pathogen-free conditions with access to mouse 
chow and water ad libitum. The experimental protocol was approved by the regional 
governmental commission for animals (Regierung von Oberbayern) and all animal 
experiments were carried out according to the guidelines of the German law of protection of 
animal life. 
 
EGFR and cMET receptor expression levels in vivo 
Receptor immunofluorescence staining was performed on dissected frozen tumor tissues. 
Tissues were fixed in 80% methanol for 5 min at 4 °C and acetone for 2 min at −20 °C. PBS 
was used for rehydration and sections were blocked with 12% bovine serum albumin/PBS for 
30 min at room temperature. An EGFR-specific antibody (1:100; monoclonal mouse IgG, 
Dako) or a cMET-specific antibody (1:100; monoclonal mouse IgG1, R&D Systems) were 
used and sections were incubated for 1 h. Afterwards, sections were incubated with an anti-
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mouse Alexa 488-conjugated secondary antibody (1:200; BD Pharmingen, Heidelberg, 
Germany). For nuclei counterstaining Hoechst bisbenzimide (1:1000; 5 mg/ml) was applied 
and sections were embedded in Fluorescent Mounting Medium (Dako). Stained sections 
were examined using an Axiovert 135 TV fluorescence microscope equipped with an 
AxioCam MRm CCD camera and AxioVision Rel. 4.8. software (Carl Zeiss, Munich, 
Germany). 
 
PET imaging studies after systemic NIS gene transfer in vivo 
Experiments started 5-6 weeks after intrahepatic injection of tumor cells. For determination of 
tumor specific NIS expression and subsequent NIS mediated iodide uptake, animals 
received LPEI-PEG-GE11/NIS polyplexes for EGFR-targeting (n=6), LPEI-PEG-cMBP/NIS 
for cMET-targeting (n=4) or both for dual-targeting (n=7). Polyplexes were administered 
systemically via the tail vein (intravenously, i.v.) at a DNA dose of 2.5 mg/kg (50 μg DNA in 
250 μL HBG). At 48 h after polyplex injection mice received the NIS-specific PET tracer 124I 
and accumulation in tumor tissue was determined by small-animal PET (Inveon, SIEMENS 
Preclinical Solutions, Erlangen, Germany). Serial scanning was performed after 1 h, 3 h and 
5 h. Regions of interest were analyzed with the software Inveon Acquisition Workplace 
(Siemens), quantified using Inveon Research Workplace (Siemens) and expressed as a 
fraction of the total amount of initial dose (% of ID). To suppress thyroidal iodide uptake, a 
10-day pretreatment with L-thyroxine (L-T4; 5 mg/ml; Sigma-Aldrich) in drinking water was 
conducted before PET-imaging. To verify NIS specific uptake, pretreatment with an 
intraperitoneal (i.p.) injection of 2 mg of the competitive NIS inhibitor sodium perchlorate 
(NaClO4) 30 min before PET tracer administration (n=2) was performed. 
 
Immunohistochemical analysis of NIS protein expression 
Immunohistochemical NIS staining of paraffin embedded tumor tissue derived from hepatic 
tumor sections after NIS gene delivery was performed using a mouse monoclonal antibody 
directed against human NIS (1:1000; Merck Millipore) as described previously [42, 153]. 
Immunohistochemically stained sections were imaged on an Olympus BX41 microscope 
equipped with an Olympus XC30 CCD camera (Olympus, Shimjukum Tokio, Japan). 
 
Radioiodide therapy studies 
Three weeks after intrahepatic tumor cell injection, when mice have received a 10-day 
pretreatment with L-T4 in drinking water, therapy trials were started. Animals were randomly 
distributed to two groups. Animals received an i.v. injection of a solution of polplexes for dual-
targeting followed by an i.p. application of 55.5 MBq 131I (n=8) or saline (n=8) 48 h later. The 
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cycle consisting of systemic NIS gene transfer followed by radioiodide was repeated for a 
total of three times on days 0/2, 3/5 and 7/9.  
Tumor growth was monitored by conventional sonography and tumor perfusion was 
determined by contrast-enhanced ultrasound (CEUS) after application of 100 µl of the 
contrast agent SonoVue® (Bracco, Switzerland) on an Acuson Sequoia 512 (Siemens) 
combined with a 15L8W ultrasound probe using the Cadence contrast pulse sequencing 
technology. 
The experiment was performed in a blinded experimental setup and evaluated by an 
experienced radiologist. CEUS was performed as described previously [45] and the contrast 
agent concentration was estimated using pre-defined calibration curves [154].  
 
Indirect immunofluorescence assay 
Immunofluorescence staining of Ki67 and CD31 was performed on dissected frozen tumor 
tissues via as described previously [46]. For Ki67, a rabbit polyclonal antibody against human 
Ki67 (1:200; Abcam, Cambridge, UK;) and an anti-rabbit Alexa488-conjugated secondary 
antibody (1:400; Jackson ImmunoResearch, West Grove, Pennsylvania, USA) were used. 
For CD31, a rat monoclonal antibody against mouse CD31 (1:200; BD Pharmingen, 
Heidelberg, Germany) was used. For detection, an anti-rat Cy3-conjugated secondary 
antibody (1:400; Jackson ImmunoResearch) was applied. Hoechst bisbenzimide (1:1000; 5 
mg/ml) was used for nuclei counterstaining and sections were embedded in Fluorescent 
Mounting Medium (Dako). ImageJ software (NIH, Bethesda, MD, USA) was used for 
quantification of proliferation (Ki67-staining) and blood vessel density (CD31-staining) by 
analyzing 6 visual fields per tumor section of every mouse. 
 
Statistics 
All in vitro experiments were carried out at least in triplicates. Results are expressed as mean 
± SEM, mean fold change ± SEM and, for survival plots, in percent. Statistical significance 
was calculated by two-tailed Student’s t-test. P values ≤0.05 were considered significant 
(*p≤0.05; **p≤0.01; ***p≤0.001). 
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5.5 Results 
 
Particle sizes 
To investigate whether different solutions of polyplexes result in unequal particle sizes, TEM 
measurements were performed. All three polyplex solutions for EGFR-targeting, cMET-
targeting and dual-targeting were analyzed. No significant differences between the three 
solutions were observed and TEM measurements revealed two different particle subtypes: 
linear and round particles. Sizes of globular particles were determined to be approximately 
50 nm and sizes of linear particles were analyzed to be 15-20 nm thin and up to 200 nm long 
(Fig. 1).  
 
 
Fig. 1: TEM size measurements of formed polyplexes revealed two different particle subtypes with no significant 
differences between the polyplex solutions for dual- or single-targeting. Globular particles were approximately 50 
nm in size and linear particles were up to 200 nm in size. Adapted from submitted manuscript. 
 
EGFR and cMET expression levels 
Three different cell lines were used for subsequent in vitro studies and were investigated for 
their EGFR and cMET expression levels. The human HCC cell line HuH7 and the human 
breast cancer cell line MCF-7 were identified to have both high EGFR and cMET cell surface 
expression. In contrast, the human follicular thyroid carcinoma cell line FTC-133 showed low 
expression levels for both receptors (Fig. 2). 
 
  Dual EGFR/cMET targeting 
72 
 
 
Fig. 2: The human HCC cell line HuH7, the human breast cancer cell line MCF-7 and the human follicular thyroid 
carcinoma cell line FTC-133 were investigated for EGFR and cMET expression levels by flow cytometry. HuH7 
and MCF-7 cells were found to have both high EGFR and cMET cell surface expression. FTC-133 cells showed 
low receptor expression levels for cMET and EGFR. An IgG-anti-mouse antibody served as control. Adapted from 
submitted manuscript. 
 
Comparison of dual-targeting and single-targeting for NIS gene transfer in vitro  
The three different human tumor cell lines were transfected with polyplex solutions to 
investigate single-targeting vs. dual-targeting in relation to cell surface receptor expression. 
Cellular binding and cellular uptake were measured by detection of fluorescence intensity of 
polyplexes containing Cy5-labelled NIS DNA (Fig. 3A-C). Binding was measured after a short 
incubation time of 30 min and revealed higher mean fluorescence intensity (MFI) values for 
dual-targeting (black bars), whereas MFI values for the single-targeted polyplexes, especially 
EGFR, were lower (Fig. 3D; red bars for EGFR-targeting, blue bars for cMET-targeting). In 
the low EGFR and cMET-expressing cell line FTC-133, the dual-targeting strategy resulted in 
lower MFI values than obtained after single cMET-targeting transfection (Fig. 3D).  
Uptake levels confirmed the trend seen in the binding studies, as a significantly higher MFI 
was detected for HuH7 and MCF-7 cells (Fig. 3E-G). In FTC-133, dual-targeting led to similar 
(compared to EGFR-targeting) or decreased (compared to cMET-targeting) MFI levels (Fig. 
3H).  
Iodide uptake verified the results from the flow cytometry experiments in the three cell lines, 
with higher uptake in HuH7 (Fig. 3I) and significantly increased uptake in MCF-7 (Fig. 3J) 
after simultaneously targeting EGFR and cMET. In the low EGFR and cMET-expressing 
FTC-133 cell line, no advantage of dual- over single-targeting was observed (Fig. 3K). Cell 
viability was not affected by 45 min incubation with the different polyplexes (Fig. 3L-N). 
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Fig. 3: Transfection efficiency of polyplexes for single- and dual-targeting was investigated. Cellular binding and 
cellular uptake were measured by detection of fluorescence intensity of polyplexes containing Cy5-labelled NIS 
DNA. In high receptor expressing cell lines, binding studies revealed higher MFI values for dual-targeted 
polyplexes (black bars), whereas MFI values for single-targeted polyplexes were lower (red bars for EGFR-
targeting, blue bars for cMET-targeting (A,B). This effect was not obtained with the low EGFR- and cMET-
expressing cell line FTC-133 (C,D) (n=3). Uptake levels confirmed binding studies, where a significantly higher 
MFI after transfection for dual-targeting was detected in HuH7 and MCF-7 cells compared to FTC-133 (E-H) 
(n=3). NIS mediated 125I uptake verified enhanced NIS expression after simultaneous targeting of EGFR and 
cMET in HuH7 and MCF-7 cells, while low iodide uptake activity was measured in FTC-133 cells (I-K) (n=4). No 
toxic effects were measured after incubation with the different polyplex mixtures for 45 min (L-N) (n=3). (*p≤0.05; 
**p≤0.01). Results are reported as mean ± SEM. Adapted from submitted manuscript. 
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Induction of iodide accumulation after systemic tumor-targeted NIS gene transfer in 
vivo 
Based on the promising in vitro results, the dual-targeting strategy was further evaluated in 
vivo. An orthotopic HuH7 liver tumor model was established that showed high EGFR (Fig. 
4A) and cMET (Fig. 4B) expression. Tumor-bearing mice were systemically injected with 
either polyplexes for single receptor targeting or dual-targeting. 48 h after NIS gene transfer, 
mice were injected i.p. with 124I and radioiodide biodistribution was assessed by small-animal 
PET imaging. Images 1 h after iodide application showed improved distribution and uptake of 
iodide in tumors of mice that received polyplexes for dual-targeting (Fig. 4C), in comparison 
to tumors of mice treated with single-targeted polyplexes (Fig. 4D,E). Physiological 
expression of NIS in thyroid and stomach leads to iodide accumulation in these tissues and 
renal elimination of radioiodide causes a signal in the bladder. NIS-specificity was verified by 
i.p. application of the NIS-specific inhibitor sodium perchlorate 30 min prior to radionuclide 
application in mice treated with dual-targeted polyplexes, which resulted in an almost 
complete inhibition of iodide uptake in the tumor and organs that physiologically express NIS 
(Fig. 4F). No additional iodide uptake was recorded in non-target organs such as lung, liver, 
kidney and spleen (Fig. 4C-F).  
Regions of interest (ROI) were quantified and as soon as 1 h after iodide application, a 
considerably higher tumoral iodide uptake was observed in tumors of mice that received 
polyplexes for dual-targeting (4.9 ± 0.6% of ID). Lower levels were obtained in tumors of 
mice treated with polyplexes for single EGFR-targeting (4.7 ± 0.7% of ID) and cMET-
targeting (3.2 ± 0.3% of ID). After 3 h, mean iodide uptake after dual-targeting (3.0 ± 0.4% of 
ID) was 0.8-0.5% higher compared to animals after single-targeting (EGFR-targeting: 2.4 ± 
0.5% of ID; cMET-targeting: 2.3 ± 0.3% of ID). 124I scans 5 h after tracer application still 
showed significantly higher iodide uptake levels demonstrating prolonged tumoral iodide 
uptake after dual-targeting (2.0 ± 0.4% of ID) compared to EGFR- (1.0 ± 0.1% of ID) and 
cMET-targeting (1.5 ± 0.3% of ID) (Fig. 4G). 
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Fig. 4: Mice bearing orthotopic HuH7 liver tumors that demonstrated high EGFR and cMET expression (A,B)  
received i.v. polyplexes for single EGFR-targeting (n=6), single cMET-targeting (n=4) or dual-targeting (n=7). At 
48 h after NIS gene transfer, mice were injected i.p. with 10 MBq 124I and radioiodide biodistribution was 
assessed by small-animal PET imaging. PET images 1 h after iodide application showed improved distribution 
and uptake of iodide in tumors of mice that received polyplexes for dual-targeting in comparison to animals 
injected with single-targeted polyplexes (C-E). NIS-specificity was verified by pretreatment of mice that received 
polyplexes for dual-targeting with the NIS-specific inhibitor sodium perchlorate 30 min prior to radionuclide 
application (n=2). This resulted in an almost complete inhibition of iodide uptake in the tumor and organs that 
physiologically express NIS (F). ROIs were quantified and higher tumoral iodide uptake over 5 h was observed in 
tumors of mice that received polyplexes for dual-targeting (*p≤0.05). Results are reported as mean % of ID ± 
SEM. Adapted from submitted manuscript. 
 
Tumor-specific NIS protein expression 
After the imaging studies, mice from the three different treatment groups were sacrificed and 
tumors dissected. Immunohistochemical staining of intrahepatic tumor sections revealed 
NIS-specific staining in all three treatment groups (Fig. 5).  
In tumors from mice treated with polyplexes for dual-targeting, a more intense NIS-specific 
immunostaining and increased amounts of clusters of membrane-associated NIS gene 
expression in the vicinity of blood vessels was observed (Fig. 5, left panel) compared to 
tumors from animals that were injected with single EGFR- (Fig. 5, middle panel) and cMET-
targeting polyplexes (Fig. 5 right panel).  
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Fig. 5: Paraffin embedded tumor sections were immunohistochemically stained for NIS expression. Tumors from 
mice treated with polyplexes for dual-targeting revealed a more intense and increased amount of clusters of 
membrane-associated NIS gene expression around blood vessels in the tumorous tissue compared to tumors 
from animals that were injected with polyplexes for single EGFR- and cMET-targeting. Adapted from submitted 
manuscript. 
 
Radioiodine therapy studies after in vivo NIS gene transfer 
After the proof of concept of effective tumoral NIS transduction using polyplexes for dual-
targeting, the therapeutic effect of the dual-targeting NIS gene therapy concept after 
application of 131I was assessed. Mice developing orthotopic liver carcinomas were treated 
according to an established treatment protocol [46]. Three weeks after tumor cell inoculation, 
mice in the therapy group received three cycles of dual-targeted polyplexes i.v. on days 0, 3 
and 7, followed by i.p. injections of 55.5 MBq 131I on days 2, 5 and 9 (n=8). Control mice 
received saline instead of iodide (n=8). Four sonographic measurements were performed on 
days 2, 9, 15 and 23 after therapy start. Mice in the therapy group exhibited significantly 
reduced tumor growth (Fig. 6A,B) compared to the control group (Fig. 6A,C), which was 
associated with significantly prolonged survival up to 45 days after therapy start in 
comparison to 29 days in the control group (Fig. 6D).  
When mice had to be sacrificed due to tumor growth, intrahepatic HCCs were dissected and 
further processed for immunofluorescence analysis. A Ki67-specific antibody (green) was 
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used to identify tumor cell proliferation and an antibody against CD31 (red) served for blood 
vessel labeling (Fig. 6E). The application of dually targeted polyplexes followed by 131I 
resulted in reduced proliferation and blood vessel density compared to tumors of mice 
treated with saline instead of iodide (Fig. 6E). 
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Fig. 6: The therapeutic effect of the dual-targeting NIS gene therapy approach after application of 131I was 
assessed. Three weeks after tumor cell inoculation, mice received three cycles of polyplexes for dual-targeting 
i.v., followed by i.p. injections of 55.5. MBq 131I (n=8). Control mice received saline instead of the therapeutic 
iodide (n=8). Animals treated with polyplexes for dual-targeting that received radioiodide showed reduced tumor 
growth during and after therapy (A, B) assessed by conventional sonography in comparison to animals that 
received saline instead (A, C) (*p≤0.05). This was accompanied by significantly enhanced survival in the therapy 
group (D) (*p≤0.05). Immunofluorescence analysis of tumors after therapy revealed reduced proliferation (Ki67, 
green) and blood vessel density (CD31, red) in mice that received the cytoxic iodide compared to tumors of mice 
treated with saline (E). Results are reported as mean ± SEM or percent for survival blot. Adapted from submitted 
manuscript. 
 
Perfusion of intrahepatic tumors determined by CEUS  
Two weeks after the last treatment cycle, tumor perfusion was assessed to compare tumors 
from mice treated with polyplexes for dual-targeting that received 131I with animals that 
received saline instead. Mice in the therapy group demonstrated an overall reduced contrast 
agent uptake and a lower maximum signal compared to mice that received saline (Fig. 7A). 
This was further associated with reduced peak enhancement (PE; 1432.7 ± 534.6) (Fig. 7B), 
wash-in area under the curve (WiAUC; 7184.2 ± 2197.6) (Fig. 7C) and retention time (RT; 
7.98 ± 0.97) (Fig. 7D) of therapy animals in comparison to control animals (PE: 2425.9 ± 
260.5; WiAUC: 19633.4 ± 1451.8; RT: 11.39 ± 0.71) (Fig. 7B–D). 
 
 
 
Fig. 7: Tumors of mice treated with polyplexes for dual-targeting that received 55.5 MBq 
131
I (n=4) demonstrated 
an overall reduced contrast agent uptake expressed in arbitrary units (a.u.) compared to mice that received saline 
instead (A) (n=3). Further, tumors of therapy mice showed reduced PE (1432.66 ± 534.55 (B)), WiAUC (7184.2 ± 
2197.6; (C)), RT (7.98 ± 0.97; (D)) after radioiodide therapy as compared to control animals (PE: 2425.9 ± 260.5; 
WiAUC: 19633.4 ± 1451.8; RT: 11.39 ± 0.71; (B–D)). Results are expressed as mean ± SEM (*p≤0.05; **p≤0.01). 
Adapted from submitted manuscript. 
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5.6 Discussion 
 
In the last decade, intensive research in the field of cancer gene therapy has made big 
strides towards novel therapeutic options. For clinical application of cancer gene therapy as 
novel therapeutic alternative, NIS has emerged as an ideal target gene, as it combines the 
features of a reporter and therapy gene. Due to its endogenous thyroidal expression, NIS 
has successfully been used over decades for the treatment of thyroid cancer [33]. The high 
amount of experience gained over the years allows a safe application in humans with a well-
known therapeutic-window and minimal side effects. Introducing NIS to non-thyroidal tumor 
cells offers the possibility to monitor tumor-specific NIS gene expression in a quantitative 
manner as well as exact localization of tumorous tissue by multimodal imaging techniques 
with various NIS-specific tracers [49, 173, 176]. At the same time, NIS expression enables 
application of therapeutic radionuclides (131I, 188Re) for the destruction of cancer cells. The 
high efficacy of the theranostic function of NIS after gene transfer to non-thyroidal tumors has 
been demonstrated in several preclinical studies [35-42, 45-47, 92, 93, 126, 151] and 
showed first promising results in clinical trials after local administration of viral NIS gene 
delivery vectors [131].  
However, in the growing sector of cancer gene therapy, tumor heterogeneity has turned out 
to be a major bottleneck, resulting in limited and diverging efficacy of therapies. Differences 
in morphological and phenotypic characteristics that define the behavior of the tumor lesion 
exist both between different tumors (inter-tumoral heterogeneity) and within tumors (intra-
tumoral heterogeneity) [5]. On the molecular level, intra-tumoral heterogeneity is mirrored by 
diverging cell populations evolved from different subclones [177]. This often lead to great 
differences in surface receptor expression, release of growth factors and cytokines, cellular 
metabolism and stromal architecture [178, 179] and hence to a discrepancy in therapy 
response.  
Also in HCC tumor heterogeneity is a well characterized phenomenon that is at least in part 
responsible for its poor prognosis due to therapy resistance and aggressive tumor 
progression [180-182]. For advanced HCC the multi-kinase inhibitors sorafenib and 
regorafenib [166], which only slightly improve progression-free survival and quality of life, and 
the second-line therapeutics Nivolumab, which is approved for application after therapy 
failure with sorafenib [183], are the only currently available systemic treatment options.  
With the ultimate goal of improved therapeutic efficacy and patient outcomes after tumor-
targeted NIS gene delivery even in heterogeneic tumors with variable receptor expression 
levels, nonviral vectors as potent novel gene delivery vehicles have to be designed and 
applied in a specialized manner for a future clinical translation. Formulation improvement 
includes the synthesis of a cationic carrier backbone for DNA binding, incorporation of 
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hydrophilic domains for polyplex shielding and endosomal buffering and integration of 
targeting ligands that are indispensable for tumor-specific gene delivery. Variable expression 
patterns of ligand binding surface receptors are often responsible for heterogenous response 
rates and expression levels of genetic information after targeted gene transfer. Bispecific 
targeting as well as combination of different therapy approaches are already well-established 
strategies in the clinical setting in the form of combination of different antibodies and 
chemotherapeutics with different modes of action to circumvent resistance and enhance 
efficacy. Thinking along the same lines, a dual-targeting approach was performed in this 
study focusing on simultaneously targeting the two receptors EGFR and cMET. EGFR and 
cMET overexpression in many different cancer types, which is often accompanied with poor 
prognosis, provide the basis for this approach with the aim of increasing the efficacy of 
targeting and transduction in heterogeneic tumors. Two underlying mechanisms that 
enhance binding and uptake of polyplexes for dual-targeting are conceivable: (1) the dual 
approach may mimic virus-like particles that use more than one receptor for uptake [68, 88] 
and (2) receptor crosslinking may trigger enhanced endocytosis and particle uptake into the 
lysosome and trafficking to the cell nucleus [84].  
As small peptide ligands exhibit favorable characteristics compared to large proteins and 
antibodies as targeting ligands due to synthesis procedures, the small peptide ligands GE11 
for EGFR-targeting and cMBP for cMET-targeting were coupled to a well-established LPEI-
PEG2kDa-backbone in this study. Both ligands demonstrated high tumor specificity with high 
targeting efficacy in former studies [39, 46, 68, 69, 151]. The polyplexes are formed by 
mixing NIS DNA with either 100% LPEI-PEG-GE11 or 100% LPEI-PEG-cMBP for single 
receptor targeting or with a solution of polymers containing 50% LPEI-PEG-GE11 and 50% 
LPEI-PEG-cMBP at a total N/P ratio of 6 for dual-targeting.  
To exclude differences in particle formation and size between polyplexes for single- or dual-
targeting that may have an impact on transduction efficiency, polyplex solutions were 
examined by TEM. All three solutions exhibited comparable sizes of round and linear formed 
particles ranging from 50-200 nm. For particles with these sizes cellular uptake is described 
to occur via a clathrin-dependent endocytosis pathway [60]. 
Detailed analysis of binding and uptake of polyplexes after single-receptor and dual-receptor 
targeting was performed by flow cytometry with labeled NIS DNA in three different cell lines. 
The HCC cell line HuH7 as well as the breast cancer cell line MCF-7 showed high EGFR and 
cMET expression, whereas for the thyroid carcinoma cell line FTC-133 low expression of 
both surface receptors was detected in vitro. HuH7 and MCF-7 exhibited higher cellular 
binding and uptake capacity after simultaneous dual-targeting, which correlated well with 
iodide uptake levels, compared to results obtained after targeting only one receptor. The low 
EGFR and cMET expressing cell line FTC-133, however, did not show any advantage of 
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dual-targeting over single-targeting, confirming that improved transfection efficiency is ligand-
dependent and the effect cannot be reproduced in low receptor expressing cells.  
As a next step, the reporter function of NIS was used for detailed investigation of NIS gene 
expression in vivo in orthotopic HuH7 HCC tumors by noninvasive small-animal PET imaging 
using 124I as tracer. A beneficial effect of the dual-targeting strategy over both single-targeting 
approaches was detected. Images of mice that received dual-targeted polyplexes showed 
higher levels of NIS-mediated radioiodine uptake in the tumor lesion. Quantification of iodide 
uptake revealed higher levels after dual-targeting at all imaging time points. Interestingly, 
single EGFR-targeting showed higher levels of radioiodide uptake 1 h after tracer application 
compared to cMET-targeting. After 3 h, tumors of both single-targeting approaches showed 
nearly the same tumoral iodide uptake levels. With dual-targeting an approximately 1% of ID 
higher uptake was achieved. After 5 h, EGFR-targeting has dropped down more rapidly 
showing higher levels of iodide efflux and therefore lower iodide retention as compared to 
dual and cMET-targeting. This is crucial for more effective therapeutic application of 131I, as 
iodide retention is an essential factor to reach a sufficiently high tumor absorbed dose, 
especially in the absence of iodide organification in liver tumors [18].  
Immunohistochemical staining showed strong tumorous NIS protein expression in all three 
treatment groups after application of polyplexes. NIS-specific immunostaining was mainly 
located in the vicinity of blood vessels and occurred in typical clusters. A trend towards more 
intensive and expanded areas of NIS-specific immunostaining was seen in sections of 
animals that received polyplexes for dual-targeting. 
After confirming the beneficial effect of dual-targeting in vivo by imaging of biodistribution and 
levels of NIS expression, the therapeutic efficacy of this NIS gene delivery strategy was 
evaluated. Animals were treated with dual-targeted polyplexes followed by application of 131I 
48 h later. As control group, animals received saline instead of the therapeutic radioiodide. 
The therapy regimen was performed according to an established treatment protocol [46, 126] 
that allows comparison to earlier studies. Tumor growth was monitored by conventional 
sonography and perfusion was assessed by CEUS with the contrast agent SonoVue®. 
Animals in the therapy group showed significantly reduced tumor growth and prolonged 
survival. The therapeutic effect was further investigated by comparing tumor cell proliferation 
and blood vessel density of the therapy and control group ex vivo. Reduced proliferation and 
a lower amount of blood vessels in tumor sections of therapy animals that received 131I 
correlated with the reduced progression of the intrahepatic tumors. CEUS perfusion data, 
which showed reduced peak enhancement, lower wash-in area under the curve and lower 
retention times in tumors of therapy animals that show lower blood vessel formation 
complemented the results and confirm the enormous therapeutic efficacy of dual-targeted 
NIS gene therapy.  
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In conclusion, this novel simultaneous targeting approach of EGFR and cMET for NIS gene 
delivery to HCC tumors combines two crucial bispecific approaches: NIS with its innate dual 
characteristics to function as reporter gene for diagnostic evaluation and as therapeutic gene 
in synergy with dual-targeting of two receptors that results in enhanced cellular uptake and 
increased NIS gene expression in the tumor lesion. Our results highlight the benefits of the 
bifunctional strategy that represents a promising concept for future clinical translation 
providing two major advantages for clinical application, enhancing safety by molecular 
imaging of biodistribution and levels of gene expression as well as overcoming the limitations 
through tumor heterogeneity by designing polyplexes that home to several targets. 
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6.1 Abstract  
 
The sodium iodide symporter (NIS) as well characterized theranostic gene represents an 
outstanding tool to target different cancer types allowing non-invasive imaging of functional 
NIS expression and therapeutic radioiodide application. Based on its overexpression on the 
surface of most cancer types, the cMET/hepatocyte growth factor receptor serves as ideal 
target for tumor-selective gene delivery. Sequence-defined polymers as non-viral gene 
delivery vehicles comprising polyethylene glycol (PEG) and cationic (oligoethanoamino) 
amide cores coupled with a cMET-binding peptide (cMBP2) were complexed with NIS-DNA 
and tested for receptor-specificity, transduction efficiency and therapeutic efficacy in 
hepatocellular cancer cells HuH7. In vitro iodide uptake studies demonstrated high 
transduction efficiency and cMET-specificity of NIS-encoding polyplexes (cMBP2-PEG-
Stp/NIS) compared to polyplexes without targeting ligand (Ala-PEG-Stp/NIS) and without 
coding DNA (cMBP2-PEG-Stp/Antisense-NIS). Tumor recruitment and vector biodistribution 
were investigated in vivo in a subcutaneous xenograft mouse model showing high tumor-
selective iodide accumulation in cMBP2-PEG-Stp/NIS-treated mice (6.61.6% ID/g 123I, 
biological half-life 3 h) by 123I-scintigraphy. Therapy studies with 3 cycles of polyplexes and 
131I application resulted in significant delay in tumor growth and prolonged survival. These 
data demonstrate the enormous potential of cMET-targeted sequence-defined polymers 
combined with the unique theranostic function of NIS allowing for optimized transfection 
efficiency while eliminating toxicity. 
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6.2 Introduction 
 
As cancer is one of the leading causes of death both in developed and developing countries 
[184], new therapy approaches are urgently needed, especially for cancer types with poor 
prognosis, where surgery, chemo- and radiotherapy often prove ineffective, such as 
advanced hepatocellular cancer [98]. Gene therapy with its broad potential to interact and 
interfere with aberrant physiological processes has emerged as a powerful tool in oncology in 
recent years [185]. However, gene therapy still faces hurdles that strongly limit its application 
[55]. Low tumor selectivity of gene delivery vehicles, immunoreactions after systemic 
application and limited effectiveness of therapy genes have driven the search for novel 
biodegradable vectors with improved safety profile and enhanced transduction efficiency [12, 
16, 68, 69, 186]. 
Based on its theranostic function, the sodium iodide symporter (NIS) represents an ideal 
therapeutic gene [16, 89, 187, 188]. The unique combination of reporter and therapy gene 
characteristics allows non-invasive imaging of vector biodistribution and functional NIS 
expression at tumor sites by 123I-scintigraphy and 124I-/18F-tetrafluoroborate positron emission 
tomography (PET) as well as exact dosimetric calculations before the assessment of 
therapeutic efficacy after application of 131I. Several groups including our own have 
successfully demonstrated the capacity of NIS to induce radioiodide accumulation in different 
non-thyroidal tumor models mediated by various gene delivery vehicles, including 
mesenchymal stem cells as well as viral and non-viral vectors [35-44, 47, 90, 92, 95, 176, 
189]. 
Further improvement of the NIS gene therapy concept is focused on generation of new 
shuttle systems with advanced efficiency, specificity and low cytotoxicity. Cationic polymers 
as a major sector of non-viral vectors offer the advantages of low immunogenicity, good 
nucleic acid binding and easy up-scaling [53]. In order to improve performance for systemic 
application and further enhance transduction efficiency, various design strategies have been 
developed for the synthesis of novel sequence-defined polymers. In this context, we 
generated small, well biocompatible polymer backbones with precisely integrated functional 
groups. These include cationic (oligoethanoamino) amide cores for nucleic acid binding, 
polyethylene glycol (PEG) linkers for surface shielding, targeting ligands for cell binding and 
protonatable amino acids with buffer function for a higher rate of endosomal escape, leading 
to optimized and DNA carrier-improved systems for systemic administration [12, 68, 69].  
Selective active ligand-mediated tumor-targeting represents an elegant method to further 
enhance tumor specificity, making use of aberrant tumor physiology that is often 
accompanied by up-regulation of various receptors on the surface of tumor cells, such as the 
epidermal growth factor receptor (EGFR) [3]. We recently reported efficient EGFR-targeting 
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with viral and non-viral gene delivery vehicles, which resulted in high tumoral iodide uptake 
after systemic NIS gene transfer that was sufficient for a delay in tumor growth and 
prolonged survival in a subcutaneous hepatocellular cancer xenograft mouse model [36, 39]. 
Another attractive and important target in cancer therapy is the receptor tyrosine kinase 
cMET/hepatocyte growth factor receptor (HGFR). High surface expression levels and 
activation of cMET/HGFR in a broad range of malignancies are implicated in tumor 
progression and are often associated with poor prognosis [190]. In order to target non-viral 
gene delivery vehicles to cMET/HGFR, a cMET-binding peptide (cMBP2) was developed via 
phage-display screening and further identified as ideal ligand with high receptor affinity that 
specifically enhances nanoparticle adhesion to the target cell [69, 123, 191, 192].  
In the current study, we combined the NIS gene therapy concept with novel sequence-
defined polymers as non-viral gene delivery vehicles coupled to cMBP2. Based on the dual 
function of NIS, the potential of this cMET-targeted gene therapy approach was investigated 
by non-invasive imaging of vector biodistribution and transduction efficiency in a 
subcutaneous hepatocellular carcinoma mouse model. Subsequently, therapeutic efficacy 
was assessed by monitoring tumor growth after application of a therapeutic dose of 131I. 
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6.3 Materials and methods 
 
Cell culture 
The human hepatocellular carcinoma cell line HuH7 (JCRB0403; Japanese Collection of 
Research Bioresources Cell Bank, Osaka, Japan) was cultured in Dulbecco’s modified eagle 
medium (DMEM; 1 g/l glucose; Sigma-Aldrich, St.Louis, Missouri, USA) and the human 
hepatocellular carcinoma cell line Hep3B (HB-8064; American Type Culture Collection 
(ATCC), Manassas, VA) was cultured in Eagle's Minimum Essential Medium (EMEM; Sigma-
Aldrich). Both media were supplemented with 10% (v/v) fetal bovine serum (FBS Superior, 
Biochrom/Merck Milipore, Berlin, Germany) and 1% (v/v) penicillin/streptomycin (Sigma-
Aldrich).  
Cells were maintained at 37°C and 5% CO2 in an incubator with a relative humidity of 95%. 
Cell culture medium was replaced every second day and cells were passaged at 80% 
confluency. 
 
Plasmid and polymer synthesis 
The expression vector pCpG-hCMV-NIS driven by the human elongation factor 1α promotor 
and human cytomegalovirus enhancer element containing the full-length codon-optimized 
NIS cDNA (Geneart, Regensburg, Germany) was generated as described previously [39]. 
For all in vitro and in vivo experiments pNIS-DNA produced and purified by Plasmid Factory 
GmbH (Bielefeld, Germany) was used. Synthesis of polymers was carried out as described 
previously [69] and polymers were used as 5 mg/ml stock solutions. Polymer syntheses were 
performed by Stephan Morys (Department of Pharmacy, Pharmaceutical Biotechnology, 
LMU). 
 
Polyplex formation 
For polyplex formation the sequence-defined histidinylated cMET-targeted polymer 
(cMBP2-PEG-Stp) or a control polymer with alanine instead of the ligand (Ala-PEG-Stp) and 
a PEG-free three-armed polymer (3-arm-Stp, #689) in a molar ratio of 70:30 to compact 
polyplexes were used [69]. The polymer blend and plasmid DNA (pDNA) were diluted in 
same volumes of HEPES buffered glucose (HBG: 20 mmol/l HEPES, 5% glucose (w/v) at pH 
7.4). Polymers were added to the DNA by rapid mixing at a N/P (nitrogen/phosphate) ratio 
(w/w) of 12 and incubated at room temperature for 30 minutes before use. For calculation, 
only protonatable nitrogen groups were considered. Final DNA concentration for in vitro 
studies was 2 µg/ml, for in vivo studies 200 µg/ml.  
 
Transient transfection and 125I uptake assay 
  cMBP2 polyplexes 
89 
 
To measure the transduction efficiency, cells were grown to 60-80% confluency (2x105 HuH7 
or Hep3B cells/well in 6-well-plates) and incubated for 4 h with DNA/polymer-solutions in 
serum- and antibiotic-free medium. Medium was then changed to normal growth medium 
and, 24 h later, iodide uptake activity was measured. NIS-mediated 125I uptake assays were 
performed as described previously [47]. Results were normalized to cell survival measured 
by cell viability assay (see below) and expressed as cpm/A620. 
 
Cell viability assay 
Cells were incubated with a commercially available MTT reagent (Sigma-Aldrich) for 2 h at 
37°C followed by a washing step with PBS (phosphate-buffered saline). Cell viability was 
measured after incubation with 10% DMSO (dimethyl sulfoxide) in isopropanol at 620 nm in a 
Sunrise microplate absorbance reader (Tecan, Männedorf, Switzerland). 
 
Flow cytometry analysis 
Cell surface cMET/HGF-receptor expression levels were quantified by flow cytometry 
analysis. HuH7 and Hep3B cells were detached with trypsin and washed with FACS buffer 
(PBS with 10% FBS). Cells were incubated with an antibody that detects human 
cMET/HGFR (1:200; monoclonal mouse IgG1, R&D Systems, Minneapolis, USA) for 1 h on 
ice. As negative control, an IgG-anti-mouse antibody (BD Bioscience, Franklin Lakes, USA) 
was used. After incubation, cells were washed with FACS-buffer, stained with an AlexaFluor 
488-labeled goat anti-mouse secondary antibody (1:400; Jackson ImmunoResearch, West 
Grove, Pennsylvania, USA) for 1 h on ice, washed and resuspended in FACS buffer. 
Analysis was performed on a BD AccuriTM C6 flow cytometer (BD Bioscience, Franklin Lakes, 
USA). Cells were gated by forward/sideward scatter and pulse width for exclusion of 
doublets. PI (propidium iodine, Sigma-Aldrich) was used for discrimination between viable 
and dead cells.  
 
Establishment of subcutaneous HuH7 tumors 
HuH7 xenografts were established in 6-week-old female CD-1 nu/nu mice (Charles River, 
Sulzfeld, Germany) by subcutaneous injection of 5x106 HuH7 cells suspended in 100 µl of 
PBS into the flank region. Animals were maintained under specific pathogen-free conditions 
with access to mouse chow and water ad libitum.  Before radionuclide application, mice were 
pretreated with L-T4 (L-thyroxine, 5 mg/l; Sigma-Aldrich) in drinking water to reduce iodide 
uptake in the thyroid gland.  
Tumor measurements were performed regularly and tumor volume was estimated using the 
equation: length x width x height x 0.52. Animals were sacrificed when the tumor volume 
reached a size of 1500 mm3 or tumors necrotized. The experimental protocol was approved 
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by the regional governmental commission for animals (Regierung von Oberbayern) and all 
animal experiments were carried out according to the guidelines of the German law of 
protection of animal life. 
 
In vivo radioiodide imaging and biodistribution studies after NIS gene transfer  
When subcutaneous HuH7 tumors reached a size of 10-15 mm in diameter, polyplex 
solutions containing 50 g of pNIS-DNA were applied via the tail vein. Animals were divided 
into three groups and treated either with cMBP2-PEG-Stp/NIS (n=15), cMBP2-PEG-
Stp/Antisense-NIS (n=5) or Ala-PEG-Stp/NIS (n=5). 48 h after polyplex administration, mice 
received an intraperitoneal injection of 18.5 MBq 123I. To determine NIS specificity, a 
subgroup of cMBP2-PEG-Stp/NIS-treated mice received NaClO4 (sodium perchlorate; 2 
mg/mouse; Sigma-Aldrich), a NIS-specific inhibitor, 30 min prior to radioiodide application 
(n=6). Vector biodistribution and tumoral NIS expression were determined by measuring the 
iodide uptake by serial gamma camera imaging (e.cam, Siemens, Munich, Germany; with a 
low-energy high resolution collimator). Regions of interest were quantified by using the 
software HERMES GOLD (Hermes Medical Solutions, Stockholm, Sweden) and are shown 
as percent of injected iodide dose per gram tumor tissue (% ID/g). 
 
Ex vivo biodistribution studies 
For ex vivo biodistribution studies, mice of the cMBP2-PEG-Stp/NIS group (n=6), 
cMBP2-PEG-Stp/NIS+NaClO4 (n=3) group, cMBP2-PEG-Stp/Antisense-NIS group (n=3) or 
Ala-PEG-Stp/NIS group (n=3) received 18.5 MBq 123I to detect iodide accumulation in the 
tumor and non-target organs. 3 h after injection of 123I, mice were sacrificed and organs were 
dissected and measured in a Packard Cobra Quantum Gamma Counter (GMI, Ramsey, 
Minnesota, USA). Results are presented as percent injected dose per organ (% ID/organ). 
 
Immunohistochemical NIS staining 
Immunohistochemical NIS staining was performed on dissected frozen tissues of HuH7 
tumors 48 h after systemic administration of polyplexes. A NIS specific mouse monoclonal 
antibody (Millipore, Darmstadt, Germany; 1:1000) was used for NIS detection and staining 
was performed as described previously [153]. Sections were imaged on an Olympus BX41 
microscope (Olympus, Shimjukum Tokio, Japan) equipped with an Olympus XC30 CCD 
camera (Olympus).  
 
Radioiodide therapy study in vivo 
Therapy studies started when subcutaneous HuH7 tumors reached a size of 5-6 mm. Three 
cycles of polyplex administration were performed on day 0, 3 and 7. Mice received either 
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cMBP2-PEG-Stp/NIS (n=10), cMBP2-PEG-Stp/Antisense-NIS (n=6) or Ala-PEG-Stp/NIS 
(n=6) followed by an intraperitoneal application of 55.5 MBq 131I 48 h later. As additional 
controls mice received cMBP2-PEG-Stp/NIS followed by saline (NaCl; n=9). Mouse survival 
was defined by a maximum tumor volume of 1500 mm3 at which animals had to be 
sacrificed. 
 
Analysis of NIS mRNA expression 
For quantification of NIS expression, total RNA was isolated from HuH7 tumors using the 
RNeasy Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer’s 
recommendations. Reverse transcription was performed using SuperScript III First-Strand 
Synthesis System (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Quantitative 
real-time PCR was run with the QuantiTect SYBR Green PCR Kit (Qiagen) in a Mastercycler 
ep gradient S PCR cycler (Eppendorf, Hamburg, Germany). Relative expression levels were 
calculated from ΔΔCt values normalised to internal β-actin. The following primers were used:  
hNIS: (5’ACACCTTCTGGACCTTCGTG-3’) and (5’-GTCGCAGTCGGTGTAGAACA-3’),  
β-Actin: (5’AGAAAATCTGGCACCACACC-3’) and (5’-TAGCACAGCCTGGATAGCAA-3’). 
 
Indirect immunofluorescence assay 
After treatment, at the end of the observation period, immunofluorescence staining was 
performed on dissected frozen tissues, which were fixed in 80% methanol at 4°C for 5 min 
and acetone at -20°C for 2 min. After rehydration in PBS and blocking with 12% bovine 
serum albumin/PBS for 30 min at room temperature, incubation with a rabbit polyclonal 
antibody against human Ki67 (Abcam, Cambridge, UK; dilution 1:1000) and a rat monoclonal 
antibody against mouse CD31 (BD Pharmingen, Heidelberg, Germany; dilution 1:200) was 
performed. This was followed by incubation with a secondary anti-rabbit Alexa488-
conjugated antibody (Jackson ImmunoResearch, West Grove, Pennsylvania, USA) for Ki67 
staining and secondary anti-rat Cy3-conjugated antibody (Jackson ImmunoResearch) for 
CD31 staining. Nuclei were counterstained with Hoechst bisbenzimide (5 mg/ml) and 
sections were embedded in Fluorescent Mounting Medium (Dako, Hamburg, Germany). 
Stained sections were examined using an Axiovert 135 TV fluorescence microscope 
equipped with an AxioCam MRm CCD camera and AxioVision Re. 4.8. software (Carl Zeiss, 
Munich, Germany). Quantification of proliferation (Ki67-staining) and blood vessel density 
(CD31-staining) was performed by evaluation of 6 visual fields per tumor using ImageJ 
software (NIH). 
 
Statistical methods 
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All in vitro experiments were carried out at least in triplicates. Results are expressed as mean 
± SEM, mean fold change ± SEM and, for survival plots, in percent. Statistical significance 
was calculated by two-tailed Student’s t-test for in vitro and ex vivo experiments or Mann-
Whitney U test for in vivo experiments. P values ≤0.05 were considered significant (*p≤0.05, 
**p≤0.01, ***p≤0.001). 
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6.4 Results 
 
In vitro cMET-targeted NIS-gene transfer in HuH7 and Hep3B cells 
cMET/HGFR expression levels on the cell surface of HuH7 and Hep3B cells were detected 
by flow cytometry (Figs. 1a,b). High cMET/HGFR expression levels on HuH7 cells correlated 
well with high levels of transduction efficiency after incubation with cMET-targeted PEGylated 
polyplexes cMBP2-PEG-Stp/NIS (Stp=succinoyl-tetraethylene pentamine), while significantly 
lower transgene expression levels were obtained after transfection of low cMET/HGFR 
expressing Hep3B cells (Fig. 1c). This led to the selection of the HuH7 cell line as model 
system for further in vitro and in vivo experiments. Transduction conditions were optimized by 
measurement of perchlorate-sensitive iodide uptake activity 24 h after NIS gene transfer and 
best conditions with lowest cytotoxicity were used in all subsequent experiments. Incubation 
of HuH7 cells with cMBP2-PEG-Stp/NIS polyplexes resulted in a 12-fold increase in 125I 
uptake compared to empty polymers, which was completely blocked upon treatment with the 
NIS-specific inhibitor sodium perchlorate. In contrast, replacement of the targeting ligand 
cMBP2 by alanine (Ala-PEG-Stp/NIS) showed a significantly lower iodide uptake activity, 
demonstrating targeting specificity of the targeting ligand cMBP2. No iodide uptake above 
background levels was seen in HuH7 cells transfected with empty polymers cMBP2-PEG-Stp 
and cMBP2-PEG-Stp/Antisense-NIS (Fig. 1d). Results were normalized to cell viability. Cell 
viability was not affected by polyplex-mediated gene transfer (Fig. 1e). 
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Fig. 1: Surface expression of cMET/HGFR on HuH7 (a) and Hep3B cells (b) was analyzed by flow cytometry with 
an antibody that specifically detects human cMET/HGFR and compared to isotype controls. 
125
I uptake levels 
were measured in HuH7 and Hep3B cells after in vitro transduction with cMBP2-PEG-Stp/NIS polyplexes (n=3) at 
an N/P ratio of 12 and results correlated well with cMET/HGFR expression levels (c). Further, to identify receptor 
specificity and NIS-dependency of iodide uptake, HuH7 cells were transfected with untargeted polyplexes Ala-
PEG-Stp/NIS (n=3), cMBP2-PEG-Stp/Antisense-NIS (n=3) and polymer without DNA (n=3) (*p<0.05; **p<0.01) 
(d). Cell viability was not affected by polyplex-mediated gene transfer, as determined by MTT assay (n=3) (f). 
Results are reported as mean ± SEM. Polymer syntheses were performed by Stephan Morys (Department of 
Pharmacy, Pharmaceutical Biotechnology, LMU). Adapted from [46]. 
 
In vivo iodide uptake studies after systemic NIS gene transfer 
To evaluate vector biodistribution and functional NIS expression after cMET-targeted gene 
transfer in HuH7 tumor-bearing mice, animals received an intraperitoneal dose of 123I 24 h or 
48 h after intravenous application of polyplexes. Radioiodide biodistribution was assessed by 
gamma camera imaging and regions of interest were quantified. A considerably higher 
tumoral iodide uptake was observed in tumors of mice that received 123I 48 h after application 
of cMBP2-PEG-Stp/NIS polyplexes as compared to 24 h (data not shown).  For all 
subsequent in vivo experiments, radionuclide application was conducted 48 h after polyplex 
administration. 
In contrast to high levels of radionuclide accumulation in 80% (7 out of 9) of tumors of mice 
treated with cMBP2-PEG-Stp/NIS (Fig. 2a), tumors of mice injected with the untargeted 
control polyplex Ala-PEG-Stp/NIS exhibited only weak tumoral iodide accumulation (Fig. 2b). 
No tumoral iodide uptake above background levels was measured after treatment with 
cMBP2-PEG-Stp/Antisense-NIS polyplexes (Fig. 2c). Physiological expression of NIS in 
thyroid and stomach resulted in iodide accumulation in theses tissues and, due to renal 
elimination of radioiodide, iodide uptake was also observed in the bladder. No additional 
iodide uptake was recorded in non-targeted organs such as lung, liver, kidney and spleen. 
NIS-specificity was confirmed by intraperitoneal application of the NIS-specific inhibitor 
sodium perchlorate 30 min prior to radionuclide application, which resulted in an almost 
complete inhibition of iodide uptake in the tumor and organs that physiologically express NIS 
(Fig. 2d). Serial scanning revealed a maximal 123I accumulation of 6.61.6% ID/g (percentage 
of the injected dose per gram tumor) in NIS-transduced HuH7 xenografts with a biological 
half-life of 3 h (Fig. 2e). A tumor-absorbed dose of 41 mGy/MBq/g tumor with an effective 
half-life of 3 h for 131I was calculated. 
 
Ex vivo biodistribution studies after systemic NIS gene transfer 
Ex vivo biodistribution was performed to further assess tumor-specific iodide uptake after 
systemic polyplex administration. 3 h after 123I application, mice were sacrificed, organs 
dissected and subsequently measured in a gamma counter. Ex vivo biodistribution results 
correlated well with gamma imaging results, showing a perchlorate-sensitive tumoral 
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radioiodide uptake of 3% of the injected dose per organ in cMBP2-PEG-Stp/NIS-treated mice 
3 h after injection of the radionuclide. Moreover, almost no iodide uptake was detected in 
non-target organs and tumors of control mice that received either Ala-PEG-Stp/NIS, cMBP2-
PEG-Stp/Antisense-NIS or cMBP2-PEG-Stp/NIS and sodium perchlorate (Fig. 2f). 
 
 
 
 
Fig. 2: 48 h after polyplex administration, vector biodistribution in mice bearing subcutaneous HuH7 xenografts 
was analyzed by 
123
I-scintigraphy. Tumoral iodide uptake of cMBP2-PEG-Stp/NIS-treated mice (n=9) (a), Ala-
PEG-Stp/NIS-treated mice, where the targeting ligand was replaced by alanine (n=5) (b), and cMBP2-PEG-
Stp/Antisense-NIS treated mice (n=5) (c) was measured 3 h post radioiodide injection. A subset of cMBP2-PEG-
Stp/NIS-treated mice was pretreated with the NIS-specific inhibitor perchlorate 30 min before 
123
I application (n=6) 
(d). Iodide accumulation in tumors over the time and the biological half-life of 
123
I were monitored by serial 
scanning (e). Ex vivo biodistribution was performed 3 h after injection of the radionuclide. Organs of cMBP2-PEG-
Stp/NIS-treated mice without (n=6) and with sodium-perchlorate-pretreatment (n=3), Ala-PEG-Stp/NIS-treated 
mice (n=3) and cMBP2-PEG-Stp/Antisense-NIS-treated mice (n=3) were dissected and 
123
I accumulation in single 
organs was measured by gamma-counting (f). Results are reported as mean ± SEM. Adapted from [46]. 
 
Immunohistochemical analysis of NIS protein expression after polyplex-mediated 
gene transfer 
Immunohistochemical analysis of NIS protein expression in HuH7 xenografts 48 h after 
cMET-targeted polyplex-mediated gene transfer revealed a heterogeneous staining pattern 
with multiple clusters of NIS-specific immunoreactivity in tumors of mice that received 
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cMBP2-PEG-Stp/NIS (Figs. 3a,b). In both control groups (Ala-PEG-Stp/NIS, cMBP2-PEG-
Stp/Antisense-NIS) no specific NIS expression was detected (Figs. 3c,d), which is 
comparable to untreated tumor tissue (Fig. 3e). 
 
 
Fig. 3: (a-e) NIS protein expression in HuH7 xenografts was analyzed by immunohistochemistry 48 h after cMET-
targeted polyplex-mediated gene transfer on frozen tumor section from mice that received cMBP2-Stp-PEG/NIS 
(a, b), from mice that received control polyplexes (Ala-PEG-Stp/NIS (c), cMBP2-PEG-Stp/Antisense-NIS (d)) and 
from untreated mice (e). Scale bar=100 µm. Adapted from [46]. 
 
Quantification of NIS mRNA expression by quantitative real-time PCR analysis 
To determine NIS mRNA levels in HuH7 xenograft, mRNA was analyzed by quantitative real-
time PCR (qPCR) 48 h after systemic NIS gene transfer (Fig. 3f). High levels of NIS gene 
expression were measured in tumors of cMBP2-PEG-Stp/NIS-treated mice and tumors of 
mice that received the NIS-specific inhibitor sodium perchlorate before administration of 
cMBP2-PEG-Stp/NIS. Lower NIS expression levels were observed in tumors of mice treated 
with Ala-PEG-Stp/NIS. No NIS expression above background levels were seen in cMBP2-
PEG-Stp/Antisense-NIS-treated mice. 
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Fig. 3: (F) Tumoral NIS mRNA expression levels after application of cMBP2-PEG-Stp/NIS with and without 
sodium-perchlorate pretreatment, Ala-PEG-Stp/NIS and cMBP2-PEG-Stp/Antisense-NIS were examined by 
qPCR (f). Adapted from [46]. 
 
Radioiodide therapy studies after cMET-targeted non-viral NIS gene delivery 
Therapeutic efficacy was evaluated after establishment of an optimal time scheme of 
repetitive polyplex and 131I application. Mice received either cMBP2-PEG-Stp/NIS, Ala-PEG-
Stp/NIS or cMBP2-PEG-Stp/Antisense-NIS followed by a therapeutic dose of 55.5 MBq 131I 
or cMBP2-PEG-Stp/NIS followed by saline 48 h later. The cycle of gene transfer and 
radioiodine application was conducted three times on days 0/2, 3/5 and 7/9. Mice treated 
with cMBP2-PEG-Stp/NIS that received radioiodide showed a significant delay in tumor 
growth as compared to all control groups (Fig. 4a). This was associated with markedly 
improved survival (Fig. 4b). While mice of control groups had to be sacrificed within 3-4 
weeks after onset of the therapy trial due to excessive tumor growth, mice treated with 
cMBP2-PEG-Stp/NIS and 131I survived up to nearly 7 weeks.  
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Fig. 4: The cycle of intravenous gene transfer and radioiodide application was conducted three times on day 0/2, 
3/5 and 7/9. Mice were treated either with cMBP2-PEG-Stp/NIS and 55.5 MBq 
131
I (n=10), cMBP2-PEG-Stp/NIS 
followed by application of NaCl (n=9), Ala-PEG-Stp/NIS+
131
I (n=6) or cMBP2-PEG-Stp/Antisense-NIS+
131
I (n=6). 
Tumor volumes (a) and animal survival (Kaplan-Meier-Plot (**p<0.01)) (b) of the different therapy groups were 
compared. Results are either reported as mean ± SEM for tumor volumes or in percent for survival plots. Adapted 
from [46]. 
 
Immunofluorescence analysis 
After therapy, at the end of the observation period, mice were sacrificed, tumors dissected 
and tissues further processed for immunofluorescence analysis. A Ki67-specific antibody 
(green) was used to determine cell proliferation and an antibody against CD31 (red) labeled 
blood vessels (Figs. 5a-d). Tumors of animals treated with cMBP2-PEG-Stp/NIS that 
received 131I, exhibited a significantly decreased proliferation and lower blood vessel density 
as compared to control groups (cMBP2-PEG-Stp/NIS+NaCl; cMBP2-PEG-Stp/Antisense-
NIS+131I; Ala-PEG-Stp/NIS+131I) (Fig. 5e,f).  
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Fig. 5: After treatment, when tumors reached a size of 1500mm
3
, mice were sacrificed and tumors dissected. 
Frozen sections of tumor tissue were stained with a Ki67-specific antibody (green) to determine cell proliferation 
and an antibody against CD31 (red) to label blood vessels (a-d). Tumor cell proliferation (e) and blood vessel 
density (f) in tumors from animals treated with cMBP2-PEG-Stp/NIS that received 
131
I (n=10) were compared to 
control groups treated with cMBP2-PEG-Stp/NIS+NaCl (n=8), Ala-PEG-Stp/NIS+
131
I (n=6) or cMBP2-PEG-
Stp/Antisense-NIS+
131
I (n=6). Nuclei were counterstained with Hoechst. Results are reported as mean ± SEM. 
Scale bar=100 µm. Adapted from [46]. 
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6.5 Discussion 
 
Gene therapy is emerging as a highly promising approach to disrupt cancer homeostasis 
through replacement or silencing of malfunctioning genes and insertion of new genes that 
directly kill cancer cells [10, 11]. In this context, NIS represents an ideal candidate gene for 
therapeutic intervention. Its unique capacity to act both as reporter and therapy gene allows 
us to monitor biodistribution of functional NIS expression by multimodal nuclear medicine 
imaging modalities and at the same time allows application of a therapeutic dose of 131I [16, 
48, 50, 97, 129, 188]. Currently, the NIS gene therapy concept is being evaluated in prostate 
cancer patients after local adenovirus-mediated NIS gene delivery (NCT00788307) [49, 174]. 
Moreover, the reporter function of NIS is being tested in various protocols in different cancer 
types, including head, neck, ovarian and peritoneal cancer to monitor biodistribution of 
genetically engineered oncolytic measles virus and mesenchymal stem cells that express 
NIS [51, 94, 130, 173, 193]. However, systemic application with its potential to target 
metastatic disease requires further improvement of shuttle systems, as the potential of 
therapeutic genes is highly dependent on efficient and tumor-selective delivery. The delivery 
pathway from injection site to distant tumor sites poses several major obstacles that need to 
be overcome [56, 57]. Besides nuclease-dependent stability of nucleic acids in blood 
circulation, stable complexes of nucleic acid and vector system need to be formed to achieve 
long-term persistence of systemically applied delivery vehicles. Further requirements include 
an enhanced safety profile for reduced interactions with blood components and low 
immunogenicity as well as high targeting specificity to minimize effects on non-target cells 
and to achieve sufficiently high gene expression levels specifically in tumor tissue. 
Additionally, after entering the target cell via endocytic cellular uptake, protection from 
lysosomal degradation along with efficient endosomal escape are crucial steps for 
intracellular delivery of genetic information [53, 56, 57].  
In our previous preclinical studies, we investigated the potential of viral and non-viral vector 
systems to deliver the NIS gene to non-thyroidal tumor cells after systemic application [35-
44, 47, 48, 93, 175, 194]. Viral vectors represent a highly efficient option due to their inherent 
capacity to insert their genetic material into host cells, as we have shown using different 
adenoviral vectors [35-37, 41, 93]. However, these vectors bear a series of limitations 
including high immunogenicity, unspecific cell tropism and uncontrolled insertion of DNA into 
the host genome [9, 53]. We further demonstrated the feasibility of non-viral delivery vehicles 
based on biodegradable pseudodendritic oligoamines and EGFR-targeted LPEI-PEG-
polymers. Application of pseudodendritic polymers G2-HD-OEI in different tumor models led 
to high NIS-mediated tumoral iodide accumulation and subsequently high therapeutic 
efficiency. As there is no specific targeting ligand, tumor selectivity was mostly obtained by 
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high intrinsic tumor affinity through the so-called “enhanced permeability and retention” effect 
in these well-vascularized tumors with leaky blood vessel structure [38, 40, 165]. Active EGF-
receptor targeting of LPEI-PEG-GE11 polymers via the GE11 ligand resulted in high specific 
iodide accumulation in tumor tissue. Receptor mediated uptake could be confirmed by 
pretreatment with the EGFR-specific antibody cetuximab showing significant decrease of 
polyplex uptake in tumor cells and NIS expression [39]. However, the main drawbacks of 
these non-viral delivery systems are the variable constitution and polydispersity as well as 
limited specificity of untargeted pseudodendritic oligoamines and the low biocompatibility and 
long-term toxicity of LPEI-derivatives. Consequently, for clinical application of synthetic non-
viral gene delivery vehicles, it is indispensable to develop highly defined substances with 
improved efficiency, low immunogenicity and a precise, constant and easily reproducible 
structure.  
These desirable features can be realized through the design of novel sequence-defined 
polymers with structure-activity relationships by solid-phase synthesis [66], allowing 
generation of precise backbones and incorporation of multiple functional groups. The optimal 
balance between the formation of stable polyplexes and efficient release of DNA at the target 
site is obtained by serial synthesis of artificial amino acid succinoyl-tetraethylenepentamine 
(Stp) repeats which contain a diaminoethane motif and form the basic polymer structure [68, 
69]. This functional site exhibits optimal DNA condensation ability, equips the polymer with 
buffering amine functions and shows enhanced biodegradability and low toxicity compared to 
the “gold standard” LPEI. Terminal cysteines further support polyplex stabilization via 
disulfide bridges. For surface shielding, hydrophilic PEG domains are incorporated that 
reduce non-specific interactions with serum components, thus leading to a higher safety 
profile and lower immunogenicity of polyplexes. Additional histidines as protonatable amino 
acids with high buffering capacity are integrated to improve endosomal escape for adequate 
release of polymers in target cells [58, 69].  
Active ligand-mediated targeting is an elegant method to enhance tumor specificity and thus 
amplify transgene expression in tumoral tissues while reducing side effects in non-target 
organs [57]. Active targeting is a prerequisite for clinical application, as polymer accumulation 
in tumor tissue by passive targeting is highly dependent on retention effects and leaky 
vascular structure [79, 80]. As growth factor receptors are often overexpressed and play a 
crucial role in tumor progression, promising candidates that act as ligands have been 
developed via phage display analysis with a focus on short peptides, as they are easy to 
synthesize and show high receptor affinity. In previous studies, we have already shown the 
efficacy of the short peptide GE11 for EGFR targeting [36, 39]. Another attractive target 
receptor in cancer therapy is cMET/HGFR. High surface expression levels and activation of 
cMET in a broad range of malignancies are implicated in tumor progression and metastasis 
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and are often associated with poor prognosis [190]. The cMET-binding peptide cMBP2 was 
identified as an ideal ligand with high receptor affinity that specifically enhances nanoparticle 
adhesion to the target cell without activating the receptor [69, 123, 191]. Peptide ligand 
specificity was confirmed by high cell binding of cMBP2-polyplexes to cMET/HGFR over-
expressing prostate cancer cells DU145 [69] and HCC cells HuH7, in contrast to alanine 
ligand control and four different scrambled sequences of cMBP2 which showed no specific 
cellular binding [69]. Furthermore, a novel flow method to assess the potential of peptides to 
specifically bind to their receptors demonstrated sequence-specificity of cMBP2 in binding to 
the cMET/HGFR expressing HuH7 HCC cell line [123]. Therefore, in this study, we selected 
cMBP2 as ligand for our innovative sequence-defined cMET-targeted polymers to direct NIS 
expression to HuH7 HCC xenograft mouse model. The HCC cell line HuH7 represents an 
attractive platform for cMET-targeted non-viral gene delivery due to its high levels of 
endogenous surface expression of cMET/HGFR.  
High levels of natural cMET expression on HuH7 cells were confirmed via flow cytometry 
analysis and expression levels were shown to correlate well with in vitro transfection 
efficiency of cMET-targeted polyplexes cMBP2-PEG-Stp/NIS in comparison to the low cMET 
expressing HCC cell line Hep3B. Further in vitro transfection studies using high 
cMET/HGFR-expressing HuH7 cells revealed an ideal ratio of 12 protonatable nitrogen 
groups in the polymer backbone per negatively charged phosphate in the nucleic acid (N/P), 
which resulted in optimal nucleic acid binding, very low toxicity and highest transfection 
levels. To optimize particle size and DNA compaction for subsequent in vivo application, the 
three-armed non-PEGylated polymer #689 (3-arm-Stp) was added at 30 molar percentage.  
As a next step, we took further advantage of the reporter function of NIS to investigate 
transduction efficiency of cMET-targeted polyplexes in vivo.123I gamma camera imaging of 
vector biodistribution and functional NIS expression in HuH7 tumor-bearing mice revealed a 
high tumor-specific iodide uptake of 6.61.6% ID/g in cMBP2-Stp-PEG/NIS-treated mice 48 h 
after intravenous polyplex administration. Significantly lower tumoral iodide accumulation 
after injection of Ala-PEG-Stp/NIS polyplexes verified improved tumor-selective transduction 
efficiency of actively targeted polyplexes. The significantly lower, but measureable iodide 
uptake after transfection with untargeted Ala-PEG-Stp/NIS polyplexes is due to basal 
transduction efficiency of the untargeted polymer based on passive targeting effects through 
the so-called “enhanced permeability and retention” effect in well-vascularized tumors [38, 
40, 165]. The significant differences in 123I uptake of cMET-targeted polyplexes in 
comparison to untargeted polyplexes in vivo underline the remarkable targeting-effects of the 
cMBP2 ligand. Pretreatment with the NIS-specific inhibitor sodium perchlorate in a subgroup 
of cMBP2-PEG-Stp/NIS-treated mice as well as an additional control group treated with 
cMBP2-PEG-Stp/Antisense-NIS polyplexes led to comparably low iodide uptake 
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demonstrating NIS-specificity. Data obtained by ex vivo biodistribution correlated well with 
results from gamma camera imaging, showing a tumoral iodide accumulation of 
3.00.5% ID/organ in cMBP2-PEG-Stp/NIS-treated mice 3 h post 123I application. In addition, 
no specific iodide accumulation was observed in tumors of control mice and non-target 
organs, confirming tumor specificity of gene delivery vehicles based on active cMET-
targeting. These results clearly demonstrate targeting specificity of cMBP2 as cMET-binding 
peptide and the efficacy of our novel sequence defined polymers as gene delivery vehicles.  
After successfully demonstrating the feasibility of this polyplex-mediated NIS gene therapy 
approach in vitro and in vivo taking advantage of NIS in its function as reporter gene, we 
addressed the question whether tumor-specific transduction is sufficiently high for a 
therapeutic effect. After three cycles of repetitive polyplex and radioiodide application, a 
significant reduction in tumor growth was observed in mice treated with cMBP2-PEG-
Stp/NIS. This was associated with a prolonged survival of up to nearly 7 weeks, whereas 
animals of control groups had to be sacrificed within 3-4 weeks. Immunohistochemical 
staining revealed a heterogenous staining pattern with clusters of membrane associated NIS-
specific immunoreactivity. As NIS gene therapy is associated with a high bystander effect 
based on the crossfire effect of the beta-emitter 131I, the cytotoxic effect is not only limited to 
transduced cells, but also affects surrounding cells increasing therapeutic effectiveness of 
the NIS gene therapy concept. These findings were confirmed by immunofluorescence 
analysis of tumors after treatment: tumors from animals treated with cMBP2-PEG-Stp/NIS 
exhibited reduced cell proliferation and blood vessel density as compared to all control 
groups. As the immunofluorescence analysis experiments were performed at the end of the 
observation period, i.e. at different time points in the control group vs. therapy group, in 
which mice were sacrificed at a later stage, other factors such as mouse age, might influence 
the results. However, as mice were sacrificed in the therapy group when significant regrowth 
of tumors had occurred, our results probably even underestimate the antiproliferative and 
antiangiogenic effects of 131I therapy following cMBP2-PEG-Stp/NIS-mediated NIS gene 
transfer.  
In our studies, a therapeutic dose of 55.5 MBq 131I (1.5 mCi) was used [35-42, 93] based on 
initial tests on radiation safety, tolerability and efficacy [35, 93]. The Food and Drug 
Administration of the United States (FDA) formulated a table of dose conversion factors that 
allows for allometric adaption from preclinical animal models to humans based on body 
surface area (BSA) [195]. Using this method, the mouse dose of 55.5 MBq translates to 13.9 
GBq (372 mCi) for a 75kg human being, which lies within the dosimetrically determined dose 
range (300 mCi – 600 mCi) in patients with advanced metastasized differentiated thyroid 
cancer [91]. In order to keep potential toxicities at a minimum, the calculated dose should not 
represent a fixed applicable dose, but a dose range that needs to be adjusted in a 
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personalized manner considering various factors including the radiation sensitivity of the 
tumor, co-morbidities of the patient and pretreatments. In this context, the concept of the 
theranostic application of the NIS gene allows optimal adjustment of the 131I dose based on 
exact dosimetric calculations of doses to the tumor and other organs from radioiodine 
imaging studies to limit side effects to non-target organs including bone marrow, spinal cord, 
salivary glands, upper gastrointestinal tract, kidneys and bladder. 
Based on these promising preclinical results, the next crucial step towards clinical application 
will be a toxicity study, specifically designed to assess potential toxicities arising from 
cMBP2-PEG-Stp/NIS application followed by saline or 131I application. For this purpose, 
naive mice without tumor will be used, cMBP2-PEG-Stp/NIS will be injected i.v. as well as 
directly into critical organs such as the liver and lungs, followed by assessment of toxicity by 
physical examination, blood and tissue sampling at early, intermediate and late time points 
(such as 1 week up to 3 months).  
Our data clearly demonstrate the therapeutic efficacy of cMET-targeted NIS gene therapy. 
Combined with our previous results targeting NIS to EGFR on tumor cells using the peptide 
GE11, this opens the exciting prospect of a possible future combination of these two 
targeting agents. The concept of dual targeting mimicks the natural process of viral cellular 
uptake, as several viruses, including adenoviruses, target two receptor types for so-called 
biphasic cell entry. The synergistic effects of targeting the receptors for EGF and transferrin 
using synthetic polymers have already been explored in vitro [68]. Studies postulating 
crosstalk between EGFR and cMET on cancer cells further substantiate the potential of dual 
targeting of these two receptors, especially as cMET amplification has been implicated in 
resistance mechanisms to escape EGFR-targeted therapy [85, 86, 196, 197]. 
In conclusion, our data demonstrate the enormous potential of sequence-defined polymers 
for cMET-targeted NIS gene delivery. The precise synthesis of these novel polymers allows 
for optimized transfection efficiency while eliminating adverse effects such as toxicity or high 
immunogenicity. High cMET expression levels on many cancer cells make this receptor an 
ideal target in cancer therapy. Combined with the unique theranostic function of NIS, our 
targeting strategy led to significant tumoral iodide uptake that was sufficient for potent 
therapeutic effects after 131I application. This innovative concept of active receptor-targeted 
non-viral gene delivery is of high clinical relevance as it optimizes efficacy and safety of 
systemic NIS gene delivery and opens the exciting prospect of application in metastatic 
disease.  
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7. EGFR targeting and shielding of pDNA lipopolyplexes via 
bivalent attachment of a sequence-defined PEG agent 
 
This chapter has been adapted from: 
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lipopolyplexes via bivalent attachment of a sequence-defined PEG agent. Macromol Biosci. 
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7.1 Abstract 
 
For successful nonviral gene delivery, cationic polymers are promising DNA carrier which 
need to comprise several functionalities. The current work focuses on the post-incorporation 
of epidermal growth factor receptor (EGFR) targeted PEGylation agents onto lipopolyplexes 
for pDNA delivery. T-shaped lipo-oligomers were previously found to be effective sequence-
defined carriers for pDNA and siRNA. Here, the bis-oleoyl-oligoaminoethanamide 454 
containing tyrosine trimer-cysteine ends was applied for complex formation with pDNA 
coding for luciferase or sodium iodide symporter (NIS). In a second step, the lipopolyplexes 
were modified via disulfide formation with sequence-defined monovalent or bivalent 
PEGylation agents containing one or two 3-nitro-2-pyridinesulfenyl (NPys)-activated 
cysteines, respectively. For targeting, the PEG agents comprise the EGFR targeting peptide 
GE11. In comparison of all transfection complexes, 454 lipopolyplexes modified with the 
bidentate PEG-GE11 agent showed the best, EGFR-dependent uptake as well as luciferase 
or NIS gene expression into receptor-positive tumor cells.  
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7.2 Introduction  
 
The growing global incidence of cancer entailed intense research for novel alternative 
treatment strategies [146]. One promising direction is cancer gene therapy, which offers the 
possibility to interfere in the complex process of tumorigenesis, invasion and metastasis 
formation [10, 198]. However, the capability to change, add, modulate and knock-out tumor 
specific gene information is highly dependent on the efficacy of nucleic acid delivery 
systems. These carriers should ensure high tumor specific transfection efficiency along with 
sustained stability and biocompatibility. As viral vector particles face disadvantages 
concerning immunobiocompatibility, safety and toxicity, nonviral vectors might present an 
alternative nanoscale delivery platform with flexible design strategies [9, 53, 56, 65, 105, 
199]. 
First-generation cationic polymers, like polyethylenimine (PEI) and polyamidoamine 
(PAMAM) dendrimer, demonstrated high efficiency but at the same time exhibited drawbacks 
regarding polydispersity, low degradability and toxicity. Within the last two decades these 
drawbacks have been dealt with by introducing biodegradable polymers and functional 
modifications including shielding and targeting domains [56]. Precision polymers can be 
generated with improved polymer chemistry; alternatively, sequence-defined peptide-like 
polymers can be generated by solid-phase assisted synthesis (SPS) [56]. Our work initiated 
from the chemical repeat unit of PEI, which is thought to be responsible for favorable nucleic 
acid binding as well as endosomal buffering [63], and resulted in the development of artificial 
amino acids containing the aminoethylene motif [66, 200, 201]. These artificial building 
blocks were assembled by SPS together with other artificial or natural units into sequence-
defined oligomers for use in intracellular nucleic acid or protein delivery [58, 83, 139, 202-
209]. Colloidal and biological characteristics of nucleic acid nanoparticles can be improved 
by incorporation of hydrophilic polymers such as polyethylene glycol (PEG) or N-(2-
hydroxypropyl)methacrylamide (HPMA). These and related agents [71-73, 210-215] were 
found to shield against aggregation or undesired biological interactions. However, covalent 
modification of cationic carriers with hydrophilic chains may also diminish nanoparticle 
compaction and other favorable properties [76, 77, 215]. Post-integration of shielding agents 
into preformed nanoparticles emerged as encouraging alternative to avoid such unfavorable 
effects [75, 133, 216-222]. Use of shielding agents with multivalent attachment sites proved 
to be especially effective, as improved shielding synergizes with lateral stabilization of the 
nanoparticle by crosslinking the carrier molecules [216, 217, 219, 222].  
In the present study, our aim was to generate novel shielded pDNA lipopolyplexes by either 
monovalent or bivalent attachment of targeted PEG agents. For the assembly of pDNA core 
nanoparticles, we selected a T-shaped, cysteine-containing bis-oleoyl-oligoethanaminoamide 
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(compound 454). This lipo-oligomer was originally developed for siRNA delivery and contains 
nanoparticle-stabilizing tyrosine trimers and cysteines [204]. After polyplex with internal 
disulfide formation, the remaining cysteine thiols on the polyplex surface are supposed to be 
available for reacting with 3-nitro-2-pyridinesulfenyl (Npys) activated Cys-PEG reagents. For 
tumor-targeting, shielding should go hand in hand with active targeting [223, 224]. For this 
purpose, specific attachment to the epidermal growth factor receptor (EGFR) by the phage 
library-derived peptide GE11 was considered. EGFR is overexpressed in most cancer types 
[151, 225] and has already been shown as an effective target for nucleic acid delivery by 
using various receptor-binding ligands [39, 68, 119, 138, 151, 218, 226-232]. Thus, as 
described in the following, four different PEGylation agents, without or with GE11 targeting 
peptide, with monovalent or bivalent attachment linkers, were synthesized by sequence-
controlled SPS. A clear effect of the ligand and the linker bivalency was demonstrated in 
cellular uptake and gene transfer studies into receptor-positive Huh7 and MCF-7 tumor cells. 
The transfection efficacy of the most effective bidentate PEG-GE11 pDNA nanoparticle was 
further demonstrated and confirmed on a functional level by using the theranostic sodium 
iodide symporter (NIS) gene [29, 30, 33, 38, 42, 46, 47, 151].  
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7.3 Materials and methods 
 
Materials  
2-Chlorotrityl chloride resin was obtained from Iris Biotech (Marktredwitz, Germany), Fmoc-
Ala-Wang resin was obtained from Novabiochem (Darmstadt, Germany), 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate (HBTU), benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and syringe reactors (PP reactor 
with PE frit) from Multisyntech GmbH (Witten, Germany). The synthesis of the cationic 
building block Fmoc-Stp(Boc)3-OH was prepared as described by Schaffert et al [66]. All 
amino acids, dimethylformamide (DMF) as well as N-methylpyrrolidon (NMP) both peptide 
grade, N,N-diisopropylethylamine (DIPEA) and trifluoroacetic acid (TFA) were used from Iris 
Biotech (Marktredwitz, Germany). Dithiothreitol (DTT), 5,5'-dithiobis-(2-nitrobenzoic acid 
(DTNB), 1-hydroxy-benzotriazole (HOBt), triisopropylsilane (TIS), dimethylsulfoxide (DMSO), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), N-Fmoc-N´-succinyl-
4,7,10-trioxa-1,13-tridecanediamine (STOTDA), oleic acid and Triton X-100 as well as 1,2-
ethanedithiol (EDT) were purchased from Sigma-Aldrich (Munich, Germany). N-hexane and 
tert-butyl methyl ether (MTBE) were obtained from Brenntag (Mühlheim an der Ruhr, 
Germany). Dichloromethane (DCM) was obtained from Bernd Kraft (Duisburg, Germany). 
Fmoc-N-amido-dPEG24-acid® was purchased from Quanta Biodesign (Powell, OH, USA). 
All solvents and other reagents were acquired from Sigma-Aldrich (Munich, Germany), Iris 
Biotech (Marktredwitz, Germany), Merck (Darmstadt, Germany) or AppliChem (Darmstadt, 
Germany). All cell culture consumables were obtained from Sarstedt (Nümbrecht, Germany). 
DMEM and DMEM/F12 were purchased from Sigma Aldrich (Munich, Germany). Fetal 
bovine serum (FBS), cell culture media, and antibiotics were purchased from Invitrogen 
(Karlsruhe, Germany), glucose from Merck (Darmstadt, Germany), HEPES from Biomol 
GmbH (Hamburg, Germany), and sodium chloride from Prolabo (Haasrode, Belgium). 
Agarose NEEO Ultra-Qualität was obtained from Carl Roth GmbH (Karlsruhe, Germany) and 
GelRed™ from VWR (Darmstadt, Germany). Heparin sulfate was purchased from 
Ratiopharm (Ulm, Germany) with 5000 IU/mL. Luciferase cell culture 5× lysis buffer and D-
luciferin sodium were obtained from Promega (Mannheim, Germany). DNA plasmids 
(pCMVLuc [233]; CMV: cytomegalovirus promotor and enhancer; Luc: firefly luciferase gene 
and pCpG-hCMV-NIS [39]; human NIS plasmid DNA driven by the human elongation factor 
1α promotor and human cytomegalovirus enhancer element) were prepared by Plasmid 
Factory GmbH (Bielefeld, Germany).  
 
Peptide synthesis  
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All syntheses were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Peptide synthesis was carried out using Fmoc-chemistry and L-amino 
acids. Prior to synthesis, 2-chlorotrityl chloride resins were loaded with the appropriate C-
terminal amino acids. For synthesis of GE11 targeting peptide (YHWYGYTPQNVI), a resin 
preloaded with Fmoc-L-Ile-OH was used. The peptide sequence was assembled with an 
automated Syro Wave (Biotage, Uppsala, Sweden) peptide synthesizer equipped with a 
microwave cavity. Double couplings were performed at 50 °C for 12 min prior to 5 repetitive 
washing steps. Per coupling and free amine 4 equivalent (eq) of HBTU, 8 eq of DIPEA, 4 eq 
of HOBt, and 4 eq of Fmoc-protected amino acid were added on the solid support; the 
solution was supplemented with 1% Triton X-100 (v/v). Amino acids and HOBt were 
dissolved in NMP, supplemented with Triton-X. HBTU was dissolved in DMF and DIPEA 
diluted with NMP. Fmoc removal was conducted by standard deprotection methods with 40% 
piperidine in DMF (v/v) supplemented with 1% Triton-X for 5 × 10 min. The peptide sequence 
was built by sequentially coupling Fmoc-L-Val-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Gln(Trt)-
OH, Fmoc-L-Pro-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Tyr(tBu)-OH, Fmoc-L-Gly-OH, Fmoc-L-
Tyr(tBu)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-His(Trt)-OH and Fmoc-L-Tyr(tBu)-OH. After the 
last coupling an analytical cleavage of a small fraction for MALDI-MS and HPLC was done. 
Data can be found in Figure S14 and S15.  
In case of pre-PEGylated oligomer 440 a commercially available Wang resin, preloaded with 
Fmoc-L-Ala-OH low-loaded (LL) was deprotected as described in SI, in case of 835, the 
GE11 peptide loaded resin (prepared as described above) was used. As coupling of dPEG24 
represents a crucial step in synthesis, this step was conducted manually, and successful 
coupling and deprotection was monitored by Kaiser test [234]. Coupling was performed for 1 
h under steady shaking with 4 eq of PyBOP, 8 eq of DIPEA, 4 eq of HOBt and 4 eq of Fmoc-
N-amido-dPEG24-acid dissolved in 50:50 (v/v) of DCM/DMF. Deprotection was performed as 
described before by addition of 40% piperidine in DMF (v/v) for 5 × 10 min. Then both 
reactors were placed in the automated Syro Wave (Biotage, Uppsala, Sweden) peptide 
synthesizer and cationic backbones were synthesized in parallel. Reagents were prepared 
as for synthesis of GE11 and double couplings were performed at RT for 1 h each. First 
Fmoc-L-His(Trt)-OH, followed by Fmoc-L-Lys(Fmoc)-OH for symmetrical branching, was 
attached. Fmoc-L-His(Trt) and our novel building block Fmoc-Stp(boc)3-OH (Stp: succinyl-
tetraethylene pentamine; Boc: tert-butyloxycarbonyl) were attached alternately four times, 
leading to five histidines and four Stp units. Synthesis was terminated by coupling of Boc-L-
Cys(Trt)-OH.  
Oligomer 454 was synthesized on a 2-chlorotrityl chloride resin preloaded with Fmoc-L-
Cys(Trt)-OH. The resin was placed in the microwave cavity of the Syro Wave peptide 
synthesizer (Biotage, Uppsala, Sweden). The cationic backbone, was attached using the 
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protocol described above. First Fmoc-L-Tyr(tBu)-OH was coupled three times, then the 
artificial amino acid Fmoc-Stp(boc)3-OH was coupled twice. Fmoc-L-Lys(Dde)-OH served as 
a mirror axis so again two Fmoc-Stp(boc)3-OH and three times Fmoc-L-Tyr(tBu)-OH were 
coupled. Coupling of Boc-L-Cys(Trt)-OH at room temperature for 2 x 1 h terminated the 
cationic backbone. To introduce the hydrophobic domains, Dde removal was conducted with 
4% hydrazine in DMF (v/v) for 15 cycles lasting 3 min each. Then Fmoc-L-Lys(Fmoc)-OH 
was coupled for symmetrical branching prior to attaching oleic acid on both arms.  
PEGylation agents were either synthesized on a preloaded Ala-Wang resin (for the Ala 
control reagent) or were attached to GE11 previously assembled on the solid support as 
described above (for the targeting reagent). First Fmoc-N-amido-dPEG24-acid was coupled 
manually. Then each resin was split in two parts, and either Boc-L-Cys(Npys) in case of 
monovalent reagent, or Fmoc-L-Lys(Fmoc)-OH in case of the bivalent reagent, was coupled. 
In case of the bivalent PEG agents, STOTDA was introduced as a short spacer before 
terminating the sequence by coupling of Boc-L-Cys(NPys)-OH. The resins were dried under 
high vacuum and then cleavage was conducted. In case of oligomers 440, 835 and 454 a 
cleavage cocktail TFA/EDT/H2O/TIS 94:2.5:2.5:1 (v/v) at a ratio of 10 mL/g resin and in case 
of post-PEGylation agents TFA/H2O/TIS 95:2.5:2.5 was chosen. Cleavage was conducted for 
90 min with the exception of 454, here the cleavage solution was precooled to 4°C and 
cleavage was only performed for 30 min to prevent side reaction at the double bond of the 
oleic acid (S. Reinhard, W. Zhang, E. Wagner, accepted manuscript). The cleaved oligomers 
were precipitated in a 50:50 (v/v) mixture of n-hexane/MTBE and purified by size exclusion 
chromatography (SEC) performed with 10 mM hydrochloric acid/acetonitrile 7:3 as solvent. 
An ÄKTA purifier system (GE Healthcare Biosciences, Uppsala, Sweden) equipped with a 
Sephadex G-10 column and a P-900 solvent pump module, a UV-900 spectrophotometrical 
detector, a pH/C-900 conductivity module and a Frac-950 automated fractionator were used. 
The product fractions were collected and combined prior to lyophilization. Analytical data (MS 
data (Maldi or ESI respectively) and RP-HPLC) of all structures can be found in Figures S14-
S28. LPEI-PEG2k-GE11 was synthesized and analyzed as described before [139]. 
  
Polyplex formation  
Indicated amounts of pDNA and oligomer at a nitrogen/phosphate (N/P) ratio of 12 were 
diluted in separate tubes. If not mentioned otherwise, suspension media was 20 mM HEPES 
buffered 5% glucose at pH 7.4 (HBG 7.4). Diluted oligomer and diluted pDNA were mixed at 
similar volume. For N/P ratio calculation, only the protonatable amino groups of the Stp units 
and N-terminal amines of cysteine residues were considered (N number) and related to the 
anionic phosphate groups (P number) in pDNA. The nucleic acid was added to the oligomer, 
mixed vigorously, and incubated for 30 min at room temperature under air exposure to 
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enhance disulfide formation. In case of 454, if indicated, PEGylation agents calculated as 
molar eq per –SH in 454 were added, carefully mixed and incubated for further 15 min.  
 
Particle size and zeta potential  
Particle size and zeta potential of polyplexes were measured by Stephan Morys (Department 
of Pharmacy, Pharmaceutical Biotechnology, LMU) by dynamic laser-light scattering (DLS) 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) and transmission 
electron microscopy (TEM) with a JEM 1011 (Jeol, Freising, Germany).  
For DLS measurements, 2 μg pDNA was dissolved in 30 μL HBG and was added to an 
amount of oligomers corresponding to N/P 12 in 30 μL HBG. After 30 min of incubation at 
room temperature, 0.5 or 1.0 eq of PEGylation agents were added, if indicated and after 
incubation at RT for further 15 min, 740 μL of 10 mM sodium chloride solution (pH 7.4) was 
added and the samples were measured. Results were plotted as Z-Average and SD out of 
three runs with 12 sub-runs each. Zeta potential (ZP) is displayed as average (mV) of three 
runs with up to 15 sub-runs each.  
For TEM, samples were prepared as follows. The formvar/carbon-coated 300 mesh copper 
grids (Ted Pella Inc., Redding, CA, USA) were activated by mild plasma cleaning. 
Afterwards, the grids were incubated with 20 μL of the polyplex solution at N/P 12 for 2.5 
min. Polyplexes were previously prepared in water with 1 μg pDNA / 0.1 ml. Excess liquid 
was blotted off using filter paper until the grid was almost dry. Prior to staining, the grids were 
washed with 5 μL of staining solution for 5 s. Then, the copper grids were incubated with 5 
μL of a 2% aqueous uranylformate solution for 5 s, excess liquid was blotted off using filter 
paper, followed by air-drying for 30 min. Samples were then analyzed at 80 kV.  
 
Ethidium bromide compaction assay and polyanionic stress test  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Polyplexes containing 2 μg pDNA were formed at N/P ratio of 12 in a 
total volume of 200 μL HBG. LPEI polyplexes formed at N/P 12 served as positive control. If 
indicated, PEG agents were added at indicated ratios. HBG buffer (200 μL) served as blank 
and 2 μg pDNA in 200 μL HBG buffer was considered as maximum ethidium bromide (EtBr) 
fluorescence intensity (100% value). These samples were prepared in parallel to the 
polyplexes. After incubation at room temperature, 700 μL of EtBr solution (c = 0.5 μg/mL) 
was added. The fluorescence intensity of EtBr was measured after an additional 3 min 
incubation using a Cary Eclipse spectrophotometer (Varian, Germany) at the excitation 
wavelength λex = 510 nm and emission wavelength λem = 590 nm. The fluorescence 
intensity of EtBr was determined in relation to free pDNA. As a further experiment, 250 IU of 
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heparin (Ratiopharm, Ulm, Germany) was added to the samples after EtBr addition to 
investigate polyplex stability against polyanionic stress.  
 
Cell culture  
The human hepatocellular carcinoma cell line Huh7 was cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (1 g/L glucose), the human breast cancer cell line MCF-7 was 
cultured in DMEM high glucose (4.5 g/L glucose) and the human follicular thyroid carcinoma 
cell line FTC-133 was cultured in DMEM/F12. All media were supplemented with 10% fetal 
bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin. Cell lines were 
cultured at 37 °C and 5% CO2 in an incubator with a relative humidity of 95%.  
 
In vitro gene transfer and metabolic activity of transfected cells (MTT assay)  
Cells were seeded 24 h prior to pDNA delivery. For determining luciferase activity, 10,000 
cells/well were seeded in 96-well plates. Transfection efficiency of oligomers at N/P 12 was 
evaluated using 200 ng pCMVLuc per well. Where indicated, PEGylated complexes were 
used. Before treatment, cells received 80 μL of fresh medium containing 10% FBS. Polyplex 
solution (20 μL) was added to each well and incubated on cells at 37 °C for either 45 min or 
24 h. In the first case, medium was replaced 45 min after transfection by fresh medium. In 
the second case, cells were incubated with polyplex solution for 24 h after initial transfection. 
All experiments were performed in quintuplicate. LPEI or LPEI-PEG2k-GE11 (N/P 6) was 
used as a positive control and HBG buffer served as negative control. Luciferase activity of 
cells was determined after lysis with 100 μL lysis buffer using a Centro LB 960 plate reader 
luminometer (Berthold Technologies, Bad Wildbad, Germany) and LAR buffer supplemented 
with 1 mM luciferin. Transfection efficiency was evaluated as relative light units (RLU) per 
well.  
For determining iodide uptake activity after NIS gene delivery, 200,000 cells/well were plated 
in 6-well plates. Transfection efficiency of oligomers at N/P 12 was evaluated using 2 μg 
hNIS pDNA. After 24 h incubation with polyplexes, cells were washed with HBSS (Hank's 
Balanced Salt Solution; Thermo Fisher Scientific, Waltham, USA) and then incubated with 
HBSS supplemented with 10 μm NaI, 0.1 μCi of Na125I / ml and 10 mm HEPES at pH 7.3 for 
45 min at 37°C. Sodium perchlorate (NaClO4; 100 μM) as NIS-specific inhibitor was added to 
control wells. After incubation with iodide, cells were washed with HBSS and trapped iodide 
was removed from cells by a 20 min incubation in 1 M NaOH and measured by γ-counting 
and expressed as counts per minute (cpm).  
Metabolic activity of transfected cells was determined 24 h after initial transfection. 10 μL of 
MTT (5 mg/mL) was added to each well in 96-well plates and 200 μL was added to each well 
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in 6-well plates. Medium with unreacted dye was removed after incubation for 2 h at 37 °C 
and washed with PBS (phosphate-buffered saline).  
Absorbance was determined after incubation with 10% DMSO (dimethyl sulfoxide) in 
isopropanol by using a Sunrise microplate absorbance reader (Tecan, Männedorf, 
Switzerland) at 620 nm. The relative cell viability (%) related to the buffer-treated control cells 
was calculated as ([A] test/[A] control) × 100%.  
 
Cellular association and internalization  
Huh7 and MCF-7 cells were seeded 24 h prior to transfection into 24-well plates at a density 
of 50,000 cells/well. Culture medium was replaced with 400 μL fresh growth medium 24 h 
after seeding the cells. pDNA polyplexes were formed with oligomers (N/P 12) and 1 μg 
pCMVLuc (20% of Cy5-labeled pCMVLuc) and incubated for 30 min in 100 μL HBG. PP-
agents were, if indicated, co-incubated for further 15 min prior to addition to cells. In case of 
cellular association, polyplexes were added to cells and incubated for 30 min on ice. 
Subsequently, cells were washed twice with 500 μL PBS, detached with trypsin/EDTA and 
resuspended in PBS with 10% FBS.  
Cellular internalization was determined after polyplex addition and incubation at 37 °C for 45 
min. Subsequently, cells were incubated with 500 μL PBS containing 1000 IU heparin for 15 
min on ice to remove any polyplexes sticking to the cell surface and afterwards washed once 
with 500 μL PBS. Cells were detached with trypsin/EDTA and resuspended in PBS with 10% 
FBS.  
Cellular association and internalization of polyplexes was measured by excitation of Cy5 at 
635 nm and detection of emission at 665 nm. PI was used to discriminate between viable 
and dead cells. Cells were properly gated by forward/sideward scatter and pulse width for 
exclusion of doublets.  
 
Statistical analysis  
Statistical analysis of the results (mean ± SD) was evaluated by unpaired t test: *p < 0.05; 
**p<0.01; ***p < 0.001; ****p < 0.0001.  
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7.4 Results and discussion  
 
pDNA nanoparticle design, peptide and oligomer syntheses  
As published in 2001 by Blessing et al [218], EGF-PEG-PEI pDNA polyplexes were 
successfully generated by two different methods; either via pre-conjugation of PEI (25 kDa) 
with EGF before pDNA complex formation, or by post-modification of previously formed 
PEI/pDNA polyplexes. Also in the current study, the pre- and post-modification strategy was 
compared for generation of EGFR-targeted polyplexes. Instead of PEI 25kDa, in the novel 
investigation shorter sequence-defined oligomers were applied as pDNA carriers, with far 
higher biocompatibility and chemical precision (Table 1). Instead of EGF as targeting ligand, 
the phage-display derived EGFR targeting peptide GE11 (YHWYGYTPQNVI) [235] was 
applied; and instead of polydisperse PEG linkers, a precise monodisperse PEG of exactly 24 
ethylenoxide repeats (dPEG24) was used. Like all other components, also the PEG agents 
required for the post-modification strategy (Table 2) were synthesized in precise fashion by 
solid-phase synthesis, with the majority of steps performed in an automated form using a 
peptide synthesizer. Analytical data can be found in Figures S14-S28 [performed by Stephan 
Morys (Department of Pharmacy, Pharmaceutical Biotechnology, LMU].  
 
 
ID Abbreviation Sequence 
440 2-arm-PEG
24
-His-Ala (C-(H-Stp)
4
-H)α,ε-K-dPEG
24
-A 
835 2-arm-PEG
24
-His-GE11 (C-(H-Stp)
4
-H)α,ε-K-dPEG
24
-YHWYGYTPQNVI 
454 T-shape C-Y3-Stp2-K-(K(OleA)α,ε)-Stp2-Y3-C 
Table 1. List of oligomers as pDNA carriers used in this study. An internal ID, an abbreviation as well as its 
sequence (N to C terminus) are displayed. Detailed chemical structures can be found in Figure S1. Synthesis of 
polymers was performed by Stephan Morys (Department of Pharmacy, Pharmaceutical Biotechnology, 
LMU).Table adapted from [67]. 
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Abbreviation Sequence 
Cys-PEG24-Ala Cys(NPys)-dPEG24-A 
Cys-PEG24-GE11 Cys(NPys)-dPEG24-YHWYGYTPQNVI 
(Cys)2-PEG24-Ala (Cys(NPys)-STOTDA)α,ε-K-dPEG24-A 
(Cys)2-PEG24-GE11 (Cys(NPys)-STOTDA)α,ε-K-dPEG24-YHWYGYTPQNVI 
 
Table 2. Sequences of PEGylation agents (N to C terminus) as well as used abbreviation are displayed. Detailed 
chemical structures can be found in Figure S2. Synthesis of polymers was performed by Stephan Morys 
(Department of Pharmacy, Pharmaceutical Biotechnology, LMU). Table adapted from [67]. 
 
The pre-conjugation strategy is based on a 2-arm oligomer topology of ligand-PEG-STP/His, 
which had already proven as effective for receptor targeted gene transfer in vitro as well as in 
vivo for several receptor/ligand combinations [46, 58, 69, 139]. Two cationizable alternating 
Stp/histidine repeats provide effective nucleic acid binding and endosomal buffering [58, 
236], a lysine as symmetrical branching point links the dPEG24 molecule, which is end-
modified with the targeting ligand. In the current case, the EGFR targeted oligomer 835 
contains GE11, whereas the analogous control structure 440 contains alanine instead (Table 
1). These oligomers also contain terminal cysteines for polyplex-stabilizing disulfide cross-
link formation.  
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Scheme 1. EGFR-targeted pDNA lipopolyplexes designed by post-modification of 454 (Table 1) core complexes 
with mono- or bi-valent PEG agents (Table 2). (A) Lipopolyplex formation. (B) Post-PEGylation via disulfide 
exchange. Scheme adapted from [67]. 
 
In the novel post-modification strategy (Scheme 1), activated disulfide exchange chemistry 
was used for introduction of the targeted PEG reagents. Core pDNA lipopolyplexes were 
formed using the T-shaped lipo-oligomer 454, which had been designed to mediate efficient 
siRNA knockdown due to its optimized structure [58]. Four units of the cationizable artificial 
amino acid Stp (12 protonatable nitrogens in total) provide nucleic acid binding and 
endosomal buffering [58, 66, 237], two centrally placed oleic acids contribute to hydrophobic 
polyplex stability and have lytic potential upon acidification within the endosome [202, 204, 
238]. Peripheral tyrosine trimers (Y3) increase polyplex stability via inter-oligomeral 𝜋- 𝜋 
stacking of aromatic rings [239]; C-terminal as well as N-terminal cysteine residues provide 
additional, disulfide triggered polyplex stabilization [237] as well as anchors for the 
subsequent post-PEGylation. This oligomer has been extensively investigated as core 
oligomer for receptor dependent siRNA delivery in vitro as well as in vivo, e.g. via folate 
receptor [75], transferrin receptor [207] as well as EGFR [232], but has been never used as 
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core carrier for receptor targeted pDNA delivery. Pre-PEGylation of 454 before polyplex 
formation was unsuccessful, resulting in polyplex aggregation (SM, unpublished results).  
For modification of 454/pDNA polyplexes via activated disulfide exchange, monovalent or 
bivalent PEGylation agents, comprising precise dPEG24 with GE11 or alanine as control, 
were synthesized by SPS with introduction of Boc-L-Cys(NPys)-OH as terminal coupling. In 
case of the bivalent agent, the diamino acid Fmoc-L-lysine(Fmoc)-OH was inserted for 
symmetrical branching following the PEG domain, and a short PEG spacer (STOTDA) was 
introduced for increasing flexibility of the reagent. The sequence was terminated by 
introduction of Boc-L-Cys(NPys)-OH on both branches.  
 
Physicochemical polyplex characterization  
Oligomer/pDNA interaction was examined in different assays, focusing on pDNA binding 
ability, stability and compaction. Polyplexes with and without post-PEGylation were 
evaluated. First, complete binding of 200 ng of pDNA by oligomers at N/P 12 was verified by 
agarose gel electrophoresis shift assays (Figure S3A). N/P 12 was previously determined as 
the required ratio for complete pDNA binding of 454 and therefore was chosen for all further 
experiments [204]. Most important, it is to note that post-modification of 454 polyplexes did 
not influence pDNA binding, independent of the amounts attached to the core particle (Figure 
S3B).  
Also pre-PEGylated polyplexes, consisting of targeted or untargeted 2-arm-His-PEG24 and 
200 ng of pDNA, showed complete pDNA retention (Figure S3A) at N/P 12. It was reported 
that lower N/P ratios for these kinds of carriers were sufficient to completely bind pDNA [69, 
215]. For reasons of comparability between post-PEGylated lipopolyplexes and pre-
PEGylated 2-arm polyplexes, all further experiments were conducted with N/P 12. After 
pDNA binding was confirmed, particle sizes and zeta potential were determined by dynamic 
light scattering. Results with 454 (post-PEGylated) polyplexes revealed very homogenous 
particles with a polydispersity index (PDI) between 0.11 and 0.20, where 1.0 represents the 
highest polydispersity (Table 3 as well as Table S1).  
At the same time polyplexes formed with 2-arm PEG-oligomers 440 and 835 showed very 
inhomogeneous particle populations with a PDI between 0.4 and 0.5. This non-homogeneity 
resulted in DH values (displayed as Z-Average in nm) of more than 1000 nm (Table 3) for 
pre-PEGylated polyplexes. This could be explained by the high degree of PEGylation in 
comparison with a rather small cationizable pDNA compacting domain and the associated 
large amount of hydrophobic GE11 peptide; it is known that hydrophobic peptides tend to 
cause aggregation [240, 241].  
. 
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Polymer Size (nm) PDI ZP (mV) 
440 1367 ± 134.0 0.39 ± 0.11 1.2 ± 0.2 
835 1947 ± 211.7 0.51 ± 0.04 4.5 ± 0.1 
454 81.4 ± 5.2 0.18 ± 0.02 29.9 ± 1.3 
454  -  1.0 eq Cys-PEG
24
-Ala 82.4 ± 0.4 0.15 ± 0.01 14.7 ± 0.9 
454  -  1.0 eq Cys-PEG
24
-GE11 121.1 ± 0.8 0.12 ± 0.01 16.9 ± 1.3 
454  -  1.0 eq (Cys)
2
-PEG
24
-Ala 83.8 ± 0.8 0.12 ± 0.02 15.6 ± 0.9 
454  -  1.0 eq (Cys)
2
-PEG
24
-GE11 283.8 ± 0.4 0.17 ± 0.01 17.7 ± 2.0 
Table 3. Particle size (Z-average), PDI and zeta potential of pDNA polyplexes formed in HBG buffer determined 
with DLS. Mean of three measurements of the same sample is indicated. Polymer at N/P 12 and 2 µg pDNA were 
separately diluted with HBG pH 7.4 to 30 µL each. Then solutions were mixed and incubated for 30 min. If 
indicated, post-PEGylation was carried out with 1.0 eq for further 15 min. Polyplexes then were diluted to 800 µl 
with 10 mM NaCl pH 7.4 prior to measurement. Polyplexes post-PEGylated with 0.5 eq can be found in Table S1. 
Measurements were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical Biotechnology, 
LMU).Table adapted from [67]. 
 
Unmodified 454 polyplexes exhibited a size of approximately 80 nm. It is to note that the 
polyplex size increased after post-modification with the monovalent GE11 reagent up to 121 
nm and with the bidentate reagent up to 284 nm (1.0 eq each). In contrast, post-PEGylation 
with alanine containing reagents (independent of its topology or amount up to 1.0 eq) did not 
influence polyplex size. Similar findings of increasing polyplex size after post-PEGylation 
were observed for 454/siRNA polyplexes post-modified with GE11-PEG28-maleimide [232]. In 
sum, these data indicate a special property of the hydrophobic GE11 ligand which can be 
better handled by the post-modification strategy. At the same time the zeta potential of post-
shielded polyplexes was reduced from 30 mV (unmodified 454) as far as 15 mV, thereby 
indicating the successful post-modification. To validate post-PEGylation, UV spectra of a 454 
polyplex before and after addition of 1.0 eq of (Cys)2-PEG24-Ala was recorded and compared 
to the reagents solely. A change in absorbance around 350-400 nm compared to the 
unconjugated PEGylation agent demonstrates the successful release of NPys. Data can be 
found in Figure S4.  
Further on, quantitative evidence of successful PEGylation of the 454/pDNA lipoplexes is 
provided by determination of free lipooligomer thiols (Figure S5A) as well as release of 3-
nitro-2-thiopyridone from PEGylation reagent (Figure S5B). Significant reduction of free thiols 
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(100% in free oligomers) to approximately 80% after polyplex formation and to 15% after 
PEGylation was observed.  
 
Fig. 1. (A) Transmission electron microscopy images (TEM) of polyplexes formed with 1 µg of pDNA at N/P 12. 
Average diameters (nm) of polyplexes (n=5) ± SD are displayed. Scale bar represents 100 nm. (B) pDNA 
compaction of polyplexes determined with an EtBr assay. Untargeted controls are displayed in white, while 
polyplexes targeted with GE11 peptide are marked with pattern. For post-PEGylation 1.0 eq was used, additional 
EtBr data can be found in Figure S6. Measurements were performed by Stephan Morys (Department of 
Pharmacy, Pharmaceutical Biotechnology, LMU). Figure adapted from [67]. 
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Next, transmission electron microscopy was performed to investigate polyplex size and 
shape. In Figure 1A and Figure S6A TEM images of pre- as well as post-PEGylated 
polyplexes are shown. Polyplexes of 835 and 440 exhibited a homogeneous size of around 
50 nm, appearing in short rods, while aggregation as determined by DLS, could not be seen. 
These findings indicate that bigger particles can either not be detected by TEM, or that they 
only occurred in minor extend, influencing size distribution by intensity in a severe manner.  
At the same time, non-PEGylated 454 polyplexes form globules of around 40 nm, not 
undergoing significant changes due to post-modification, regardless of the topology of 
applied reagents (monovalent or bivalent). These findings suggest that the mean particle size 
could be much smaller as determined by dynamic light scattering, facilitating cellular uptake 
by standard pathways [62].  
Next, the ability of the oligomers to compact pDNA was investigated by an ethidium bromide 
(EtBr) compaction assay. Interestingly, a significant difference between 2-arm-PEG24-His and 
post-PEGylated 454 polyplexes was found (Figure 1B). While in the first group the remaining 
EtBr fluorescence was determined as more than 20% (compared to untreated pDNA). In 
comparison to polyplexes formed with 440 and 835, EtBr compaction of polyplexes formed 
with 454 was decreased by 50% to approximately 10% in total, even in case of post-
functionalization with 1.0 eq.  
No difference between modified (data for 0.5 eq can be found in Figure S6B) and unmodified 
454 polyplex was observed, indicating that post-PEGylation does not have an influence on 
pDNA compaction of the core particle. Also no difference between C-terminal alanine or the 
GE11 peptide was found. The highest pDNA compaction nevertheless can be achieved by 
LPEI, a far larger polycation, with a remaining EtBr fluorescence of less than 5%. To the 
same samples 250 IU of heparine sulfate was added to determine anionic stress tolerance 
(Figure S6C). Here we found, as reported previously [215], that LPEI polyplexes are very 
sensitive, leading to 100% EtBr fluorescence corresponding to full pDNA release. These 
effects were minor pronounced for LPEI-PEG2k-GE11, retaining approximately 13% pDNA, 
nevertheless they were notably increased in comparison to 454 based polyplexes, where 
only 70% could be released. By increasing the cationic charge, even better pDNA retention 
could be achieved. While no difference between unmodified 454/pDNA polyplexes and post-
PEGylated could be observed, pre-PEGylated polyplexes were also very prone to heparine 
stress and fully released pDNA. This could be explained by the increased size, also leading 
to looser polyplexes.  
Stability of polyplexes in the protein environment presents a most critical issue. Therefore, 
polyplexes have been investigated by DLS after incubation with 10% FBS supplemented cell 
culture media or full serum (FBS). Pre-PEGylated polyplexes formed with 440 and 835 
underwent immediate aggregation under both conditions (Figure S7C-F). Non-modified 454 
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polyplexes increased from 80 nm to 250 nm with no further changes over time. 454 
polyplexes post-modified with the monovalent structures showed immediate size increase 
from 100 nm in 10 mM NaCl to approximately 200 nm in both conditions. Between 4 h and 
24 h these polyplexes aggregated to particles >800 nm (Figure S7I-L). For 454 post-modified 
with 1.0 eq (Cys)2-PEG24-GE11 a size of 280 nm in 10 mM NaCl was determined that 
changed to approximately 300 nm after addition of full serum or cell culture media. Between 
4 h and 24 h these polyplexes underwent no changes in full serum (Figure S7O). As in 454 
polyplexes post-modified with the bivalent structures (Cys)2-PEG24-Ala/GE11 the aggregation 
was less profound, higher stability is suggested. 
 
Luciferase gene transfections  
For evaluation of pDNA transfection efficiency, the hepatocellular cell line Huh7 (Figure 2A) 
and the breast cancer cell line MCF-7 (Figure 2B), both showing high EGFR cell surface 
expression (Figure S8), as well as the low EGFR expressing cell line FTC-133 (Figure S11) 
were used. Cells were either incubated for 45 min or 24 h with pDNA complexes and 
luciferase intensity was determined after 24 h. Polyplexes post-PEGylated (with monovalent 
or bivalent polymers) were compared to PEG-free core particle complexes (454) and 2-arm 
histidine-containing pre-PEGylated polymers. LPEI-PEG2k-GE11, which already has shown 
high transduction efficacy and EGFR specificity in vitro and in vivo, was used as positive 
control [39, 68, 151].  
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Fig. 2: Luciferase reporter gene expression in two EGFR positive human cancer cell lines. (A) Human 
hepatocellular cancer cells Huh7 and (B) human breast cancer cell line MCF-7. pCMVLuc polyplexes were 
incubated on cells for 45 min (left) or 24 h (right). Untargeted controls are displayed in white, while polyplexes 
targeted with GE11 peptide are marked with pattern. Figure adapted from [67]. 
 
The EGFR-targeted bivalent structure (Cys)2-PEG24-GE11 coupled to 454 core polyplexes at 
a molar ratio of 1.0 eq demonstrated a strong EGFR-targeting effect in both cell lines, in 
contrast to the alanine containing structure. Moreover, significantly higher expression levels 
compared to all other polymers were detected. The pre-PEGylated polyplexes (835 and 440 
control) revealed similar transfection level as LPEI-PEG2k-GE11 in Huh7 cells and even 
lower results in MCF-7 cells. Based on sizes measured by DLS, which showed sizes over 1 
μm for both pre-PEGylated polymers, transfection efficacy might be attributed to high 
aggregation and not due to specific uptake. Transfection of non-PEGylated 454 
demonstrated equal (in Huh7) or slightly higher (MCF-7) expression level compared to LPEI-
PEG-GE11. None of the polyplexes mediated cytotoxicity after 45 min and 24 h of incubation 
(Figure S9) For post-integration of PEG onto core polyplexes, monovalent and bivalent 
structures were compared at two different molar ratios. One eq proved to be more efficient 
than 0.5 eq. Results for 0.5 eq are displayed in Figure S10A-B, with no occurring cytotoxicity 
(Figure S10C-D). Interestingly, transduction efficacy was not influenced by post-modification 
of 454 polyplexes with up to 1.0 eq of (Cys)2-PEG24-Ala in comparison to the unshielded core 
polyplexes, thereby highlighting this approach as possibility to circumvent the so called 
“PEG-dilemma” of pre-PEGylated structures [103]. It is widely accepted that PEI-like 
polyplexes require a combined effect of osmotic endosomal eruption and direct phospholipid 
destabilization by the cationized vehicle for endosomal escape [56, 65, 105]. PEG obviously 
can interfere with this direct cationic membrane destabilization. Consistently, bioreversible 
PEGylation was introduced to resolve this dilemma [69, 230, 231] and also the disulfide 
conjugation of oligomer and PEG used in the present work could possibly be cleaved off by 
intracellular glutathion (GSH) as demonstrated in other work [61, 208, 242].  
In comparison to Huh7 and MCF-7 cells that demonstrated strong EGFR dependency of 
transfection rates, this was not detected in low EGFR expressing FTC-133 cells. FTC-133 
cells demonstrated no differences in transfection rates of post-PEGylated monovalent and 
bivalent structures coupled to either GE11 or Ala after 45 min incubation time. This further 
indicates the beneficial EGFR targeting strategy of polyplexes post-modified with GE11 
targeted PEGylation reagents (Figure S11A). At the same time, no polyplex mediated 
cytotoxicity was observed after 45 min of incubation (Figure S11B).  
After 24 h of polyplex incubation, an overall increased transduction efficacy was measurable 
due to unspecific uptake mechanisms that occur after long-time incubation. Due to residual 
positive charge polyplexes tend to adhere unspecifically to the negatively charged cell 
membrane and particles get taken up unspecifically over time, leading to a diminished 
  GE11 lipopolyplexes 
125 
 
targeting effect. Nevertheless, the advantageous bivalent conjugation of EGFR-targeted PEG 
to 454 is still evident after 24 h of incubation.  
 
Cellular binding and internalization of bivalent post-PEGylated polyplexes  
For a more detailed investigation, cellular association and uptake of Cy5 labeled pDNA 
complexes were determined by flow cytometry. Best-performing condition (1 eq) was used. 
Binding efficiency of bivalent post-PEGylated (EGFR-targeted and untargeted) lipopolyplexes 
in comparison to unshielded lipopolyplexes (454) was examined (Figure 3). All three 
lipoplexes showed efficient binding after 30 min incubation on ice. Far higher Cy5 
fluorescence intensity was measured in cells transfected with the post-PEGylated EGFR-
targeted bidentate structure. This emphasizes the suitability of GE11 as EGFR specific 
ligand and at the same time demonstrates that the bidentate structure represents the most 
promising post-PEGylation reagent. Shielding with PEG did not result in diminished 
interaction with cell surface, as can be seen by comparing fluorescence activity between 
non-shielded 454 and bivalent post-PEGylated alanine control. No difference in fluorescence 
activity was detected. Experiments were also performed with monovalent PEGylation 
reagents, which did not result in any enhancement of binding in comparison to 454 and the 
alanine control in Huh7 and MCF-7 (Figure S12A,C). Complementary uptake and binding 
results of LPEI-PEG2k-GE11 and 2-arm pre-PEGylated structures are shown in Figure 
S13A,C.  
Results of uptake studies were consistent with binding studies, showing highest intracellular 
uptake after transfection with the bivalent post-PEGylated structure in comparison to 
unshielded 454 and alanine control (Figure 3) and lower uptake was obtained after 
transfection with LPEI-PEG2k-GE11, pre-PEGylated structures and monovalent post-
PEGylation complexes (Figure S12B,D and S13B,D). 
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Fig. 3: Cellular association of 454 polyplexes post-PEGylated with 1.0 eq of bidentate reagents on Huh7 (A) and 
MCF-7 (B) after 30 min incubation at 4 °C was determined by flow cytometry. In (C) and (D) corresponding mean 
fluorescence intensity (MFI) values are displayed. Cellular internalization of polyplexes after 45 min of incubation 
at 37 °C followed by removal of extracellularly bound polyplexes is displayed in (E) and (F). Corresponding MFI 
values can be found in (G) and (H). Logarithmic X-scale in (A) and (B) as well as (E) and (F) represents Cy5 
fluorescence of polyplexes. Figure adapted from [67]. 
 
For nanoparticles different uptake pathways are described depending on cell type, 
nanoparticle formulation, nanoparticle size and incorporation of ligands for active targeting. 
Various studies have been performed to rule out the exact mechanisms.  
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Size-dependent uptake studies determined that particles up to 500 nm were internalized into 
cells by energy based processes [60, 62]. A clathrin-dependent uptake mechanism, as well 
as caveolae assistant uptake, was detected for particles up to 200 nm. For lipoplexes, the 
clathrin dependent way is the major mechanism, whereas for polyplexes, both ways are 
possible [60].  
The lipoplexes used in this study lay around 200 nm or smaller, which suggests a clathrin 
dependend uptake. However, uptake is not only size dependent, but also ligand dependent. 
Referring to this point, a study comparing the ligand GE11 and EGF for receptor mediated 
uptake revealed following that GE11 targeted polyplexes were taken up into the cell via 
clathrin-mediated endocytosis. This GE11-mediated uptake showed no activation of EGFR 
with constant EGFR levels after transfection and demonstrated an alternative actin-
dependent pathway [243].  
In conclusion, EGFR-targeted lipoplexes in this study are designed to achieve characteristics 
for an active targeted, clathrin-dependent uptake mechanism, which was proved to be the 
process of lipoplexes and polyplexes with the GE11 ligand [243].  
After the successful uptake into endosomes, the endosomal buffer capacity of the Stp units 
in the oligomer backbone of the lipoplexes leads to protonation. The cationic function as well 
as the hydrophobic domains lead to enhanced interaction with the lysosomal membrane 
followed by destabilization of the membrane and degradation of the lipoplex and hence 
release of the pDNA in the cytosol.  
 
Iodide uptake activity after hNIS gene delivery  
After the proof of concept using the sensitive luciferase reporter capability for quantifying 
transduction efficacy, the sodium iodide symporter (NIS) was used as a clinically more 
relevant target gene. NIS features the beneficial dual characteristic as diagnostic and 
therapeutic gene [60, 62]. This theranostic function gives the possibility of exact 
determination of tumoral NIS gene expression in vivo by non-invasive imaging modalities as 
well as therapeutic investigation by application of cytotoxic radionuclides [35-39, 41, 42, 45-
47, 126, 151].  
In cell culture studies, NIS gene expression after lipopolyplex mediated delivery can be 
detected by measuring iodide (125I) uptake activity of transfected cells by gamma-counter 
analysis. To verify NIS-dependent 125I cell uptake, cells were pretreated with the NIS-specific 
inhibitor perchlorate (NaClO4) that results in a blockade of NIS mediated iodide uptake.  
As already observed in transfection, binding and uptake studies with the luciferase reporter 
gene, superiority of the post-integration approach of EGFR-targeted bidentate structures 
over non- and pre-PEGylated structures as well as untargeted complexes were confirmed 
(Figure 4A). Measured iodide uptake was perchlorate-sensitive verifying NIS mediated 
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uptake. No effects on cell viability were observed after transfection (Figure 4B). The 
advantageous new EGFR specific delivery vehicles combine high transduction efficacy, high 
biocompatibility, ideal size along with optimal shielding that was introduced by post-
integration of the bivalent (Cys(NPys)-STOTDA)α,ε-K-dPEG24 via disulfide exchange reaction.  
 
 
 
 
Fig. 4: (A) Transfection of polyplexes on Huh7 cells. A sodium iodide symporter (NIS) coding pDNA was used. 
After 
125
I application, iodide uptake was determined as counts per minute (cpm). Results are displayed with 
(black) and without (white) blockade of NIS by application of NaClO4 prior to measurement. (B) MTT performed in 
parallel to transfections. Untargeted controls are displayed in white, while polyplexes targeted with GE11 peptide 
are marked with pattern. Figure adapted from [67]. 
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7.5 Conclusions  
 
pDNA polyplexes can be functionalized with shielding and targeting domains either by pre-
conjugation or by post-modification strategies. The current study aimed at the design of 
EGFR-targeted pDNA polyplexes, based on precise sequence-defined oligomers available 
by SPS. A side-by-side comparison was made for polyplexes which were obtained from a 
pre-conjugation strategy using GE11-PEG-STP/His 2-arm oligomers, with lipopolyplexes that 
were post-modified with mono- or bivalent PEG-GE11 reagents. These studies identified 
peculiarities of the alternative approaches and the best-performing carrier for EGFR specific 
pDNA gene delivery. Pre-conjugation was previously found as effective for the targeting 
ligands folate or a c-met binding peptide, however was hampered by the hydrophobicity of 
GE11 and resulting in significant polyplex aggregation. For post-integration into core 
lipopolyplexes, the bivalent structure Cys(Npys)2-PEG24-GE11 was found to be the best 
agent, yielding highly specific, EGFR dependent gene transfer, demonstrated with luciferase 
marker gene and sodium iodide symporter (NIS) gene expression studies. Previous work 
already pointed out that post-modification represents a promising tool for shielding and 
targeting pDNA [36-43] as well as siRNA polyplexes [75, 207, 232]. The superior effect of the 
bivalent over monovalent linkage is well consistent with similar findings using multivalent 
coatings of nucleic acid nanoparticles [216, 217, 219].  
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7.6 Supporting information  
 
7.6.1 Supporting methods  
 
Oligomer syntheses and analytical experiments were performed by Stephan Morys (Department of Pharmacy, 
Pharmaceutical Biotechnology, LMU). 
 
Resin loading  
Loading of a chlorotrityl chloride resin with Fmoc-L-Ile-OH  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Chlorotrityl chloride resin (1.2 mmol chloride, 750 mg) was swollen in 7 
mL dry DCM for 10 min, a solution of 0.3 eq Fmoc-L-Ile-OH (119.3 mg) in 5 mL dry DCM and 
173.3 μL DIPEA (0.9 eq) were added and the resin was shaken for 1 h in an overhead 
shaker. The reaction solvent was drained and 5 mL of a mixture of dry DCM/MeOH/DIPEA 
(80/15/5) was added for 30 min. After the removal of the reaction mixture, the resin was 
washed 5 times with DCM.  
Forty mg of the wet resin were separated and dried to determine the loading of the resin. 
Therefore, an exactly weighted amount of the dry resin was treated with 1 mL deprotection 
solution (20% piperidine in DMF) for 1 h. Afterwards, the solution was diluted and absorption 
was measured at 301 nm. The loading was then calculated according to the equation: resin 
load [mmol/g] = (A × 1000)/(m [mg] × 7800 × df) with df as dilution factor.  
The resin was treated five times with 20% piperidine in DMF to remove the fmoc protection 
group. Successful deprotection was evaluated by Kaiser test [234]. Afterwards, the resin was 
washed with DMF, DCM and n-hexane and dried in vacuum.  
 
Loading of a chlorotrityl chloride resin with Fmoc-Cys(Trt)-OH  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Chlorotrityl chloride resin (1.2 mmol chloride, 750 mg) was swollen in 7 
mL dry DCM for 10 min, a solution of 197.7 mg Fmoc-Cys(Trt)-OH (0.3 eq) in 5 mL DCM and 
173.3 μL DIPEA (0.9 eq) were added and the resin was shaken for 1 h in an overhead 
shaker. From now on the same protocol was applied as mentioned above.  
 
pDNA binding assay by electrophoresis  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). For investigation of the pDNA binding ability of the oligomers, a 1% 
agarose gel was prepared. Therefore, agarose was suspended in TBE buffer (trizma base 
10.8 g, boric acid 5.5 g, EDTA 0.75 g per 1 L of water) and the mixture was heated until 
boiling and total dissolution. After cooling down to approximately 60 °C, GelRed (Biotium 
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Inc., Hayward, CA, USA) for detection of the nucleic acid was added and the agarose 
solution was casted into an electrophoresis unit and left to form a solid gel. Then polyplexes 
consisting of oligomers at N/P 12 were prepared with 200 ng pDNA in a total volume of 20 
μL. After 30 min (and if indicated, further 15 min of post-modification), 4 μL of 6x loading 
buffer (6 mL of glycerol, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of bromophenol blue) 
was added to each sample and applied to the gel. Electrophoresis was performed for 80 min 
at 120 V.  
 
UV spectrometrical investigation of polyplex modification  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Polyplexes consisting of 8 μg pDNA and 454 at N/P 12 in 50 μL HBG 
were prepared. After 30 min samples were either diluted to 100 μL HBG or post-modified 
with 1.0 eq of Ala-PEG24-Cys(NPys)2 for 15 min prior to dilution. HBG served as blank; 8μg 
pDNA in HBG, its correlating amount of 454 at N/P 12 and 1.0 eq of Ala-PEG24-K-(STOTDA-
(Cys(NPys))2 were treated as controls. For all samples UV/Vis spectra from 200-700 nm 
were recorded with a Genesys 10S UV-VIS spectrophotometer (Thermo Scientific, Schwerte, 
Germany).  
 
Ellman’s assay  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Polyplexes were formed in 50 μL HBG (containing 8μg pDNA and 454 
at N/P 12). Solutions containing unmodified 454/pDNA polyplexes as well as post-modified 
polyplexes (15 min with 1.0 eq (Cys)2-PEG24-Ala), were diluted with 275 μL Ellman’s Buffer 
(0,2M Na2HPO4, 1mM EDTA, pH 8,0) and eight μL of a DTNB solution (4mg/ml dissolved in 
MeOH). After addition of DTNB, both solutions were incubated for 15 min at 37 °C and A412 
was measured. Post-modified polyplex absorption was measured at 412 nm prior and after 
DTNB addition in order to exclude distortion mediated by 3-nitro-2-thiopyridone, which is 
released during post-modification. A Genesys 10S UV-VIS spectrophotometer (Thermo 
Scientific, Schwerte, Germany) was used for measurement. A412 of PEGylated polyplexes 
then was calculated according to the following formula: A412 (Sample) = A412 (+DTNB) – A412 
(-DTNB). The percentage of free mercapto groups is based on the theoretical amount 
(100%) of thiols.  
 
Release of 3-Nitro-2-Thiopyridone  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). The amount of (Cys)2-PEG24-Ala corresponding to 1.0 molar eq of 454 
was diluted with HBG (pH 7.4) to 300 μL and 33 μL of a 1M DTT (dithiothreitol) solution was 
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added to the solution. As determined in previous experiments (see Figure S4), the maximum 
absorbance of 3-nitro-2-thiopyridone was detected at 324 nm. Absorbance at A324 was 
measured and compared to the amount released from the PEGylated polyplex. Therefore 50 
μL of polyplex solution (containing 8 μg of pDNA, and 454 at N/P 12) was post-modified with 
1.0 eq (Cys)2-PEG24-Ala for 15 min and the polyplex solution was diluted with 275 μL of 
Ellman’s Buffer prior to measurement. Absorbance of (Cys)2-PEG24-Ala reduced with 1M 
DTT was considered as 100% and was correlated to 3-nitro-2-thiopyridone release after 
PEGylation.  
 
Stability of polyplexes in serum and media  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Determination of polyplex stability in full serum (FBS) as well as in 
DMEM supplemented with 10% serum was determined by DLS. Polyplexes were prepared 
as described previously with 8 μg pDNA and oligomers at N/P 12 in a total volume of 50 μL 
HBG. After incubation for 30 min, if indicated, polyplexes were PEGylated for 15 min, then 
HBG and FBS or DMEM were added. 60 μL were placed in a DTS1070 cuvette and t=0 min 
was determined. Polyplexes in serum or media were incubated under steady shaking at 37 
°C and aliquots were taken for further measurements after 4 and 24 h. Each time point 
represents one measurement averaged from 6 sub runs.  
 
EGF receptor measurement  
1×106 Huh7, MCF-7 or FTC-133 cells were detached with trypsin, washed with PBS 
supplemented with 10% FBS and incubated with an EGFR-specific antibody (1:100; 
monoclonal mouse IgG1 - Dako, Glostrup, Denmark) or with an IgG-anti-mouse antibody (BD 
Bioscience, Franklin Lakes, USA) as negative control for 1 h on ice. Afterwards cells were 
washed with PBS supplemented with 10% FBS and incubated with an AlexaFluor 488 
labeled goat anti-mouse secondary antibody (1:400 - Invitrogen, Langenselbold, Germany) 
for 1 h on ice. After a final washing step, cells were resuspended in PBS supplemented with 
10% FBS and flow cytometry analysis was performed on a BD Accuri C6 flow cytometer (BD 
Bioscience, Franklin Lakes, USA). Cells were gated by forward/sideward scatter and pulse 
width for exclusion of doublets. PI (propidium iodide, Sigma-Aldrich) was used for 
discrimination between viable and dead cells.      
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7.6.2 Analytical methods  
 
Analytical experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). 
 
ESI mass spectrometry  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Electrospray ionization (ESI) mass spectrometry was carried out using 
a Thermoscientific LTQ FT Ultra Fourier transform ion cyclotron and an IonMax source. 
Samples were dissolved in water containing 1% formic acid to a concentration of 1 mg/ml. 
Data is shown after positive ionization (M+H).  
 
MALDI mass spectrometry  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). One μL matrix consisting of a saturated solution of Super-DHB 
(mixture of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) in acetonitrile / 
water (1:1) containing 0.1% (v/v) trifluoroacetic acid was applied on a MTP AnchorChip 
(Bruker Daltonics, Bremen, Germany). After the Super-DHB matrix dried and crystalized, one 
μL of the sample solution (10 mg/mL in water) was added to the matrix spot. Samples were 
analyzed using an Autoflex II mass spectrometer (Bruker Daltonics, Bremen, Germany).  
 
Analytical RP-HPLC  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Reversed-phase HPLC (RP-HPLC) was carried out with a VWR-
Hitachi Chromaster 5160 Pump System (VWR, Darmstadt, Germany), VWR-Hitachi 
Chromaster 5260 Autosampler (VWR, Darmstadt, Germany) and a Diode Array Detector 
(VWR-Hitachi Chromaster 5430; VWR, Darmstadt, Germany) at 214 nm detection 
wavelength. As a column either a YMC Hydrosphere 302 C18 (YMC Europe, Dinslaken, 
Germany) or a Waters Sunfire C18 (Waters, Saint-Quentin en Yvelines Cedex, France) was 
used. A gradient starting at 95:5 (water / acetonitrile) to 0:100 within 20 min was applied. All 
solvents were supplemented with 0.1% trifluoroacetic acid.  
 
Proton NMR spectroscopy  
Experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). 1H-NMR spectra were recorded using an AVANCE III HD500 (500 
MHz) by Bruker with a 5 mm CPPBBO probe. Spectra were recorded without TMS as 
internal standard and therefore all signals were calibrated to the residual proton signal of the 
deuterium oxide (D2O) solvent. Chemical shifts are reported in ppm and refer to the solvent 
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as internal standard (D2O at 4.79). Integration was performed manually. The spectra were 
analyzed using MestreNova (Ver.9.0 by MestReLab Research). Integrals were normalized to 
the succinic acid peaks. 
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7.6.3 Supplemental figures and tables 
 
Polymer Size (nm) PDI ZP (mV) 
454  -  0.5 eq Cys-PEG24-Ala 85.1 ± 1.3 0.13 ± 0.01 17.8 ± 0.3 
454  -  0.5 eq Cys-PEG24-GE11 95.2 ± 0.3 0.11 ± 0.01 20.8 ± 1.4 
454  -  0.5 eq (Cys)2-PEG24-Ala 79.3 ± 0.5 0.18 ± 0.01 14.7 ± 0.8 
454  -  0.5 eq (Cys)2-PEG24-GE11 189.0 ± 1.4 0.20 ± 0.02 22.0 ± 1.5 
 
Table S1. Particle size (Z-average), PDI and zeta potential of pDNA polyplexes formed in HBG buffer determined 
with DLS. Mean of three measurements of the same sample is indicated. Polymer at N/P 12 and 2 µg pDNA were 
separately diluted with HBG pH 7.4 to 30 µL each. Then solutions were mixed and incubated for 30 min. If 
indicated, PEGylation was carried out with 0.5 eq for further 15 min. Polyplexes then were diluted to 800 µl with 
10 mM NaCl pH 7.4 prior to measurement. Measurements were performed by Stephan Morys (Department of 
Pharmacy, Pharmaceutical Biotechnology, LMU). Table adapted from [67] supplemental information. 
 
 
Figure S1. Chemical structures from N to C terminus of oligomers 440 (A), 835 (B) and 454 (C). Oleic acid (OleA) 
is shown in (D). Figure adapted from [67] supplemental information. 
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Figure S2. Chemical structures from N- to C- terminus of Cys(NPys)-dPEG24-Ala (A), Cys(NPys)-dPEG24-GE11 
(B), (Cys(NPys)-STOTDA)α,ε-K-dPEG24-Ala (C) and (Cys(NPys)-STOTDA)α,ε-K-dPEG24-GE11 (D). Figure 
adapted from [67] supplemental information. 
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Figure S3. Retardation of formed pDNA complexes in agarose gel at N/P 12. (A) Pre-conjugated 2-arm-His-
PEG24 (440 and 835) as well as unmodified 454. (B) Post-PEGylated 454 polyplexes with indicated PEGylation 
agents. Measurements were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Figure adapted from [67] supplemental information. 
 
 
 
  GE11 lipopolyplexes 
138 
 
 
Figure S4. UV/Vis detection of PEGylation reaction. (A) 8 µg of pDNA, corresponding amount of 454 at N/P 12 
and 1.0 eq of Ala-PEG24-K-(STOTDA-Cys(NPys))2 were used. 454 - (Cys(NPys)-STOTDA)2-K-PEG24-Ala mixed 
without pDNA served as positive control (mol Cys 454 / mol Cys(Npys)). (B) The same reagents were used to 
form polyplexes. 454/pDNA, as well as 454/pDNA PEGylated with 1.0 eq of (Cys)2-PEG24-Ala indicated 
successful reaction. Measurements were performed by Stephan Morys (Department of Pharmacy, 
Pharmaceutical Biotechnology, LMU). Figure adapted from [67] supplemental information. 
 
 
Figure S5. (A) Percentage of residual cysteine mercapto (SH) groups as determined with Ellman’s assay for 454 
polyplexes before (black) and after (grey) modification with 1.0 molar eq of (Cys)2-PEG24-Ala. The percentage of 
free mercapto groups is based on the theoretical amount (100%) of cysteines (two molar eq in Oligomer 454) 
applied in the polyplex formation. (B) Release of 3-nitro-2-thiopyridone (detected at 324 nm) from 1.0 molar eq 
(Cys)2-PEG24-Ala after reduction. Complete 3-nitro-2-thiopyridone release after addition of 1M DTT solution (black 
bar) and after addition to a 454/pDNA polyplex for further 15 min (grey bar) is displayed. Measurements were 
performed by Stephan Morys (Department of Pharmacy, Pharmaceutical Biotechnology, LMU). Figure adapted 
from [67] supplemental information. 
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Figure S6. (A) Transmission electron microscopy images (TEM) of pre-conjugated polyplexes 440 and 835 
formed with 1 µg of pDNA at N/P 12. Average diameters (nm) of polyplexes (n=5) ± SD are displayed. Scale bar 
represents 100 nm. (B) displays pDNA compaction of polyplexes post-PEGylated with 0.5 eq of reagents 
determined with EtBr assay. (C) shows polyplex stability in presence of 250 IU heparine determined with EtBr 
assay. Untargeted controls are displayed in white, while polyplexes targeted with GE11 peptide are marked with 
pattern. Measurements were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Figure adapted from [67] supplemental information. 
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Figure S7. Intensity mean curves maintained by DLS. Full serum (A) or DMEM (supplemented with 10% FBS) (B) 
is displayed in green and polyplexes of the 454/pDNA in 10 mM NaCl in red. These references should help to 
discriminate between polyplex and serum (left column) /media (right column) peaks. (C) – (P) Display behavior of 
polyplexes with indicated oligomers in FBS (left) / DMEM (right) over time. Measurements were performed by 
Stephan Morys (Department of Pharmacy, Pharmaceutical Biotechnology, LMU). Figure adapted from [67] 
supplemental information. 
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Figure S8. EGFR expression of EGFR positive cell lines Huh7 (A), MCF-7 (B) as well as low EGFR expressing 
cell line FTC-133 (C) are displayed, obtained with a monoclonal mouse anti-human EGFR antibody and IgG 
control. Alexa 488-labeled goat anti-mouse secondary antibody was used for the detection of receptor expression 
by flow cytometry. Control cells are presented in black, EGFR positive cells are presented in grey. Figure adapted 
from [67] supplemental information. 
 
 
Figure S9. Cell viability assay of (A) Huh7 and (B) MCF-7 was performed in parallel to luciferase transfection. 
MTT was performed after 45 min (left), and after 24 h (right). Figure adapted from [67] supplemental information. 
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Figure S10. Transfection of 454 polyplexes PEGylated with 0.5 eq after 45 min (left) and 24 h (right) are shown. 
Luciferase gene expression was determined on Huh7 (A) and MCF-7 (B), corresponding MTT assays were 
performed in parallel and are displayed in (C) and (D) respectively. Figure adapted from [67] supplemental 
information. 
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Figure S11. Luciferase gene expression was determined on the low EGFR expressing cell line FTC-133 (A). 
Transfection results after 45 min of polyplex incubation are shown. The corresponding MTT assay was performed 
in parallel is displayed in (B). Figure adapted from [67] supplemental information. 
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Figure S12. Flow cytometry results of 454 polyplexes PEGylated with 1.0 eq of monovalent reagents as well as 
corresponding mean fluorescence intensity are displayed. Cellular association of polyplexes on Huh7 (A) and 
MCF-7 (C) after 30 min incubation at 4 °C was determined by flow cytometry. In (B) and (D) cellular internalization 
of polyplexes after 45 min of incubation at 37 °C followed by removal of extracellularly bound polyplexes is 
displayed. Logarithmic X-scale in (A) - (D) represents Cy5 fluorescence of polyplexes. Figure adapted from [67] 
supplemental information. 
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Figure S13. Flow cytometry results of pre-conjugated polyplexes as well as corresponding mean fluorescence 
intensity. Cellular association of polyplexes on Huh7 (A) and MCF-7 (C) after 30 min incubation at 4 °C was 
determined by flow cytometry. In (B) and (D) cellular internalization of polyplexes after 45 min of incubation at 37 
°C followed by removal of extracellularly bound polyplexes is displayed. Logarithmic X-scale in (A) - (D) 
represents Cy5 fluorescence of polyplexes. Figure adapted from [67] supplemental information. 
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Analytical data 
 
Analytical experiments were performed by Stephan Morys (Department of Pharmacy, Pharmaceutical 
Biotechnology, LMU). Figures adapted from [67] supplemental information. 
Maldi-MS and RP-HPLC of GE11 peptide 
 
 
 
Figure S14. MALDI-MS of GE11 peptide: Calculated mass [M+H] of C75H97N17O19: 1541.70 g/mol. Adapted from 
[67] supplemental information. 
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Figure S15. RP-HPLC of GE11 peptide. Adapted from [67] supplemental information. 
 
 
 
1H-NMR and RP-HPLC of oligomer 440 
 
 
Figure S16. 
1
H-NMR spectrum of 440 in D2O. δ (ppm) = 1.3-1.45 (comp, 3H, βH alanine), 1.6-2.0 (comp, 6H, 
βγδH lysine), 2.4-2.6 (comp, 34 H, -CO-CH2-CH2-CO- succinic acid -CO-CH2-dPEG24 ), 3.0 -3.65 (comp, 156 H, -
CH2- tepa, H lysine, βH cysteine, βH histidine), 3.70 (s, 98H, -CH2-O-dPEG24, -CH2-N-dPEG24), 3.75-4.75 (comp, 
15 H, αH cysteine, lysine, histidine), 4.79 (s, HDO), 7.2-7.4 (m, 11 H, aromatic H histidine), 8.5-8.7 (m, 11 H, 
aromatic H histidine). comp indicates a group of overlaid protons. Adapted from [67] supplemental information. 
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Figure S17. RP-HPLC of 440. Adapted from [67] supplemental information. 
 
1H-NMR and RP-HPLC of oligomer 835 
 
 
Figure S18. 
1
H-NMR spectrum of 835 in D2O δ (ppm) = 0.75-1.0 (m, 19H, γH threonine β-CH3 γδH isoleucine, β-
CH3 valine), 1.60-1.80 (m, 6H, βγδH lysine), 2.35-2.54 (m, 34 H, -CO-CH2-CH2-CO- succinic acid, -CO-CH2- 
dPEG24), 3.1-3.65 (m, 174 H, -CH2- tepa, H asparagine, βH cysteine, βH histidine, βH tryptophan, βH tyrosine, 
δH proline, βH asparagine, βH valine, εH lysine), 3.74-3.8 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.1-
4.65 (m, 26 H, αH amino acids), 4.75 (s, HDO), 6.7-7.42 (m, 29 H, aromatic ring H tyrosine, tryptophan, 
imidazole), 8.52-8.70 (m, 11 H, imidazole). Adapted from [67] supplemental information. 
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Figure S19. RP-HPLC of 835. Adapted from [67] supplemental information. 
 
Maldi-MS of oligomer 454 
 
 
Figure S20. MALDI MS of 454: Calculated mass [M-H] of C234H421N62O63S2: 3074.07 g/mol. Adapted from [67] 
supplemental information. 
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ESI MS and RP-HPLC of Ala-PEG24-Cys(NPys) 
 
 
Figure S21. ESI MS of Ala-PEG24-Cys(NPys): Calculated Mass [M+Na] of C62H114N5O30S2Na: 1495.71 g/mol. 
Adapted from [67] supplemental information. 
 
 
 
Figure S22. RP-HPLC of Ala-PEG24-Cys(NPys). Adapted from [67] supplemental information. 
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ESI MS and RP-HPLC of GE11-PEG24-Cys(NPys) 
 
 
Figure S23. ESI MS of GE11-PEG24-Cys(NPys): Calculated Mass [M+Na] of C134H204N21O47S2Na: 2948.33 g/mol. 
Adapted from [67] supplemental information. 
 
 
 
Figure S24. RP-HPLC of GE11-PEG24-Cys(NPys). Adapted from [67] supplemental information. 
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ESI MS and RP-HPLC pf Ala-PEG24-Cys(NPys)2 
 
 
Figure S25. ESI MS of Ala-PEG24-Cys(NPys)2: Calculated Mass [M+Na] of C104H185N14O44S4Na: 2486.93 g/mol. 
Adapted from [67] supplemental information. 
 
 
 
Figure S26. RP-HPLC of Ala-PEG24-Cys(NPys)2. Adapted from [67] supplemental information. 
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ESI MS and RP-HPLC pf GE11-PEG24-Cys(NPYS)2 
 
 
Figure S27. ESI MS of GE11-PEG24-Cys(NPys)2: Calculated Mass [M+Na] of C176H275N30O61S4Na: 3938,53 
g/mol. Adapted from [67] supplemental information. 
 
 
 
Figure S28. RP-HPLC of GE11-PEG24-Cys(NPys)2. Adapted from [67] supplemental information. 
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Conjugate Calculated Mass (g/mol) Detected Mass (g/mol) 
GE11 Peptide 1541.70 [M+H] 1537.83 
454 3074.07 [M-H] 3074.84 
Ala-PEG24-Cys(NPys) 1495.71 [M+Na] 1492.76 
GE11-PEG24-Cys(NPys) 2948.33 [M+Na] 2945.43 
Ala-PEG24-Cys(NPys)2 2486.93 [M+Na] 2484.3 
GE11-PEG24-Cys(NPys)2 3939.53 [M+Na] 3939.96 
 
Table S2. Calculated and detected mass of conjugates. Adapted from [67] supplemental information. 
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8. Summary 
 
Polymers as gene delivery vehicles gained great success for cancer gene therapy over the 
last years. At the same time, the sodium iodide symporter (NIS) emerged as outstanding 
therapy gene. The combinatorial “theranostic” function as a reporter and therapy gene, 
based on the capacity to transport various radionuclides into the cell, allows for exact 
quantification of NIS gene expression in the tumor lesion by multimodal imaging of 
radionuclide uptake as well as therapeutic intervention by application of cytotoxic 
radionuclides. However, one of the biggest obstacles for nonviral polymer-mediated NIS 
gene therapy is the design of safe, specific and efficient carriers.  
The innovative concept of active receptor-targeted nonviral NIS gene delivery owns 
enormous potential with high clinical relevance for systemic treatment of solid tumors as well 
as metastases. But despite the current standard, major progress must be made in the further 
development of the polymeric delivery systems to improve efficacy, in particular in 
heterogeneic tumors, biocompatibility, safety, selectivity, uptake and endosomal escape. In 
the course of this thesis, novel tumor-targeted systems were established and applied for 
image-guided NIS gene therapy.  
The first step was, to set up a broad repertoire of highly efficient and tumor specific ligands. 
This enables application of the ligand-mediated NIS gene delivery in a broad range of 
malignancies that exhibit different receptor expression profiles. The peptide ligands B6 (high 
tumor-cell binding affinity), GE11 (targeting EGFR) and cMBP (targeting cMET) were coupled 
to the well-established LPEI-PEG2kDa backbone, which had already been verified as 
advantageous system with improved performance in vivo. B6-conjugated nonviral delivery 
vehicles specifically introduce NIS to cancer tissue with high efficacy after systemic 
application, which was assessed by 123I gamma-camera imaging. In a therapy trial, significant 
NIS-mediated 131I accumulation induced decelerated tumor growth with prolonged animal 
survival.  
As a next step, EGFR-targeted LPEI-PEG2kDa polyplexes were applied in a colon cancer 
metastases model. This valuable tool was selected to reflect the clinical situation on a 
morphological and molecular level including the natural tumor microenvironment and tumor 
stroma to allow a better prediction of therapy outcome. Using the novel NIS PET-tracer 18F-
TFB, specific imaging of NIS gene expression in single metastases was obtained. Images 
demonstrated high resolution with exact mapping of metastases that showed significantly 
increased tracer uptake after EGFR-targeting compared to animals treated with untargeted 
control polyplexes. Subsequent evaluation of the therapeutic efficacy of the EGFR-targeted 
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NIS gene delivery approach resulted in reduced hepatic metastases load of animals treated 
with 131I, monitored by contrast-enhanced ultrasound, and prolonged animal survival.  
With respect to a future translation to humans, where tumor heterogeneity displays a major 
hurdle causing therapy resistance and limited efficacy, a combinatorial ligand set-up was 
applied to cope with variable receptor expression levels. Simultaneous targeting of EGFR 
and cMET for NIS gene therapy combined two outstanding bispecific approaches: (1) 
application of NIS with its innate dual characteristics to function as reporter and therapy gene 
and (2) using the synergy of dual-targeting of two receptors. Enhanced uptake and increased 
NIS gene expression in vitro and in vivo highlighted the benefits of the bifunctional strategy. 
Therapeutic intervention by application of cytotoxic 131I resulted in efficient cancer treatment 
mirrored by reduced tumor growth and improved animal survival and allows successful 
application even in heterogeneic tumors.  
To further improve applicability of delivery vectors, solid-phase methodology was applied for 
synthesis and design of novel functionalized nanosystems that contain precise numbers of 
molecules with structure-activity relationship. The precise synthesis allowed for integration of 
DNA binding sites, shielding domains, amino acids with high buffering capacity and specific 
ligands that resulted in optimized transfection efficiency, while adverse effects such as 
toxicity or high immunogenicity were reduced. Based on high cMET expression level on 
many cancer cells, this receptor serves as an ideal target for cancer therapy. Coupling novel 
sequence defined polymers to a cMET-binding peptide ligand, systemic NIS gene delivery 
led to significant tumoral NIS mediated iodide uptake that was sufficiently high for a potent 
therapeutic effect after 131I application.  
To optimize particle structure and performance of shielded PEGylated vectors, a 
postintegration strategy was conducted. Preformed oleic acid containing sequence defined 
oligomers were complexed with luciferase or NIS pDNA. As a second step, 1-arm and 2-arm 
structures composed of PEG coupled to the EGFR-specific peptide ligand GE11 were added 
to the preformed lipopolyplexes. Chemical characteristics and transfection efficiency were 
determined in vitro and superiority of 2-arm structures was detected. This strategy forms the 
basis for a future application in vivo with the advantage of exact formed lipopolyplexes were 
the effect on size and looser compaction of the shielding domain can be reduced and 
hydrophobic ligands can be introduced. 
In conclusion, in the course of this thesis, the concept of active receptor targeted nonviral 
NIS gene therapy has been refined. High efficacy and tumor specificity in advanced tumor 
models was obtained and together with further development of LPEI-based delivery vectors 
to defined systems, a more efficient and safe application of the image-guided NIS gene 
therapy was performed. This highlights the enormous potential of nonviral polymeric systems 
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as gene transfer systems as well as the outstanding property of NIS in cancer therapy and 
forms the basis for successful future clinical translation of the NIS gene therapy concept. 
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Bartenstein P, Wagner E, Spitzweg C.  Sequence defined cMET/HGFR‐targeted polymers as 
gene delivery vehicles for the theranostic sodium iodide symporter (NIS) gene.  
 
9.5 Awards 
 
Participation at the 87th Annual Meeting of the American Thyroid Association Trainee Grant 
Program, Victoria, Canada, October 2017 
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Travel grant, European Thyroid Association 
40th Annual Meeting of the European Thyroid Association, Belgrade, Serbia, September 
2017. Urnauer S, Müller AM, Schug C, Schmohl KA, Tutter M, Schwenk N, Rödl W, Morys S, 
Ingrisch M, Bertram J, Bartenstein P, Clevert DA, Wagner E, Spitzweg C. EGFR‐targeted 
nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer 
metastases. 
 
Travel grant, German Society of Endocrinology 
60th Annual Meeting of the German Society of Endocrinology, Würzburg, Germany, April 
2017. Urnauer S, Müller AM, Schug C, Schmohl KA, Tutter M, Schwenk N, Rödl W, Morys S, 
Ingrisch M, Bertram J, Bartenstein P, Clevert DA, Wagner E, Spitzweg C. EGFR-targeted 
polyplex-mediated NIS gene therapy of metastatic colorectal cancer. 
 
Travel grant, German Society of Endocrinology 
86th Annual Meeting of the American Thyroid Association, Denver, USA, October 2016. 
Urnauer S, Müller AM, Morys S, Oos R, Bartenstein P, Clevert DA, Wagner E, Spitzweg C. 
Systemic epidermal growth factor receptor-targeted sodium iodide symporter (NIS) gene 
therapy in an advanced tumor model of hepatic colon cancer metastasis  
 
Participation at the 86th Annual Meeting of the American Thyroid Association Trainee Grant 
Program, Denver, USA, October 2016 
 
Travel grant, German Society of Endocrinology 
15th International Thyroid Congress, Orlando, Florida, USA, October 2015. Urnauer S, 
Morys S, Levacic AK, Schug C, Schwenk N, Carlsen J, Zach C, Wagner E, Spitzweg C. 
Systemic non-viral cMET/HGFR-targeted gene delivery using the theranostic function of the 
sodium iodide symporter (NIS) 
 
Travel grant, European Society of Endocrinology 
15th International Thyroid Congress, Orlando, Florida, USA, October 2015. Urnauer S, 
Morys S, Levacic AK, Schug C, Schwenk N, Carlsen J, Zach C, Wagner E, Spitzweg C. 
Systemic non-viral cMET/HGFR-targeted gene delivery using the theranostic function of the 
sodium iodide symporter (NIS) 
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